nct_id,ctgov_group_code,time_frame,event_type,default_vocab,default_assessment,subjects_affected,subjects_at_risk,description,event_count,adverse_event_term,frequency_threshold,vocab,assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Dehydration,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Dehydration,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Disease progression,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Disease progression,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Staphylococcal skin infection,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Staphylococcal skin infection,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Abdominal pain,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Abdominal pain,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Gait disturbance,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Gait disturbance,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Apraxia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Apraxia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Jugular vein thrombosis,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Jugular vein thrombosis,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Implant site abscess,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Implant site abscess,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Sepsis,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Sepsis,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Thrombocytopenia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Thrombocytopenia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Ventricular fibrillation,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Ventricular fibrillation,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Pyrexia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Pyrexia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Pneumonia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Pneumonia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Muscular weakness,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Muscular weakness,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Pneumonitis,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Pneumonitis,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Ileus paralytic,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Ileus paralytic,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Catheter related infection,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Catheter related infection,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Upper respiratory tract infection,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",serious,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Upper respiratory tract infection,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,6,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",11,Fatigue,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,8,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",11,Fatigue,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,5,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",9,Pyrexia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,6,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",16,Pyrexia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,6,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",6,Infusion site pain,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Infusion site pain,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,6,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",7,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Injection site reaction,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,5,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",9,Injection site reaction,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Asthenia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Asthenia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Chest pain,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Chest pain,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Chills,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Chills,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Disease progression,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Disease progression,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Gait disturbance,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Gait disturbance,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Oedema,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Oedema,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,17,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",29,Nausea,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,16,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",32,Nausea,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,5,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",5,Constipation,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,9,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",10,Constipation,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,8,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",14,Vomiting,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,6,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",19,Vomiting,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,4,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Diarrhoea,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,5,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",10,Diarrhoea,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Dyspepsia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Dyspepsia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Abdominal pain,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Abdominal pain,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Abdominal discomfort,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Abdominal discomfort,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Gastrooesophageal reflux disease,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Gastrooesophageal reflux disease,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,6,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",7,Dizziness,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,5,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",8,Dizziness,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,6,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",6,Headache,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Headache,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Dysgeusia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Dysgeusia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Hypoparaesthesia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Hypoparaesthesia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Anorexia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,5,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",5,Anorexia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",5,Hypokalaemia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,4,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",9,Hypokalaemia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Dehydration,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,4,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Dehydration,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Hypoalbuminaemia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Hypoalbuminaemia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,7,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",8,Pruritus,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Pruritus,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,4,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",5,Rash,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Rash,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,4,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Skin exfoliation,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Skin exfoliation,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Alanine aminotransferase increased,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Alanine aminotransferase increased,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Aspartate aminotransferase increased,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Aspartate aminotransferase increased,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Blood alkaline phosphatase increased,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Blood alkaline phosphatase increased,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Blood lactate dehydrogenase increased,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Blood lactate dehydrogenase increased,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Upper respiratory tract infection,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Upper respiratory tract infection,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Cellulitis,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Cellulitis,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,5,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",6,Pain in extremity,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,5,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",5,Pain in extremity,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Myalgia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Myalgia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Muscular weakness,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Muscular weakness,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Back pain,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Back pain,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,4,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Dyspnoea,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Dyspnoea,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Cough,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Cough,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Flushing,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,4,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Flushing,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Phlebitis,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Phlebitis,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Tachycardia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",6,Tachycardia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Eosinophilia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Eosinophilia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Lymphadenopathy,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Lymphadenopathy,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Thrombocytopenia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,3,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Thrombocytopenia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Confusional state,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Confusional state,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",1,Insomnia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",4,Insomnia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Mucosal inflammation,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Mucosal inflammation,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Abdominal distension,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Abdominal distension,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Stomatitis,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Stomatitis,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Hypomagnesaemia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Hypomagnesaemia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Rash maculo-papular,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Rash maculo-papular,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Decreased appetite,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Decreased appetite,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Blood creatinine increased,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Blood creatinine increased,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Blood magnesium decreased,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Blood magnesium decreased,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Blood uric acid increased,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Blood uric acid increased,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Body temperature increased,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Body temperature increased,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Herpes simplex,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Herpes simplex,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Pneumonia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Pneumonia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Sepsis,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Sepsis,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Skin infection,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Skin infection,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Tinea pedis,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Tinea pedis,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Muscle spams,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,1,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Muscle spams,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Neck pain,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Neck pain,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Hiccups,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Hiccups,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Nasal congestion,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Nasal congestion,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Hypotension,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Hypotension,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Anaemia,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Anaemia,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",3,Vertigo,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Vertigo,5,MedDRA,Systematic Assessment
NCT00274651,EG000,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,0,29,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",0,Hypersensitivity,5,MedDRA,Systematic Assessment
NCT00274651,EG001,"Throughout study, up to 4 weeks after last drug administration",other,NA,NA,2,24,"Follow-up of the AE (adverse event) was required during the study and after completion, withdrawal or discontinuation of the study if the event was still ongoing. The Investigator was to continuously monitor patients with AEs until the event had returned to baseline or ≤ Grade 1 or until the patient started another type of antineoplastic therapy.",2,Hypersensitivity,5,MedDRA,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,4,434,NA,4,Anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,4,222,NA,4,Anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Coagulopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Coagulopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Disseminated intravascular coagulation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Disseminated intravascular coagulation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Hypoprothrombinaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Hypoprothrombinaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Iron deficiency anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Iron deficiency anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Thrombocytopenia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Thrombocytopenia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Acute myocardial infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Acute myocardial infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Angina pectoris,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Angina pectoris,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,7,434,NA,8,Atrial fibrillation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,5,222,NA,5,Atrial fibrillation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Atrial flutter,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Atrial flutter,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Atrial tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Atrial tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,8,434,NA,9,Cardiac arrest,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,4,222,NA,4,Cardiac arrest,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cardiac failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Cardiac failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cardiac failure acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Cardiac failure acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,4,434,NA,4,Cardiac failure congestive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,4,222,NA,4,Cardiac failure congestive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cardiac valve vegetation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cardiac valve vegetation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cardio-respiratory arrest,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Cardio-respiratory arrest,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Cardiogenic shock,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cardiogenic shock,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cardiomyopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cardiomyopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cardiopulmonary failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cardiopulmonary failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Coronary artery disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Coronary artery disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Electromechanical dissociation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Electromechanical dissociation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Endocarditis noninfective,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Endocarditis noninfective,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Intracardiac thrombus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Intracardiac thrombus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Ischaemic cardiomyopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Ischaemic cardiomyopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Mitral valve disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Mitral valve disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Mitral valve stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Mitral valve stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,4,434,NA,4,Myocardial infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Myocardial infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Pericardial effusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Pericardial effusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Pericardial haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Pericardial haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Sick sinus syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Sick sinus syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Sinus bradycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Sinus bradycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Tachyarrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Tachyarrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Ventricular tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,4,222,NA,4,Ventricular tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,4,434,NA,4,Atrial septal defect,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Atrial septal defect,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Hereditary cerebral degeneration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Hereditary cerebral degeneration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Diplopia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Diplopia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Abdominal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Abdominal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Colitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Colitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Diarrhoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Diarrhoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Gastritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Gastritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Gastrointestinal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,3,222,NA,3,Gastrointestinal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Gastrooesophageal reflux disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Gastrooesophageal reflux disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Gingival bleeding,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Gingival bleeding,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Haematemesis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haematemesis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Haematochezia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haematochezia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Ileus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Ileus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Intestinal obstruction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Intestinal obstruction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Pancreatic mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Pancreatic mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Pancreatitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Pancreatitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Peritonitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Peritonitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Retroperitoneal haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Retroperitoneal haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Retroperitoneal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Retroperitoneal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Small intestinal obstruction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Small intestinal obstruction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Umbilical hernia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Umbilical hernia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Brain death,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Brain death,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,4,Chest discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Chest discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Extravasation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Extravasation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,General physical health deterioration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,General physical health deterioration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Multi-organ failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Multi-organ failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Non-cardiac chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Non-cardiac chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Oedema due to cardiac disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Oedema due to cardiac disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Oedema peripheral,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Oedema peripheral,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Pyrexia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Pyrexia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Systemic inflammatory response syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Systemic inflammatory response syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Vessel puncture site haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Vessel puncture site haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Vessel puncture site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Vessel puncture site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cholecystitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cholecystitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Anaphylactic reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Anaphylactic reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Abdominal wall infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Abdominal wall infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Appendicitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Appendicitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Bacteraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Bacteraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Bacteriuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Bacteriuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Cellulitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cellulitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Clostridium difficile colitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Clostridium difficile colitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Endocarditis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Endocarditis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Endocarditis bacterial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Endocarditis bacterial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Gangrene,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Gangrene,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Gastroenteritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Gastroenteritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Haematoma infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haematoma infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Infected skin ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Infected skin ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Lobar pneumonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Lobar pneumonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Lung infection pseudomonal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Lung infection pseudomonal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,16,434,NA,17,Pneumonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,8,222,NA,8,Pneumonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Pneumonia primary atypical,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Pneumonia primary atypical,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Postoperative wound infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Postoperative wound infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Pulmonary sepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Pulmonary sepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Respiratory tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Respiratory tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,6,434,NA,6,Sepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,5,222,NA,5,Sepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Sepsis syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Sepsis syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Septic shock,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Septic shock,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,8,434,NA,11,Urinary tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,7,222,NA,7,Urinary tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Urosepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Urosepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Wound infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Wound infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Aortic injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Aortic injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Arterial injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Arterial injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,7,434,NA,7,Brain herniation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,3,Brain herniation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cardiac procedure complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cardiac procedure complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cervical vertebral fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cervical vertebral fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Concussion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Concussion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Difficult to wean from ventilator,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Difficult to wean from ventilator,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Drug dispensing error,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Drug dispensing error,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Fall,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Fall,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Feeding tube complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Feeding tube complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Femoral neck fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Femoral neck fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Femur fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Femur fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Head injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Head injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Hip fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Hip fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Medication error,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Medication error,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Post procedural haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Post procedural haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Rib fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Rib fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Stent occlusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Stent occlusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Subdural haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Subdural haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Thermal burn,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Thermal burn,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Thrombosis in device,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Thrombosis in device,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Vascular injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Vascular injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Vascular procedure complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Vascular procedure complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Ventriculoperitoneal shunt malfunction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Ventriculoperitoneal shunt malfunction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Activated partial thromboplastin time prolonged,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Activated partial thromboplastin time prolonged,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Blood culture positive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Blood culture positive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Blood glucose increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Blood glucose increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Blood magnesium decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Blood magnesium decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Blood osmolarity decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Blood osmolarity decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Blood phosphorus decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Blood phosphorus decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Computerised tomogram abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Computerised tomogram abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Electrocardiogram ST segment abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Electrocardiogram ST segment abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Electroencephalogram abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Electroencephalogram abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Haematocrit decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haematocrit decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,NIH stroke scale score increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,NIH stroke scale score increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Oxygen saturation decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Oxygen saturation decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Troponin increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Troponin increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Weight decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Weight decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Acid-base balance disorder mixed,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Acid-base balance disorder mixed,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Anorexia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Anorexia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Dehydration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Dehydration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Diabetes mellitus insulin-dependent,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Diabetes mellitus insulin-dependent,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Failure to thrive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Failure to thrive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Hyperglycaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Hyperglycaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Hypokalaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Hypokalaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Arthralgia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Arthralgia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Muscular weakness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Muscular weakness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Osteoarthritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Osteoarthritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Pain in extremity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Pain in extremity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Pain in jaw,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Pain in jaw,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Glioblastoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Glioblastoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Gliomatosis cerebri,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Gliomatosis cerebri,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Lung adenocarcinoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Lung adenocarcinoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Lung neoplasm malignant,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Lung neoplasm malignant,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Metastatic neoplasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Metastatic neoplasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Prostate cancer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Prostate cancer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Aphasia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Aphasia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Brain compression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Brain compression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,46,434,NA,46,Brain oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,19,222,NA,20,Brain oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Brain stem infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Brain stem infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Carotid artery dissection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Carotid artery dissection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Carotid artery occlusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Carotid artery occlusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Carotid artery stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Carotid artery stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cerebellar haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cerebellar haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Cerebellar infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cerebellar infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Cerebral haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Cerebral haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,8,434,NA,8,Cerebral haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,8,222,NA,8,Cerebral haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,9,434,NA,9,Cerebral infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Cerebral infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,18,434,NA,19,Cerebrovascular accident,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,12,222,NA,12,Cerebrovascular accident,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Cerebrovascular disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Cerebrovascular disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Coma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Coma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Complex partial seizures,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Complex partial seizures,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,9,434,NA,9,Convulsion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,9,222,NA,9,Convulsion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Depressed level of consciousness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Depressed level of consciousness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Dizziness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Dizziness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Encephalopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Encephalopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Facial spasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Facial spasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,12,434,NA,12,Haemorrhage intracranial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,8,222,NA,8,Haemorrhage intracranial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Haemorrhagic cerebral infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haemorrhagic cerebral infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Haemorrhagic stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haemorrhagic stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,6,434,NA,6,Haemorrhagic transformation stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,6,222,NA,6,Haemorrhagic transformation stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Headache,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Headache,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Hemiparesis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Hemiparesis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Hydrocephalus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Hydrocephalus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Intracranial haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Intracranial haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Intracranial pressure increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Intracranial pressure increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Intraventricular haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Intraventricular haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,6,434,NA,7,Ischaemic stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Ischaemic stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Lethargy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,3,222,NA,3,Lethargy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Mental impairment,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Mental impairment,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Migraine,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Migraine,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,12,434,NA,13,Neurological symptom,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,4,222,NA,4,Neurological symptom,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Presyncope,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Presyncope,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,2,Status epilepticus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Status epilepticus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Stroke in evolution,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Stroke in evolution,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,6,434,NA,6,Subarachnoid haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Subarachnoid haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Syncope,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Syncope,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Thalamic infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Thalamic infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Transient ischaemic attack,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Transient ischaemic attack,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Tremor,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Tremor,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Aggression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Aggression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Agitation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Agitation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Anxiety,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Anxiety,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,2,Confusional state,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Confusional state,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Delirium tremens,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Delirium tremens,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Depression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Depression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Emotional disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Emotional disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,6,434,NA,7,Mental status changes,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Mental status changes,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Suicide attempt,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Suicide attempt,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Haematuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haematuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Nephrolithiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Nephrolithiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Renal failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Renal failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Renal failure acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Renal failure acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Renal failure chronic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Renal failure chronic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Renal mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Renal mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Urinary retention,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Urinary retention,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Pelvic pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Pelvic pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Acute pulmonary oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,2,Acute pulmonary oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Acute respiratory distress syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Acute respiratory distress syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Acute respiratory failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Acute respiratory failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Apnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Apnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Aspiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Aspiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Atelectasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Atelectasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,3,434,NA,3,Dyspnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Dyspnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Epistaxis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Epistaxis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Haemoptysis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Haemoptysis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,5,434,NA,5,Hypoxia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Hypoxia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Lung infiltration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Lung infiltration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Obstructive airways disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Obstructive airways disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,6,434,NA,6,Pneumonia aspiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Pneumonia aspiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Pneumothorax,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Pneumothorax,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,4,434,NA,4,Pulmonary embolism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,8,222,NA,8,Pulmonary embolism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Pulmonary haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Pulmonary haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Pulmonary oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Pulmonary oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Respiratory arrest,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Respiratory arrest,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,5,434,NA,5,Respiratory distress,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,4,222,NA,4,Respiratory distress,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,18,434,NA,18,Respiratory failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,5,222,NA,5,Respiratory failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Angioneurotic oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Angioneurotic oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Decubitus ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Decubitus ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Skin ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Skin ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Aortic valve replacement,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Aortic valve replacement,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Cardiac pacemaker insertion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Cardiac pacemaker insertion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cardiac pacemaker replacement,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cardiac pacemaker replacement,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Carotid endarterectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,3,Carotid endarterectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Cholecystectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Cholecystectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Craniectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Craniectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,9,434,NA,9,Cranioplasty,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,3,222,NA,3,Cranioplasty,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Intubation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,2,Intubation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Medical device implantation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Medical device implantation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Mitral valve replacement,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Mitral valve replacement,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Nephrectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Nephrectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Surgery,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Surgery,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Tracheostomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Tracheostomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Aortic arteriosclerosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Aortic arteriosclerosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Aortic stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Aortic stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Arterial restenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Arterial restenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Arterial thrombosis limb,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Arterial thrombosis limb,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,7,434,NA,7,Deep vein thrombosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Deep vein thrombosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Femoral artery occlusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Femoral artery occlusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Haemodynamic instability,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haemodynamic instability,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,2,434,NA,2,Haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,4,434,NA,4,Hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,2,222,NA,2,Hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Hypertensive crisis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Hypertensive crisis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Hypertensive emergency,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Hypertensive emergency,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,6,434,NA,6,Hypotension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,6,222,NA,6,Hypotension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Iliac artery thrombosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Iliac artery thrombosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Peripheral arterial occlusive disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Peripheral arterial occlusive disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Peripheral artery aneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Peripheral artery aneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Peripheral embolism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Peripheral embolism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Peripheral ischaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Peripheral ischaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Peripheral vascular disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Peripheral vascular disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,1,434,NA,1,Shock,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,0,222,NA,0,Shock,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,serious,NA,NA,0,434,NA,0,Thrombophlebitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,serious,NA,NA,1,222,NA,1,Thrombophlebitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,39,434,NA,41,Anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,16,222,NA,17,Anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Coagulopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Coagulopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Haemorrhagic disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Haemorrhagic disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hilar lymphadenopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hilar lymphadenopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Iron deficiency anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Iron deficiency anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,7,Leukocytosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,5,Leukocytosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Lymphadenopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Lymphadenopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Lymphadenopathy mediastinal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Lymphadenopathy mediastinal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Pernicious anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pernicious anaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Splenic infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Splenic infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Thrombocytopenia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,5,Thrombocytopenia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Acute myocardial infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Acute myocardial infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Angina pectoris,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Angina pectoris,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Aortic valve disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Aortic valve disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Aortic valve stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Aortic valve stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Arrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Arrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Arrhythmia supraventricular,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Arrhythmia supraventricular,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,37,434,NA,41,Atrial fibrillation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,21,222,NA,22,Atrial fibrillation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,4,Atrial flutter,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Atrial flutter,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Atrioventricular block,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Atrioventricular block,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,18,434,NA,19,Bradycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,9,222,NA,9,Bradycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Bundle branch block right,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Bundle branch block right,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Cardiac disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cardiac disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Cardiac failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cardiac failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cardiac failure acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cardiac failure acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,16,434,NA,17,Cardiac failure congestive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,7,222,NA,8,Cardiac failure congestive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Cardiac valve disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cardiac valve disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cardiac valve vegetation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cardiac valve vegetation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cardiogenic shock,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cardiogenic shock,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Cardiomegaly,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Cardiomegaly,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cardiomyopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Cardiomyopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cardiovascular disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cardiovascular disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Coronary artery disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Coronary artery disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Diastolic dysfunction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Diastolic dysfunction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Intracardiac thrombus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Intracardiac thrombus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Ischaemic cardiomyopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Ischaemic cardiomyopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Mitral valve stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Mitral valve stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Myocardial infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Myocardial infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Myocardial ischaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Myocardial ischaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Nodal arrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Nodal arrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Palpitations,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Palpitations,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Sick sinus syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Sick sinus syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Sinus arrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Sinus arrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Sinus bradycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,7,222,NA,7,Sinus bradycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Sinus tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Sinus tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Supraventricular tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Supraventricular tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,15,434,NA,16,Tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,9,222,NA,9,Tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Ventricular arrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Ventricular arrhythmia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Ventricular extrasystoles,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Ventricular extrasystoles,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Ventricular tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Ventricular tachycardia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Atrial septal defect,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Atrial septal defect,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Congenital cystic kidney disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Congenital cystic kidney disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Homocystinaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Homocystinaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Cerumen impaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cerumen impaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Deafness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Deafness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Ear pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Ear pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Vertigo,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Vertigo,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Diabetes insipidus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Diabetes insipidus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hypothyroidism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Hypothyroidism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Conjunctival haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Conjunctival haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Conjunctivitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Conjunctivitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Dry eye,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Dry eye,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Eye disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Eye disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,2,Eye pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Eye pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Eye swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Eye swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Eyelid oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Eyelid oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,3,Eyelid ptosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Eyelid ptosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Ocular hyperaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Ocular hyperaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Pupil fixed,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Pupil fixed,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Scleral oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Scleral oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Ulcerative keratitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Ulcerative keratitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Vision blurred,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Vision blurred,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Abdominal discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Abdominal discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Abdominal distension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Abdominal distension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Abdominal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Abdominal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Abdominal pain upper,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Abdominal pain upper,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Abnormal faeces,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Abnormal faeces,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Anal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Anal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Ascites,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Ascites,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Bowel movement irregularity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Bowel movement irregularity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,41,434,NA,43,Constipation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,26,222,NA,27,Constipation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,21,434,NA,21,Diarrhoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,9,222,NA,9,Diarrhoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Dyspepsia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,4,222,NA,4,Dyspepsia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,14,434,NA,14,Dysphagia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Dysphagia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Faecal incontinence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Faecal incontinence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Flatulence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Flatulence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Food poisoning,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Food poisoning,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Gastritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Gastritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Gastritis haemorrhagic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Gastritis haemorrhagic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Gastrointestinal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Gastrointestinal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Gastrooesophageal reflux disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Gastrooesophageal reflux disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Gingival bleeding,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,6,222,NA,6,Gingival bleeding,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Gingivitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Gingivitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Haematemesis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Haematemesis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Haematochezia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Haematochezia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Haemorrhoids,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Haemorrhoids,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hiatus hernia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hiatus hernia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Hypoaesthesia oral,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hypoaesthesia oral,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Ileus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Ileus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Impaired gastric emptying,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Impaired gastric emptying,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Inguinal hernia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Inguinal hernia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Loose tooth,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Loose tooth,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Melaena,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Melaena,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Mouth haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Mouth haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,43,434,NA,45,Nausea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,17,222,NA,18,Nausea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Oesophageal stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Oesophageal stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Periproctitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Periproctitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Rectal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Rectal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Retroperitoneal haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Retroperitoneal haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Salivary hypersecretion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Salivary hypersecretion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Stomach discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Stomach discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Swollen tongue,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Swollen tongue,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Tongue haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Tongue haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Tongue ulceration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Tongue ulceration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Toothache,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Toothache,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,39,434,NA,40,Vomiting,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,21,222,NA,22,Vomiting,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Adverse drug reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Adverse drug reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Asthenia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Asthenia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Catheter site bruise,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Catheter site bruise,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Catheter site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Catheter site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Catheter site related reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Catheter site related reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Chest discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Chest discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,17,434,NA,17,Chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,9,222,NA,10,Chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Chills,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Chills,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Extravasation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Extravasation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Face oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Face oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Facial pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Facial pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,10,434,NA,10,Fatigue,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Fatigue,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Feeling cold,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Feeling cold,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Generalised oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Generalised oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Hyperthermia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Hyperthermia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Implant site pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Implant site pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,2,Infusion site erythema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Infusion site erythema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Infusion site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Infusion site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Infusion site oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Infusion site oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Injection site extravasation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Injection site extravasation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Local swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Local swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Malaise,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Malaise,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Non-cardiac chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Non-cardiac chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,23,434,NA,29,Oedema peripheral,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,13,222,NA,15,Oedema peripheral,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,30,434,NA,32,Pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,14,222,NA,16,Pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Pitting oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Pitting oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Puncture site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Puncture site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,35,434,NA,36,Pyrexia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,31,222,NA,32,Pyrexia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Systemic inflammatory response syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Systemic inflammatory response syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Vessel puncture site bruise,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Vessel puncture site bruise,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,15,434,NA,15,Vessel puncture site haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Vessel puncture site haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Vessel puncture site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Vessel puncture site haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cholecystitis acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cholecystitis acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hepatomegaly,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hepatomegaly,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Drug hypersensitivity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Drug hypersensitivity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hypersensitivity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hypersensitivity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Abdominal wall abscess,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Abdominal wall abscess,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Abscess limb,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Abscess limb,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Bacteraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Bacteraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Bronchitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,4,222,NA,4,Bronchitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Bronchitis acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Bronchitis acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Candidiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Candidiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Cellulitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cellulitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Chest wall abscess,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Chest wall abscess,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Clostridial infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Clostridial infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Clostridium difficile colitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Clostridium difficile colitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cystitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cystitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Diarrhoea infectious,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Diarrhoea infectious,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Enterococcal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Enterococcal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Eye infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Eye infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Fungal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Fungal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Fungal skin infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Fungal skin infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Gastroenteritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Gastroenteritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Herpes simplex,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Herpes simplex,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Herpes zoster,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Herpes zoster,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Infusion site infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Infusion site infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Lobar pneumonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Lobar pneumonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Lower respiratory tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Lower respiratory tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Lymphadenitis bacterial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Lymphadenitis bacterial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Nail infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Nail infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Nasopharyngitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Nasopharyngitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Onychomycosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Onychomycosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,16,434,NA,16,Oral candidiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,6,222,NA,6,Oral candidiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Oral fungal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Oral fungal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Orchitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Orchitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,36,434,NA,39,Pneumonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,8,222,NA,8,Pneumonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Pneumonia staphylococcal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pneumonia staphylococcal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Pneumonia streptococcal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pneumonia streptococcal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Respiratory tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Respiratory tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Sepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Sepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,7,Sinusitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Sinusitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Skin infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Skin infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Staphylococcal bacteraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Staphylococcal bacteraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Staphylococcal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Staphylococcal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Staphylococcal sepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Staphylococcal sepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Subacute endocarditis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Subacute endocarditis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Tooth abscess,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Tooth abscess,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Tracheobronchitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Tracheobronchitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Upper respiratory tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Upper respiratory tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,90,434,NA,104,Urinary tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,46,222,NA,51,Urinary tract infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Urinary tract infection bacterial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Urinary tract infection bacterial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Urosepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Urosepsis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Vaginal candidiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Vaginal candidiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Vaginal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Vaginal infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Vulvovaginal mycotic infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Vulvovaginal mycotic infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Wound infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Wound infection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Wound infection bacterial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Wound infection bacterial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Alcohol poisoning,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Alcohol poisoning,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Brain herniation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Brain herniation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Conjunctival abrasion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Conjunctival abrasion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Contrast media reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Contrast media reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,26,434,NA,30,Contusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,9,222,NA,12,Contusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Device lead damage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Device lead damage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Difficult to wean from ventilator,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Difficult to wean from ventilator,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Drug administration error,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Drug administration error,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Epicondylitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Epicondylitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,4,Excoriation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Excoriation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,13,434,NA,15,Fall,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,18,222,NA,18,Fall,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Feeding tube complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,2,Feeding tube complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Haematuria traumatic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Haematuria traumatic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Hand fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hand fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Incision site complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,3,Incision site complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Incision site oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Incision site oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Intubation complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Intubation complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Joint dislocation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Joint dislocation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Joint sprain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Joint sprain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Laceration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Laceration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Medication error,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Medication error,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Mouth injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Mouth injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Muscle strain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Muscle strain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Pacemaker complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pacemaker complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Periorbital haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Periorbital haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Post procedural haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Post procedural haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Post procedural haematuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Post procedural haematuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Post procedural haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Post procedural haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Post-traumatic pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Post-traumatic pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Procedural complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Procedural complication,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Procedural hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Procedural hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Renal injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Renal injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Rib fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Rib fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Skin injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Skin injury,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,9,Skin laceration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Skin laceration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Stress fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Stress fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Tracheostomy malfunction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Tracheostomy malfunction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Transfusion reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Transfusion reaction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Traumatic fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Traumatic fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Traumatic haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Traumatic haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Upper limb fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Upper limb fracture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Wound,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Wound,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Wrong technique in drug usage process,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Wrong technique in drug usage process,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Activated partial thromboplastin time prolonged,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Activated partial thromboplastin time prolonged,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Bacteria stool identified,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Bacteria stool identified,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Blood albumin abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood albumin abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood alkaline phosphatase increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Blood alkaline phosphatase increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Blood cholesterol increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood cholesterol increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Blood creatine phosphokinase increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood creatine phosphokinase increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Blood creatinine increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood creatinine increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Blood culture positive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood culture positive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood electrolytes abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Blood electrolytes abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Blood fibrinogen decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood fibrinogen decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Blood fibrinogen increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood fibrinogen increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Blood glucose abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood glucose abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood glucose increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood glucose increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood lactate dehydrogenase increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Blood lactate dehydrogenase increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Blood magnesium decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Blood magnesium decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Blood phosphorus decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Blood phosphorus decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Blood potassium decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood potassium decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood pressure decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blood pressure decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Blood pressure increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Blood pressure increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood test abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Blood test abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood thyroid stimulating hormone decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Blood thyroid stimulating hormone decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood urea abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Blood urea abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Blood urea increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Blood urea increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Body temperature increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,3,Body temperature increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Breath sounds abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,3,Breath sounds abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,C-reactive protein increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,C-reactive protein increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cardiac enzymes increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cardiac enzymes increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Cardiac stress test abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cardiac stress test abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Chest X-ray abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Chest X-ray abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Computerised tomogram abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Computerised tomogram abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Culture urine positive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Culture urine positive,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Drug level fluctuating,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Drug level fluctuating,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Electrocardiogram ST segment abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Electrocardiogram ST segment abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Electrocardiogram ST segment depression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Electrocardiogram ST segment depression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Electrocardiogram ST segment elevation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Electrocardiogram ST segment elevation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Electroencephalogram abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Electroencephalogram abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Free prostate-specific antigen increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Free prostate-specific antigen increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Full blood count abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Full blood count abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Haematocrit decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Haematocrit decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Haematology test abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Haematology test abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Haemoglobin,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Haemoglobin,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Haemoglobin abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Haemoglobin abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,9,Haemoglobin decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Haemoglobin decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Heart rate decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Heart rate decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Inspiratory capacity decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Inspiratory capacity decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,International normalised ratio increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,International normalised ratio increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Myoglobin blood increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Myoglobin blood increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,NIH stroke scale score increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,NIH stroke scale score increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Neurological examination abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Neurological examination abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Oxygen saturation decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Oxygen saturation decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Platelet count decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Platelet count decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Platelet count increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Platelet count increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Prothrombin time prolonged,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Prothrombin time prolonged,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Pulmonary function test decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pulmonary function test decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Red blood cell count decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Red blood cell count decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Red blood cell sedimentation rate increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Red blood cell sedimentation rate increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Residual urine volume,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Residual urine volume,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Scan with contrast abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Scan with contrast abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Troponin I increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Troponin I increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,10,434,NA,10,Troponin increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Troponin increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Urine output decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Urine output decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Urine output increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Urine output increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Venous pressure jugular increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Venous pressure jugular increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Weight decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Weight decreased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Weight increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Weight increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,13,434,NA,13,White blood cell count increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,White blood cell count increased,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Anorexia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Anorexia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Appetite disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Appetite disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Dehydration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Dehydration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Diabetes mellitus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Diabetes mellitus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Diabetes mellitus non-insulin-dependent,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Diabetes mellitus non-insulin-dependent,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,23,434,NA,25,Electrolyte imbalance,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,7,222,NA,7,Electrolyte imbalance,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Fluid imbalance,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Fluid imbalance,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Fluid overload,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Fluid overload,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Fluid retention,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Fluid retention,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Gout,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Gout,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hyperammonaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hyperammonaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hyperchloraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hyperchloraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Hypercholesterolaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hypercholesterolaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,31,434,NA,31,Hyperglycaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,11,222,NA,11,Hyperglycaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hyperhomocysteinaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hyperhomocysteinaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Hyperkalaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Hyperkalaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Hyperlipidaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,10,222,NA,10,Hyperlipidaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Hypernatraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Hypernatraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Hypoalbuminaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hypoalbuminaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Hypocalcaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hypocalcaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Hypoglycaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hypoglycaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,40,434,NA,40,Hypokalaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,18,222,NA,20,Hypokalaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Hypomagnesaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hypomagnesaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,14,434,NA,14,Hyponatraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,7,222,NA,7,Hyponatraemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Hypophosphataemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hypophosphataemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Hypovolaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hypovolaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Lactose intolerance,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Lactose intolerance,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Malnutrition,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Malnutrition,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Metabolic acidosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Metabolic acidosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Metabolic alkalosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Metabolic alkalosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Vitamin D deficiency,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,5,Vitamin D deficiency,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,22,434,NA,25,Arthralgia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,7,222,NA,7,Arthralgia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,23,434,NA,24,Back pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,13,222,NA,13,Back pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Buttock pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Buttock pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Flank pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Flank pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Groin pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Groin pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Haemarthrosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Haemarthrosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Joint effusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Joint effusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Joint swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Joint swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Limb discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Limb discomfort,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Monarthritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Monarthritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Muscle haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Muscle haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Muscle spasms,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,6,Muscle spasms,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Muscle twitching,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Muscle twitching,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Muscular weakness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Muscular weakness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Musculoskeletal chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Musculoskeletal chest pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Musculoskeletal disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Musculoskeletal disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,18,434,NA,18,Musculoskeletal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,8,222,NA,8,Musculoskeletal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Musculoskeletal stiffness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Musculoskeletal stiffness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Myalgia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Myalgia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,7,Neck pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,5,Neck pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,28,434,NA,31,Pain in extremity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,12,222,NA,17,Pain in extremity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Pain in jaw,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pain in jaw,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Periarthritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Periarthritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Rheumatoid arthritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Rheumatoid arthritis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Rotator cuff syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Rotator cuff syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Sacral pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Sacral pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Spinal disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Spinal disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Trigger finger,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Trigger finger,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Chondromatosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Chondromatosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Colon cancer recurrent,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Colon cancer recurrent,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Thyroid neoplasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Thyroid neoplasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Amnesia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Amnesia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Aphasia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Aphasia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Balance disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Balance disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,10,434,NA,10,Brain oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,15,222,NA,16,Brain oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Carotid arterial embolus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Carotid arterial embolus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,8,Carotid artery dissection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Carotid artery dissection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Carotid artery stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Carotid artery stenosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Cerebellar haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cerebellar haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Cerebral artery embolism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cerebral artery embolism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,26,434,NA,26,Cerebral haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,7,222,NA,7,Cerebral haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cerebral infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cerebral infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Cerebrovascular accident,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,2,Cerebrovascular accident,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cerebrovascular spasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cerebrovascular spasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Cognitive disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cognitive disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Complex regional pain syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Complex regional pain syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,16,434,NA,19,Convulsion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,5,Convulsion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Coordination abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Coordination abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Depressed level of consciousness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Depressed level of consciousness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Disturbance in attention,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Disturbance in attention,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,15,434,NA,17,Dizziness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Dizziness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Dysgeusia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Dysgeusia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Dystonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Dystonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Encephalomalacia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Encephalomalacia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Encephalopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Encephalopathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Facial palsy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Facial palsy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Grand mal convulsion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Grand mal convulsion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,43,434,NA,43,Haemorrhage intracranial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,14,222,NA,14,Haemorrhage intracranial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Haemorrhagic cerebral infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Haemorrhagic cerebral infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Haemorrhagic stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Haemorrhagic stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,35,434,NA,35,Haemorrhagic transformation stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,18,222,NA,18,Haemorrhagic transformation stroke,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,80,434,NA,86,Headache,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,51,222,NA,55,Headache,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hemiparesis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hemiparesis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hydrocephalus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hydrocephalus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,4,Hypoaesthesia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Hypoaesthesia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Intention tremor,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Intention tremor,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Intracranial aneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Intracranial aneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Intracranial haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Intracranial haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Intraventricular haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Intraventricular haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,6,Lethargy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,5,Lethargy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Loss of consciousness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Loss of consciousness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Mental impairment,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Mental impairment,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Muscle spasticity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Muscle spasticity,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,12,434,NA,12,Neurological symptom,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,5,Neurological symptom,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Neuropathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Neuropathy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Paraesthesia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Paraesthesia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Partial seizures,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Partial seizures,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Presyncope,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Presyncope,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Putamen haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Putamen haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Restless legs syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Restless legs syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Sciatica,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Sciatica,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Sensory loss,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Sensory loss,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Somnolence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,4,222,NA,4,Somnolence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Subarachnoid haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Subarachnoid haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Syncope,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Syncope,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Transient ischaemic attack,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Transient ischaemic attack,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Tremor,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Tremor,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Unresponsive to stimuli,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Unresponsive to stimuli,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Vascular dementia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Vascular dementia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Pregnancy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pregnancy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Acute psychosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Acute psychosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Aggression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Aggression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,31,434,NA,32,Agitation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,18,222,NA,19,Agitation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Alcohol withdrawal syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Alcohol withdrawal syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,24,434,NA,25,Anxiety,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,10,222,NA,11,Anxiety,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Bruxism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Bruxism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Catatonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Catatonia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Confusional state,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Confusional state,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Delirium,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Delirium,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Delirium tremens,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Delirium tremens,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Depressed mood,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Depressed mood,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,43,434,NA,44,Depression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,18,222,NA,19,Depression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Disorientation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Disorientation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Dysthymic disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Dysthymic disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Emotional disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Emotional disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,7,Hallucination,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hallucination,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,"Hallucination, visual",0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,"Hallucination, visual",0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,"Hallucinations, mixed",0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,"Hallucinations, mixed",0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Impulsive behaviour,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Impulsive behaviour,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,26,434,NA,28,Insomnia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,11,222,NA,11,Insomnia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Insomnia related to another mental condition,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Insomnia related to another mental condition,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Mental status changes,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,6,222,NA,7,Mental status changes,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Osmophobia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Osmophobia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Panic attack,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Panic attack,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Posturing,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Posturing,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Psychotic disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Psychotic disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Restlessness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,6,222,NA,6,Restlessness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Suicidal ideation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Suicidal ideation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Azotaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Azotaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Bladder disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Bladder disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Dysuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Dysuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,24,434,NA,25,Haematuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,13,222,NA,13,Haematuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Hypertonic bladder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Hypertonic bladder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Incontinence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Incontinence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Nephrolithiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Nephrolithiasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Neurogenic bladder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Neurogenic bladder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Oliguria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Oliguria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Pollakiuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pollakiuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Proteinuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Proteinuria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Renal disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Renal disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Renal failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Renal failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Renal failure acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Renal failure acute,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Renal impairment,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Renal impairment,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Urethral discharge,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Urethral discharge,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,7,Urinary incontinence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Urinary incontinence,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,13,434,NA,13,Urinary retention,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,6,222,NA,7,Urinary retention,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Urine odour abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Urine odour abnormal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Urogenital haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Urogenital haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Adnexa uteri mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Adnexa uteri mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Benign prostatic hyperplasia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Benign prostatic hyperplasia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Breast mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Breast mass,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Dysmenorrhoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Dysmenorrhoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Female genital tract fistula,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Female genital tract fistula,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Genital haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Genital haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Menorrhagia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Menorrhagia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Penile swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Penile swelling,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Prostatitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Prostatitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Scrotal erythema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Scrotal erythema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Vaginal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Vaginal haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Vaginal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Vaginal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Acute pulmonary oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Acute pulmonary oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Acute respiratory failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Acute respiratory failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Apnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Apnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,7,Aspiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Aspiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Atelectasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,4,222,NA,4,Atelectasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Bronchospasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Bronchospasm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Cheyne-Stokes respiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cheyne-Stokes respiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Choking,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Choking,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Chronic obstructive pulmonary disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Chronic obstructive pulmonary disease,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,9,434,NA,9,Cough,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cough,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Dry throat,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Dry throat,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,7,Dyspnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,8,222,NA,8,Dyspnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Dyspnoea exertional,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Dyspnoea exertional,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Emphysema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Emphysema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,17,434,NA,18,Epistaxis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Epistaxis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Haemoptysis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Haemoptysis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Hiccups,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Hiccups,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Hypoventilation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hypoventilation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,7,434,NA,7,Hypoxia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Hypoxia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Increased bronchial secretion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Increased bronchial secretion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Increased viscosity of bronchial secretion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Increased viscosity of bronchial secretion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Lung infiltration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Lung infiltration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Nasal congestion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Nasal congestion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Nasal dryness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Nasal dryness,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Nocturnal dyspnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Nocturnal dyspnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Pharyngolaryngeal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Pharyngolaryngeal pain,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Pleural effusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,4,222,NA,4,Pleural effusion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,13,434,NA,16,Pneumonia aspiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,10,222,NA,10,Pneumonia aspiration,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Pneumothorax,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pneumothorax,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Productive cough,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Productive cough,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Pulmonary congestion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pulmonary congestion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Pulmonary embolism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pulmonary embolism,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Pulmonary hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pulmonary hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,21,434,NA,22,Pulmonary oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Pulmonary oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Rales,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Rales,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Respiratory alkalosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Respiratory alkalosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Respiratory disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Respiratory disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Respiratory distress,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Respiratory distress,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,10,434,NA,10,Respiratory failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Respiratory failure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Respiratory tract congestion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,4,222,NA,4,Respiratory tract congestion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Rhonchi,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,3,Rhonchi,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Sleep apnoea syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Sleep apnoea syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,9,Tachypnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Tachypnoea,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Tracheal oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Tracheal oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Upper airway resistance syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Upper airway resistance syndrome,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Upper respiratory tract congestion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Upper respiratory tract congestion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Vocal cord cyst,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Vocal cord cyst,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,8,434,NA,8,Wheezing,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Wheezing,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Angioneurotic oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Angioneurotic oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Blister,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Blister,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,7,Decubitus ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,4,222,NA,4,Decubitus ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Dermatitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Dermatitis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,3,Dermatitis allergic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Dermatitis allergic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Dermatitis contact,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Dermatitis contact,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Dry skin,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Dry skin,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,6,Ecchymosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,6,222,NA,9,Ecchymosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,6,Erythema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,3,Erythema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Hyperhidrosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Hyperhidrosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Melanosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Melanosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Periorbital oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Periorbital oedema,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Petechiae,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Petechiae,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Pruritus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Pruritus,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Pruritus generalised,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Pruritus generalised,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Psoriasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Psoriasis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,17,434,NA,17,Rash,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,8,222,NA,8,Rash,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,2,Rash erythematous,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Rash erythematous,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Rash generalised,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Rash generalised,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Rash pruritic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Rash pruritic,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,6,434,NA,7,Skin disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,4,Skin disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Skin haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,3,222,NA,3,Skin haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Skin irritation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Skin irritation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Skin ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Skin ulcer,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Swelling face,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Swelling face,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,4,434,NA,4,Urticaria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Urticaria,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Drug abuser,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Drug abuser,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Inadequate diet,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Inadequate diet,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Atrial septal defect repair,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Atrial septal defect repair,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cardiac pacemaker insertion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cardiac pacemaker insertion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Carotid endarterectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,2,222,NA,2,Carotid endarterectomy,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Cataract operation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cataract operation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Cerebral oedema management,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Cerebral oedema management,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Cranioplasty,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Cranioplasty,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Gastrointestinal tube removal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Gastrointestinal tube removal,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Gastrostomy tube insertion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Gastrostomy tube insertion,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,High frequency ablation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,High frequency ablation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Knee arthroplasty,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Knee arthroplasty,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Mitral valve replacement,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Mitral valve replacement,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Peripheral nerve decompression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Peripheral nerve decompression,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Skin neoplasm excision,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Skin neoplasm excision,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Surgery,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Surgery,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Toe amputation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Toe amputation,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Accelerated hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Accelerated hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Aortic aneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Aortic aneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Aortic arteriosclerosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Aortic arteriosclerosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Artery dissection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Artery dissection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,11,434,NA,11,Deep vein thrombosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Deep vein thrombosis,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Femoral artery dissection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Femoral artery dissection,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,14,434,NA,16,Haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,5,222,NA,6,Haematoma,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,5,434,NA,5,Haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Haemorrhage,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Haemorrhagic infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Haemorrhagic infarction,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,30,434,NA,32,Hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,16,222,NA,16,Hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,34,434,NA,34,Hypotension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,23,222,NA,23,Hypotension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Labile blood pressure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Labile blood pressure,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Labile hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Labile hypertension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,2,434,NA,2,Orthostatic hypotension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Orthostatic hypotension,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Peripheral artery aneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Peripheral artery aneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Peripheral ischaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Peripheral ischaemia,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Peripheral vascular disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Peripheral vascular disorder,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,3,434,NA,3,Thrombophlebitis superficial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Thrombophlebitis superficial,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Vascular pseudoaneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Vascular pseudoaneurysm,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,1,434,NA,1,Vascular rupture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,0,222,NA,0,Vascular rupture,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG000,NA,other,NA,NA,0,434,NA,0,Venous thrombosis limb,0,MedDRA 10.X,Systematic Assessment
NCT00359424,EG001,NA,other,NA,NA,1,222,NA,1,Venous thrombosis limb,0,MedDRA 10.X,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Anaemias NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Anaemias NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Lymphatic system disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Lymphatic system disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",6,Thrombocytopenias,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Thrombocytopenias,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Ischaemic coronary artery disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Ischaemic coronary artery disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Pericardial disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Pericardial disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Supraventricular arrhythmias,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Supraventricular arrhythmias,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Inner ear signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Inner ear signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Tympanic membrane disorders (excl infections),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Tympanic membrane disorders (excl infections),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Thyroid disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Thyroid disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Thyroid hyperfunction disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Thyroid hyperfunction disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Glaucomas (excl congenital),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Glaucomas (excl congenital),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,"Retinal structural change, deposit and degeneration",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,"Retinal structural change, deposit and degeneration",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Abdominal findings abnormal,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Abdominal findings abnormal,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,"Abdominal hernias, site unspecified",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,4,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",4,"Abdominal hernias, site unspecified",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Acute and chronic pancreatitis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Acute and chronic pancreatitis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Diarrhoea (excl infective),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Diarrhoea (excl infective),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Duodenal and small intestinal stenosis and obstruction,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Duodenal and small intestinal stenosis and obstruction,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Dyspeptic signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Dyspeptic signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Gastric and oesophageal haemorrhages,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Gastric and oesophageal haemorrhages,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Gastritis (excl infective),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Gastritis (excl infective),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,11,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",13,Gastrointestinal and abdominal pains (excl oral and throat),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,4,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",4,Gastrointestinal and abdominal pains (excl oral and throat),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Gastrointestinal atonic and hypomotility disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Gastrointestinal atonic and hypomotility disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Gastrointestinal inflammatory disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Gastrointestinal inflammatory disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Gastrointestinal necrosis and gangrene (excl gangrenous hernia),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Gastrointestinal necrosis and gangrene (excl gangrenous hernia),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,14,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",15,Gastrointestinal stenosis and obstruction NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,12,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",17,Gastrointestinal stenosis and obstruction NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Large intestinal stenosis and obstruction,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Large intestinal stenosis and obstruction,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",5,Nausea and vomiting symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,4,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",5,Nausea and vomiting symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Non-site specific gastrointestinal haemorrhages,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Non-site specific gastrointestinal haemorrhages,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,18,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",22,Peritoneal and retroperitoneal disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,6,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",6,Peritoneal and retroperitoneal disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Peritoneal and retroperitoneal fibrosis and adhesions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Peritoneal and retroperitoneal fibrosis and adhesions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Device issues NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Device issues NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Febrile disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,2,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Febrile disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,General signs and symptoms NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,General signs and symptoms NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Hernias NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,2,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Hernias NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Injection site reactions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Injection site reactions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Oedema NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Oedema NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Pain and discomfort NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Pain and discomfort NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Therapeutic and nontherapeutic responses,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Therapeutic and nontherapeutic responses,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Cholecystitis and cholelithiasis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Cholecystitis and cholelithiasis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Cholestasis and jaundice,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Cholestasis and jaundice,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Gallbladder disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Gallbladder disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Allergic conditions NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Allergic conditions NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Abdominal and gastrointestinal infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,2,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Abdominal and gastrointestinal infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Aspergillus infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Aspergillus infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Bacterial infections NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Bacterial infections NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Dental and oral soft tissue infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Dental and oral soft tissue infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Ear infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Ear infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Herpes viral infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,2,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Herpes viral infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Influenza viral infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Influenza viral infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Lower respiratory tract and lung infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Lower respiratory tract and lung infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,"Sepsis, bacteraemia, viraemia and fungaemia NEC",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,"Sepsis, bacteraemia, viraemia and fungaemia NEC",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Streptococcal infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,3,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",4,Streptococcal infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Upper respiratory tract infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Upper respiratory tract infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Urinary tract infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Urinary tract infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Vascular infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Vascular infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Abdominal injuries NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Abdominal injuries NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Lower limb fractures and dislocations,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Lower limb fractures and dislocations,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Non-site specific injuries NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Non-site specific injuries NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,7,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",8,Non-site specific procedural complications,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Non-site specific procedural complications,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Pelvic fractures and dislocations,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Pelvic fractures and dislocations,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Spinal fractures and dislocations,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,2,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Spinal fractures and dislocations,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Upper limb fractures and dislocations,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Upper limb fractures and dislocations,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Digestive enzymes,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Digestive enzymes,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",5,Liver function analyses,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Liver function analyses,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Renal function analyses,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Renal function analyses,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Skeletal and cardiac muscle analyses,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Skeletal and cardiac muscle analyses,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Tissue enzyme analyses NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Tissue enzyme analyses NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Appetite disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Appetite disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Diabetes mellitus (incl subtypes),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Diabetes mellitus (incl subtypes),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Bone related signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Bone related signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Intervertebral disc disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Intervertebral disc disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Joint related signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Joint related signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Metabolic bone disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Metabolic bone disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Musculoskeletal and connective tissue pain and discomfort,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Musculoskeletal and connective tissue pain and discomfort,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Osteoarthropathies,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Osteoarthropathies,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Soft tissue disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Soft tissue disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Spine and neck deformities,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Spine and neck deformities,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Bone neoplasms benign (excl cysts),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Bone neoplasms benign (excl cysts),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Endocrine neoplasms malignant and unspecified NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Endocrine neoplasms malignant and unspecified NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Gastrointestinal neoplasms malignant NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Gastrointestinal neoplasms malignant NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,14,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",16,Metastases to specified sites,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,13,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",13,Metastases to specified sites,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Neoplasms malignant site unspecified NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Neoplasms malignant site unspecified NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Neoplasms unspecified malignancy and site unspecified NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Neoplasms unspecified malignancy and site unspecified NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Nervous system neoplasms unspecified malignancy NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Nervous system neoplasms unspecified malignancy NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Non-small cell neoplasms malignant of the respiratory tract cell type specified,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Non-small cell neoplasms malignant of the respiratory tract cell type specified,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Oncologic complications and emergencies,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Oncologic complications and emergencies,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,61,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",80,Ovarian neoplasms malignant (excl germ cell),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,41,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",46,Ovarian neoplasms malignant (excl germ cell),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Rectal neoplasms malignant,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Rectal neoplasms malignant,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Skin neoplasms malignant and unspecified (excl melanoma),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Skin neoplasms malignant and unspecified (excl melanoma),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Vaginal neoplasms malignant,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Vaginal neoplasms malignant,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Central nervous system haemorrhages and cerebrovascular accidents,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Central nervous system haemorrhages and cerebrovascular accidents,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Disturbances in consciousness NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Disturbances in consciousness NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Neurological signs and symptoms NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Neurological signs and symptoms NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Peripheral neuropathies NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Peripheral neuropathies NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Seizures and seizure disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Seizures and seizure disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Speech and language abnormalities,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Speech and language abnormalities,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Transient cerebrovascular events,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Transient cerebrovascular events,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Anxiety symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Anxiety symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Depressive disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Depressive disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Renal failure and impairment,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Renal failure and impairment,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Renal obstructive disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Renal obstructive disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Ureteric disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Ureteric disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Breast disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Breast disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Pelvic prolapse conditions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Pelvic prolapse conditions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Uterine disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Uterine disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Breathing abnormalities,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Breathing abnormalities,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,7,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",9,Pneumothorax and pleural effusions NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,5,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",5,Pneumothorax and pleural effusions NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",3,Pulmonary thrombotic and embolic conditions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Pulmonary thrombotic and embolic conditions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Connective tissue disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Connective tissue disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Dermal and epidermal conditions NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Dermal and epidermal conditions NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Dermatitis and eczema,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Dermatitis and eczema,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Accelerated and malignant hypertension,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Accelerated and malignant hypertension,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,1,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Aortic embolism and thrombosis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Aortic embolism and thrombosis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,3,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",6,Lymphangiopathies,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Lymphangiopathies,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Lymphoedemas,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Lymphoedemas,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,2,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2,Non-site specific embolism and thrombosis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,0,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Non-site specific embolism and thrombosis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,serious,NA,NA,0,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",0,Peripheral embolism and thrombosis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,serious,NA,NA,1,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",1,Peripheral embolism and thrombosis,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,98,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",177,Diarrhoea (excl infective),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,41,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",64,Diarrhoea (excl infective),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,45,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",69,"Flatulence, bloating and distension",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,25,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",33,"Flatulence, bloating and distension",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,183,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",300,Gastrointestinal and abdominal pains (excl oral and throat),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,81,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",125,Gastrointestinal and abdominal pains (excl oral and throat),5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,82,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",115,Gastrointestinal atonic and hypomotility disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,38,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",54,Gastrointestinal atonic and hypomotility disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,130,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",325,Nausea and vomiting symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,64,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",138,Nausea and vomiting symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,191,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",431,Asthenic conditions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,89,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",240,Asthenic conditions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,67,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",111,Febrile disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,40,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",73,Febrile disorders,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,34,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",42,Feelings and sensations NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,14,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",25,Feelings and sensations NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,44,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",75,General signs and symptoms NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,19,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",25,General signs and symptoms NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,467,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",4906,Injection site reactions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,222,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",2352,Injection site reactions,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,61,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",82,Oedema NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,32,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",39,Oedema NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,37,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",44,Pain and discomfort NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,20,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",22,Pain and discomfort NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,43,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",49,Lower respiratory tract and lung infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,8,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",8,Lower respiratory tract and lung infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,142,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",242,Upper respiratory tract infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,70,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",124,Upper respiratory tract infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,80,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",114,Urinary tract infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,27,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",33,Urinary tract infections,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,33,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",46,Physical examination procedures,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,20,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",33,Physical examination procedures,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,41,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",59,Bone related signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,26,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",44,Bone related signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,134,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",263,Joint related signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,67,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",112,Joint related signs and symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,59,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",104,Muscle pains,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,35,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",59,Muscle pains,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,171,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",355,Musculoskeletal and connective tissue pain and discomfort,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,79,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",212,Musculoskeletal and connective tissue pain and discomfort,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,83,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",227,Headaches NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,38,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",86,Headaches NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,42,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",63,Neurological signs and symptoms NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,25,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",30,Neurological signs and symptoms NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,46,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",57,Peripheral neuropathies NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,25,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",28,Peripheral neuropathies NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,31,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",37,Disturbances in initiating and maintaining sleep,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,17,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",24,Disturbances in initiating and maintaining sleep,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,38,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",47,Bladder and urethral symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,25,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",30,Bladder and urethral symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,48,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",59,Breathing abnormalities,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,23,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",26,Breathing abnormalities,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,43,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",51,Coughing and associated symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,25,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",31,Coughing and associated symptoms,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,40,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",76,Erythemas,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,22,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",37,Erythemas,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,30,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",50,Pruritus NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,15,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",16,Pruritus NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,33,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",47,"Rashes, eruptions and exanthems NEC",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,19,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",23,"Rashes, eruptions and exanthems NEC",5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG000,4 years,other,NA,NA,49,592,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",62,Peripheral vascular disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00418574,EG001,4 years,other,NA,NA,26,294,"Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)",35,Peripheral vascular disorders NEC,5,MedDRA 13.1,Systematic Assessment
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Renal acute failure,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hyperkalaemia,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Abscess limb,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Pneumocystis jiroveci,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Adrenal insufficiency,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Hypokalaemia,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Oedema,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Fatigue,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Nausea,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypotension,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Renal impairment,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Myocardial infarction,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Pulmonary embolism,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,serious,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Uterine polyp,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,7,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",30,Nausea,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,9,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",29,Hypokalaemia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,4,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",8,Decreased apetite,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",3,Hyperkalaemia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Dehydratation,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypernatremia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypertriglyceridaemia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypocalcaemia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypomagnesaemia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hyponatraemia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,4,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",11,vomiting,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Diarrhoea,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Dry mouth,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Labyrinthitis,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Nasopharyngitis,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Parotitis,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Pneumonia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Sputum purulent,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Upper respiratory tract infection,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,6,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",14,Adrenal insuffisiency,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Steroid withdrawal syndrome,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypothyroidism,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,7,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",21,Fatigue,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,3,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",5,Pyrexia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",4,Oedema peripheral,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Oedema,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,pain,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,3,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",3,C-reactive protein increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",3,Blood creatinine increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Protein total decrased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Blood albumin decreased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Blood corticotrophin increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Blood cortisol increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Blood urea increased,5,MedDRA 15.0,NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,High density lipoprotein decreased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",NA,Alanine aminotransferase increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Blood pressure decreased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Blood thyroid stimulating hormone increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Cortisol free urine,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hepatic enzyme increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Laboratory test abnormal,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Low density lipoprotein increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Osteocalcin increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Proteinuria,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Transaminases increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,urine potassium increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,urine sodium increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Weight increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",3,Microalbuminuria,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Nocturia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Renal failure acute,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Haematuria,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Micturition frequency increased,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Pollakiuria,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Back pain,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Muscular weakness,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,osteoarthritis,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Pain in jaw,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,5,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",25,Headache,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Tremor,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Ageusia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Burning sensation,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Dizziness,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypersomnia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Memory impairment,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Somnolence,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypotension,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,2,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",2,Orthostatic hypotension,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Hypertension,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Alopecia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Pigmentation disorder,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Rash,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,3,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",4,Anaemia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Thrombocytopenia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Chest pain,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Cough,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Dyspnoea,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,oropharyngeal pain,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Rhinorrhoea,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Palpitations,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Endometrial hyperplasia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Endometrial hypertrophy,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Diplopia,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Depression,5,MedDRA (15.0),NA
NCT00422201,EG000,Adverse events were collected from enrollment to the end of the study ie up to 12 months.,other,NA,NA,1,17,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",1,Gynaecomastia,5,MedDRA (15.0),NA
NCT00457951,EG000,D1 to D90,serious,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Retroperitoneal haematoma,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,serious,NA,NA,0,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Retroperitoneal haematoma,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,serious,NA,NA,1,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Retroperitoneal haematoma,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,serious,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Upper gastrointestinal haemorrhage,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,serious,NA,NA,0,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Upper gastrointestinal haemorrhage,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,serious,NA,NA,1,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Upper gastrointestinal haemorrhage,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,serious,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Guillain-barre syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,serious,NA,NA,1,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Guillain-barre syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,serious,NA,NA,0,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Guillain-barre syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,serious,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,serious,NA,NA,1,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,serious,NA,NA,0,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,serious,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Acute respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,serious,NA,NA,1,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Acute respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,serious,NA,NA,0,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Acute respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,serious,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Chronic obstructive pulmonary disease,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,serious,NA,NA,1,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Chronic obstructive pulmonary disease,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,serious,NA,NA,0,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Chronic obstructive pulmonary disease,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,serious,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Cardiopulmonary failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,serious,NA,NA,1,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Cardiopulmonary failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,serious,NA,NA,0,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Cardiopulmonary failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,serious,NA,NA,1,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,serious,NA,NA,0,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,serious,NA,NA,0,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,other,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",0,ALT Increased,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,other,NA,NA,7,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",8,ALT Increased,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,other,NA,NA,26,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",33,ALT Increased,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,other,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",0,AST Increased,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,other,NA,NA,6,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",6,AST Increased,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,other,NA,NA,22,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",29,AST Increased,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,other,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Diarrhoea,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,other,NA,NA,3,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Diarrhoea,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,other,NA,NA,4,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Diarrhoea,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG000,D1 to D90,other,NA,NA,0,13,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Constipation,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG001,D1 to D90,other,NA,NA,1,65,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Constipation,5,MedDRA (Unspecified),Systematic Assessment
NCT00457951,EG002,D1 to D90,other,NA,NA,4,69,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",NA,Constipation,5,MedDRA (Unspecified),Systematic Assessment
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,0,168,NA,0,Anaemia,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,2,167,NA,2,Anaemia,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,39,168,NA,57,Cardiac failure,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,23,167,NA,32,Cardiac failure,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,6,168,NA,6,Pneumonia,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,4,167,NA,5,Pneumonia,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,4,168,NA,4,Lead Dislodgement,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,3,167,NA,3,Lead Dislodgement,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,1,168,NA,1,Dyspnoea,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,serious,NA,NA,2,167,NA,3,Dyspnoea,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,7,168,NA,10,Cardiac failure,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,3,167,NA,3,Cardiac failure,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,7,168,NA,9,Ventricular tachycardia,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,0,167,NA,0,Ventricular tachycardia,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,8,168,NA,9,Chest pain,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,3,167,NA,3,Chest pain,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,6,168,NA,8,Oedema peripheral,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,3,167,NA,4,Oedema peripheral,2,NA,NA
NCT00480077,EG000,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,19,168,NA,24,Dyspnoea,2,NA,NA
NCT00480077,EG001,mean follow up period (months): 14.9 +/- 5.4,other,NA,NA,11,167,NA,13,Dyspnoea,2,NA,NA
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Bradycardia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Constipation,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Intestinal perforation,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Rectal haemorrhage,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Oedema peripheral,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pyrexia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Serum sickness,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Cellulitis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Influenza,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Sepsis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Myalgia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Myositis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Myelodysplastic syndrome,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Renal failure acute,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,serious,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pulmonary embolism,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Anaemia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Febrile neutropenia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Neutropenia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pancytopenia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Thrombocytopenia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Arrhythmia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Tachycardia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Deafness,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Conjunctival haemorrhage,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Eye pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Scleral hyperaemia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Visual impairment,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Abdominal distension,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Abdominal pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Abdominal tenderness,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,10,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Diarrhoea,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Dry mouth,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Dysphagia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Haemorrhoidal haemorrhage,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Mouth haemorrhage,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Mouth ulceration,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,5,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Nausea,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Oral pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Rectal haemorrhage,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Toothache,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,4,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Vomiting,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Catheter site pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Chills,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Fatigue,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Injection site reaction,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Local swelling,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Non-cardiac chest pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Oedema,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Oedema peripheral,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,9,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pyrexia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Cytokine release syndrome,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Serum sickness,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Central line infection,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Epstein-Barr virus infection,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Folliculitis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Gastroenteritis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Lower respiratory tract infection,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Nasopharyngitis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Staphylococcal infection,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Upper respiratory tract infection,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Transfusion reaction,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Blood glucose increased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Blood lactate dehydrogenase increased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Blood phosphorus decreased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Blood potassium decreased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Blood sodium increased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Blood urine present,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hepatic enzyme increased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Liver function test abnormal,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Neutrophil count decreased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Platelet count decreased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Protein urine present,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Weight increased,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Anorexia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Decreased appetite,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hyperglycaemia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hypocalcaemia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,4,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hypokalaemia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hypomagnesaemia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hypophosphataemia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,5,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Arthralgia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Arthritis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Back pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Bone pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Flank pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Muscle spasms,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Musculoskeletal chest pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Musculoskeletal pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Myalgia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Neck pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pain in extremity,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pain in jaw,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Benign intracranial hypertension,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Dizziness,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Dysgeusia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,6,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Headache,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Lethargy,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Paraesthesia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Syncope,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Tremor,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Insomnia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Genital ulceration,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Menorrhagia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Menstrual disorder,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Sexual dysfunction,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Vaginal haemorrhage,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Cough,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Dyspnoea,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Dyspnoea exertional,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,4,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Epistaxis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hypoxia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Oropharyngeal pain,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Alopecia,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Dermatitis allergic,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Dry skin,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Ecchymosis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Eczema,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Erythema,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hyperhidrosis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pain of skin,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Petechiae,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pruritus,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Pruritus generalised,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Purpura,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,5,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Rash,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Rash erythematous,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Rash macular,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Rash maculo-papular,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Rash pruritic,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Skin chapped,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Skin exfoliation,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Skin lesion,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Stasis dermatitis,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Swelling face,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,1,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Cardiovascular insufficiency,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,2,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Flushing,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,3,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hypertension,0,MedDRA 12.0,Systematic Assessment
NCT00542828,EG000,Adverse events were collected for approximately 19 months (includes all events which presented after the start of treatment through the end of study).,other,NA,NA,4,14,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (""number of affected participants"") of both adverse event tables.",NA,Hypotension,0,MedDRA 12.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Disseminated Intravascular Coagulation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Disseminated Intravascular Coagulation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Anaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Anaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Febrile Neutropenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Febrile Neutropenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Hilar Lymphadenopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Hilar Lymphadenopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Iron Deficiency Anaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Iron Deficiency Anaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Lymphadenopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Lymphadenopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Neutropenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Neutropenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Pancytopenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Pancytopenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,9,703,NA,NA,Cardiac Failure,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,3,712,NA,NA,Cardiac Failure,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Angina Pectoris,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,7,712,NA,NA,Angina Pectoris,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,5,703,NA,NA,Myocardial Infarction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,3,712,NA,NA,Myocardial Infarction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,4,703,NA,NA,Atrial Fibrillation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Atrial Fibrillation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,3,703,NA,NA,Coronary Artery Disease,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Coronary Artery Disease,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Acute Myocardial Infarction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Acute Myocardial Infarction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cardiac Arrest,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Cardiac Arrest,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Cardiac Failure Congestive,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cardiac Failure Congestive,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cardio-Respiratory Arrest,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Cardio-Respiratory Arrest,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Acute Coronary Syndrome,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Acute Coronary Syndrome,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Angina Unstable,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Angina Unstable,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Atrial Flutter,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Atrial Flutter,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Bradycardia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Bradycardia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Cardiac Disorder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Cardiac Disorder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Cardiac Failure Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Cardiac Failure Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cardiac Failure Chronic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cardiac Failure Chronic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Diastolic Dysfunction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Diastolic Dysfunction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Hypertensive Cardiomyopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Hypertensive Cardiomyopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Mitral Valve Incompetence,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Mitral Valve Incompetence,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Prinzmetal Angina,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Prinzmetal Angina,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Sinus Bradycardia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Sinus Bradycardia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Ventricular Fibrillation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Ventricular Fibrillation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Congenital Aortic Valve Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Congenital Aortic Valve Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Phimosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Phimosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Vertigo,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Vertigo,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Hypothyroidism,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Hypothyroidism,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Cataract,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cataract,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Macular Hole,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Macular Hole,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Abdominal Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Abdominal Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Diarrhoea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Diarrhoea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Inguinal Hernia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Inguinal Hernia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Abdominal Hernia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Abdominal Hernia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Abdominal Pain Upper,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Abdominal Pain Upper,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Abdominal Wall Haematoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Abdominal Wall Haematoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Constipation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Constipation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Duodenitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Duodenitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Dyspepsia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Dyspepsia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Food Poisoning,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Food Poisoning,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Gastric Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Gastric Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Gastric Ulcer Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Gastric Ulcer Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Gastritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Gastritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Gastritis Haemorrhagic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Gastritis Haemorrhagic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Intestinal Obstruction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Intestinal Obstruction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Large Intestine Perforation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Large Intestine Perforation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Mallory-Weiss Syndrome,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Mallory-Weiss Syndrome,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Pancreatitis Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Pancreatitis Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Peptic Ulcer Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Peptic Ulcer Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Pneumatosis Intestinalis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Pneumatosis Intestinalis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Rectal Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Rectal Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Rectourethral Fistula,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Rectourethral Fistula,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Small Intestinal Obstruction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Small Intestinal Obstruction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Vomiting,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Vomiting,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,4,703,NA,NA,Oedema Peripheral,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Oedema Peripheral,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Death,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Death,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Pyrexia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Pyrexia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Asthenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Asthenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Chest Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Chest Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Device Dislocation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Device Dislocation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,General Physical Health Deterioration,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,General Physical Health Deterioration,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Granuloma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Granuloma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Hypothermia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Hypothermia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Impaired Healing,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Impaired Healing,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Malaise,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Malaise,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Medical Device Complication,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Medical Device Complication,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Multi-Organ Failure,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Multi-Organ Failure,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Non-Cardiac Chest Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Non-Cardiac Chest Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Bile Duct Stone,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Bile Duct Stone,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Cholecystitis Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Cholecystitis Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cholelithiasis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cholelithiasis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Hepatic Failure,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Hepatic Failure,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Hepatic Function Abnormal,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Hepatic Function Abnormal,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Liver Disorder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Liver Disorder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,7,703,NA,NA,Pneumonia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,5,712,NA,NA,Pneumonia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Urinary Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,3,712,NA,NA,Urinary Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Bronchopneumonia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Bronchopneumonia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Lower Respiratory Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Lower Respiratory Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Pyelonephritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Pyelonephritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Upper Respiratory Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Upper Respiratory Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Anal Abscess,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Anal Abscess,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Appendicitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Appendicitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Cellulitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cellulitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Chronic Sinusitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Chronic Sinusitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cystitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cystitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Diverticulitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Diverticulitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Lung Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Lung Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Parainfluenzae Virus Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Parainfluenzae Virus Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Pneumonia Bacterial,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Pneumonia Bacterial,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Pyelonephritis Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Pyelonephritis Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Respiratory Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Respiratory Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Scrotal Abscess,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Scrotal Abscess,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Septic Shock,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Septic Shock,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Sinusitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Sinusitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Staphylococcal Sepsis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Staphylococcal Sepsis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Tooth Abscess,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Tooth Abscess,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Urosepsis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Urosepsis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Wound Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Wound Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Chest Injury,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Chest Injury,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Rib Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Rib Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Subdural Haematoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Subdural Haematoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Cystitis Radiation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cystitis Radiation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Fall,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Fall,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Femur Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Femur Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Gastroenteritis Radiation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Gastroenteritis Radiation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Heat Illness,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Heat Illness,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Hip Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Hip Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Injury,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Injury,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Open Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Open Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Patella Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Patella Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Radiation Proctopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Radiation Proctopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Spinal Compression Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Spinal Compression Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Thoracic Vertebral Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Thoracic Vertebral Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Ulna Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Ulna Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Upper Limb Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Upper Limb Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Wrist Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Wrist Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Haemoglobin Decreased,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Haemoglobin Decreased,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,International Normalised Ratio Increased,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,International Normalised Ratio Increased,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Diabetes Mellitus,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Diabetes Mellitus,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Diabetic Foot,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Diabetic Foot,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Hyponatraemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Hyponatraemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Osteoarthritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Osteoarthritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Bone Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Bone Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Intervertebral Disc Protrusion,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Intervertebral Disc Protrusion,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Musculoskeletal Chest Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Musculoskeletal Chest Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Musculoskeletal Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Musculoskeletal Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Osteoporotic Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Osteoporotic Fracture,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Spinal Column Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Spinal Column Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Systemic Lupus Erythematosus,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Systemic Lupus Erythematosus,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Gastric Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,5,712,NA,NA,Gastric Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,4,703,NA,NA,Basal Cell Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Basal Cell Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Colon Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,3,712,NA,NA,Colon Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Rectal Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Rectal Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Benign Urinary Tract Neoplasm,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Benign Urinary Tract Neoplasm,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Bladder Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Bladder Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Bladder Transitional Cell Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Bladder Transitional Cell Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Bladder Transitional Cell Carcinoma Recurrent,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Bladder Transitional Cell Carcinoma Recurrent,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Colorectal Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Colorectal Cancer,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Gastrointestinal Tract Adenoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Gastrointestinal Tract Adenoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Glioblastoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Glioblastoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Hepatic Neoplasm Malignant,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Hepatic Neoplasm Malignant,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Lung Neoplasm Malignant,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Lung Neoplasm Malignant,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Malignant Melanoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Malignant Melanoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Myelodysplastic Syndrome,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Myelodysplastic Syndrome,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Neuroendocrine Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Neuroendocrine Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Pancreatic Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Pancreatic Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Pancreatic Carcinoma Metastatic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Pancreatic Carcinoma Metastatic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Porocarcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Porocarcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Renal Neoplasm,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Renal Neoplasm,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Small Cell Lung Cancer Stage Unspecified,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Small Cell Lung Cancer Stage Unspecified,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Transitional Cell Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Transitional Cell Carcinoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Cerebrovascular Accident,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cerebrovascular Accident,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Dizziness,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Dizziness,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Ischaemic Stroke,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Ischaemic Stroke,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Syncope,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Syncope,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Transient Ischaemic Attack,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Transient Ischaemic Attack,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Brain Stem Stroke,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Brain Stem Stroke,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cerebellar Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cerebellar Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Cerebral Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Cerebral Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cerebral Infarction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cerebral Infarction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Cerebral Ischaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cerebral Ischaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cerebrovascular Disorder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cerebrovascular Disorder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Cerebrovascular Insufficiency,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Cerebrovascular Insufficiency,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Leukoencephalopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Leukoencephalopathy,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Parkinsonism,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Parkinsonism,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Subarachnoid Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Subarachnoid Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Completed Suicide,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Completed Suicide,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Delirium,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Delirium,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Suicidal Ideation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Suicidal Ideation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Hydronephrosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,7,712,NA,NA,Hydronephrosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,5,703,NA,NA,Renal Failure Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Renal Failure Acute,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,3,703,NA,NA,Calculus Ureteric,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Calculus Ureteric,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Renal Failure,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,3,712,NA,NA,Renal Failure,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Urinary Tract Obstruction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,3,712,NA,NA,Urinary Tract Obstruction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Haematuria,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,2,712,NA,NA,Haematuria,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Renal Impairment,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Renal Impairment,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Urinary Retention,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Urinary Retention,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Azotaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Azotaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Bladder Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Bladder Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Calculus Bladder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Calculus Bladder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Calculus Urinary,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Calculus Urinary,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Cystitis Haemorrhagic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Cystitis Haemorrhagic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Renal Disorder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Renal Disorder,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Urethral Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Urethral Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Benign Prostatic Hyperplasia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Benign Prostatic Hyperplasia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Calculus Prostatic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Calculus Prostatic,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Pelvic Haematoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Pelvic Haematoma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Prostatic Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Prostatic Haemorrhage,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,3,703,NA,NA,Pulmonary Embolism,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,4,712,NA,NA,Pulmonary Embolism,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,3,703,NA,NA,Chronic Obstructive Pulmonary Disease,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Chronic Obstructive Pulmonary Disease,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,3,703,NA,NA,Dyspnoea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Dyspnoea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Emphysema,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Emphysema,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Pleural Effusion,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Pleural Effusion,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Asthma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Asthma,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Epistaxis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Epistaxis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Lung Consolidation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Lung Consolidation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Pneumonia Aspiration,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Pneumonia Aspiration,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Pneumothorax,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Pneumothorax,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Pulmonary Hypertension,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Pulmonary Hypertension,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Pulmonary Infarction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Pulmonary Infarction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Sleep Apnoea Syndrome,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Sleep Apnoea Syndrome,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Angioedema,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Angioedema,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Peau D'orange,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Peau D'orange,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,2,703,NA,NA,Deep Vein Thrombosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,3,712,NA,NA,Deep Vein Thrombosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Aortic Aneurysm,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Aortic Aneurysm,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Arterial Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Arterial Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Arteritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Arteritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,1,703,NA,NA,Femoral Arterial Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,0,712,NA,NA,Femoral Arterial Stenosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Iliac Artery Occlusion,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Iliac Artery Occlusion,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Intermittent Claudication,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Intermittent Claudication,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Temporal Arteritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Temporal Arteritis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,Thrombosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,Thrombosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,serious,NA,NA,0,703,NA,NA,twqVenous Thrombosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,serious,NA,NA,1,712,NA,NA,twqVenous Thrombosis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,46,703,NA,NA,Anaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,23,712,NA,NA,Anaemia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,64,703,NA,NA,Constipation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,76,712,NA,NA,Constipation,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,46,703,NA,NA,Diarrhoea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,63,712,NA,NA,Diarrhoea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,59,703,NA,NA,Nausea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,61,712,NA,NA,Nausea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,268,703,NA,NA,Oedema Peripheral,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,88,712,NA,NA,Oedema Peripheral,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,71,703,NA,NA,Fatigue,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,79,712,NA,NA,Fatigue,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,35,703,NA,NA,Asthenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,43,712,NA,NA,Asthenia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,56,703,NA,NA,Rhinitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,17,712,NA,NA,Rhinitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,43,703,NA,NA,Urinary Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,54,712,NA,NA,Urinary Tract Infection,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,34,703,NA,NA,Nasopharyngitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,45,712,NA,NA,Nasopharyngitis,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,40,703,NA,NA,Decreased Appetite,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,33,712,NA,NA,Decreased Appetite,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,40,703,NA,NA,Arthralgia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,54,712,NA,NA,Arthralgia,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,33,703,NA,NA,Back Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,49,712,NA,NA,Back Pain,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,188,703,NA,NA,Headache,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,82,712,NA,NA,Headache,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,46,703,NA,NA,Dizziness,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,39,712,NA,NA,Dizziness,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,23,703,NA,NA,Haematuria,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,36,712,NA,NA,Haematuria,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,176,703,NA,NA,Nasal Congestion,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,39,712,NA,NA,Nasal Congestion,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,49,703,NA,NA,Dyspnoea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,33,712,NA,NA,Dyspnoea,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,48,703,NA,NA,Nasal Obstruction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,4,712,NA,NA,Nasal Obstruction,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG000,NA,other,NA,NA,36,703,NA,NA,Cough,5,MedDRA 14.0,Systematic Assessment
NCT00626548,EG001,NA,other,NA,NA,34,712,NA,NA,Cough,5,MedDRA 14.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Anaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Anaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Anaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Anaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Iron deficiency anaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Iron deficiency anaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Iron deficiency anaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Iron deficiency anaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Acute left ventricular failure,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute left ventricular failure,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute left ventricular failure,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute left ventricular failure,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute myocardial infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute myocardial infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Acute myocardial infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute myocardial infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Adams-Stokes syndrome,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Adams-Stokes syndrome,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Adams-Stokes syndrome,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Adams-Stokes syndrome,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Angina pectoris,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Angina pectoris,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Angina pectoris,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Angina pectoris,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Atrial fibrillation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Atrial fibrillation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Atrial fibrillation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Atrial fibrillation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bradycardia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bradycardia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Bradycardia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bradycardia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Cardiac failure congestive,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cardiac failure congestive,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cardiac failure congestive,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cardiac failure congestive,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Coronary artery disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Coronary artery disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Coronary artery disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Coronary artery disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Myocardial infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Myocardial infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Myocardial infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Myocardial infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cataract,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Cataract,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cataract,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cataract,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Abdominal pain,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Abdominal pain,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Abdominal pain,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Abdominal pain,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Diarrhoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Diarrhoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Diarrhoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Diarrhoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Faecal incontinence,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Faecal incontinence,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Faecal incontinence,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Faecal incontinence,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Gastritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Gastritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Gastritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Gastritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intestinal ischaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intestinal ischaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Intestinal ischaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intestinal ischaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Nausea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Nausea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Nausea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Nausea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Vomiting,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Vomiting,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Vomiting,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Vomiting,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Death,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Death,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Death,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Death,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,General physical health deterioration,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,General physical health deterioration,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,General physical health deterioration,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,General physical health deterioration,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Granuloma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Granuloma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Granuloma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Granuloma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Anal abscess,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Anal abscess,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Anal abscess,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Anal abscess,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Appendicitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Appendicitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Appendicitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Appendicitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bacteraemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bacteraemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Bacteraemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bacteraemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bronchopneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Bronchopneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bronchopneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Bronchopneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Clostridium difficile colitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Clostridium difficile colitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Clostridium difficile colitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Clostridium difficile colitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Escherichia bacteraemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Escherichia bacteraemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Escherichia bacteraemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Escherichia bacteraemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Herpes zoster oticus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Herpes zoster oticus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Herpes zoster oticus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Herpes zoster oticus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Lower respiratory tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Lower respiratory tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Lower respiratory tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Lower respiratory tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Meningitis viral,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Meningitis viral,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Meningitis viral,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Meningitis viral,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Otitis media,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Otitis media,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Otitis media,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Otitis media,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Periorbital cellulitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Periorbital cellulitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Periorbital cellulitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Periorbital cellulitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Pneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Pyelonephritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pyelonephritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pyelonephritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pyelonephritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Respiratory tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Respiratory tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Respiratory tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Respiratory tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Sepsis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Sepsis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Sepsis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Sepsis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urinary tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Urinary tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urinary tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urinary tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urosepsis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urosepsis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Urosepsis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urosepsis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Clavicle fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Clavicle fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Clavicle fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Clavicle fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Fall,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Fall,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Fall,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Fall,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Femoral neck fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Femoral neck fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Femoral neck fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Femoral neck fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Femur fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Femur fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Femur fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Femur fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Heat illness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Heat illness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Heat illness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Heat illness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hip fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hip fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hip fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hip fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Humerus fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Humerus fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Humerus fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Humerus fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Jaw fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Jaw fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Jaw fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Jaw fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Joint dislocation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Joint dislocation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Joint dislocation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Joint dislocation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,2,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Multiple injuries,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Multiple injuries,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Multiple injuries,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Multiple injuries,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Overdose,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Overdose,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Overdose,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Overdose,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Radius fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Radius fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Radius fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Radius fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Rib fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Rib fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Rib fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Rib fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Skull fractured base,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Skull fractured base,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Skull fractured base,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Skull fractured base,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Spinal compression fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Spinal compression fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Spinal compression fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Spinal compression fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Spinal fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Spinal fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Spinal fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Spinal fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subdural haematoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Subdural haematoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Subdural haematoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subdural haematoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Subdural haemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subdural haemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Subdural haemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subdural haemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Tendon rupture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Tendon rupture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Tendon rupture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Tendon rupture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Upper limb fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Upper limb fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Upper limb fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Upper limb fracture,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,ECG signs of myocardial ischaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,ECG signs of myocardial ischaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,ECG signs of myocardial ischaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,ECG signs of myocardial ischaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Liver function test abnormal,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Liver function test abnormal,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Liver function test abnormal,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Liver function test abnormal,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Weight decreased,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Weight decreased,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Weight decreased,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Weight decreased,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Decreased appetite,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Decreased appetite,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Decreased appetite,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Decreased appetite,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dehydration,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dehydration,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Dehydration,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dehydration,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypokalaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hypokalaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypokalaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypokalaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Intervertebral disc protrusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intervertebral disc protrusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intervertebral disc protrusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intervertebral disc protrusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Osteoarthritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Osteoarthritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Osteoarthritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Osteoarthritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pain in extremity,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Pain in extremity,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pain in extremity,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pain in extremity,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Spinal osteoarthritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Spinal osteoarthritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Spinal osteoarthritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Spinal osteoarthritis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute myeloid leukaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Acute myeloid leukaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute myeloid leukaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Acute myeloid leukaemia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Adenocarcinoma pancreas,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Adenocarcinoma pancreas,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Adenocarcinoma pancreas,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Adenocarcinoma pancreas,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Basal cell carcinoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Basal cell carcinoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Basal cell carcinoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Basal cell carcinoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Breast cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Breast cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Breast cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Breast cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Colorectal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Colorectal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",4,Colorectal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Colorectal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Gastric cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Gastric cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Gastric cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Gastric cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Glioblastoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Glioblastoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Glioblastoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Glioblastoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Keratoacanthoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Keratoacanthoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Keratoacanthoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Keratoacanthoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Lung neoplasm malignant,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Lung neoplasm malignant,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Lung neoplasm malignant,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Lung neoplasm malignant,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Malignant melanoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Malignant melanoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Malignant melanoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Malignant melanoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to central nervous system,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to central nervous system,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Metastases to central nervous system,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to central nervous system,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to liver,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to liver,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Metastases to liver,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to liver,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to lung,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to lung,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Metastases to lung,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Metastases to lung,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Prostate cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Prostate cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Prostate cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Prostate cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Rectal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Rectal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Rectal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Rectal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Renal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Renal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Renal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Renal cancer,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Squamous cell carcinoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Squamous cell carcinoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Squamous cell carcinoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Squamous cell carcinoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aphasia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Aphasia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aphasia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aphasia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Cerebral infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cerebral infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cerebral infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cerebral infarction,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cerebral microhaemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Cerebral microhaemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cerebral microhaemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Cerebral microhaemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Cerebrovascular accident,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cerebrovascular accident,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cerebrovascular accident,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Cerebrovascular accident,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Convulsion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Convulsion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Convulsion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Convulsion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dementia Alzheimer's type,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dementia Alzheimer's type,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dementia Alzheimer's type,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dementia Alzheimer's type,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Dizziness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Dizziness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dizziness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dizziness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Epilepsy,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Epilepsy,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Epilepsy,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Epilepsy,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,2,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intracranial hypotension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intracranial hypotension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Intracranial hypotension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Intracranial hypotension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Ischaemic stroke,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Ischaemic stroke,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Ischaemic stroke,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Ischaemic stroke,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Loss of consciousness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Loss of consciousness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Loss of consciousness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Loss of consciousness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Perineurial cyst,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Perineurial cyst,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Perineurial cyst,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Perineurial cyst,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Presyncope,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Presyncope,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Presyncope,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Presyncope,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Quadriparesis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Quadriparesis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Quadriparesis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Quadriparesis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Radiculopathy,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Radiculopathy,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Radiculopathy,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Radiculopathy,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Senile dementia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Senile dementia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Senile dementia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Senile dementia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Status epilepticus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Status epilepticus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Status epilepticus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Status epilepticus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Subarachnoid haemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subarachnoid haemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subarachnoid haemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subarachnoid haemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subdural hygroma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subdural hygroma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Subdural hygroma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Subdural hygroma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Syncope,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Syncope,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Syncope,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Syncope,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,6,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",8,Vasogenic cerebral oedema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,12,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",20,Vasogenic cerebral oedema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Vasogenic cerebral oedema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",7,Vasogenic cerebral oedema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Abnormal behaviour,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Abnormal behaviour,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Abnormal behaviour,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Abnormal behaviour,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aggression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aggression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Aggression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aggression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Agitation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Agitation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Agitation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Agitation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Alcohol abuse,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Alcohol abuse,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Alcohol abuse,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Alcohol abuse,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Alcoholic psychosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Alcoholic psychosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Alcoholic psychosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Alcoholic psychosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Confusional state,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Confusional state,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Confusional state,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Confusional state,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Delirium,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Delirium,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Delirium,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Delirium,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Depression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Depression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Depression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Depression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hallucination,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hallucination,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hallucination,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hallucination,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Impulsive behaviour,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Impulsive behaviour,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Impulsive behaviour,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Impulsive behaviour,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Jealous delusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Jealous delusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Jealous delusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Jealous delusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Suicide attempt,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Suicide attempt,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Suicide attempt,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Suicide attempt,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Renal failure acute,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Renal failure acute,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Renal failure acute,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Renal failure acute,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Prostatitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Prostatitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Prostatitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Prostatitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Asthma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Asthma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Asthma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Asthma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Chronic obstructive pulmonary disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Chronic obstructive pulmonary disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Chronic obstructive pulmonary disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Chronic obstructive pulmonary disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dyspnoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Dyspnoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dyspnoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dyspnoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Nasal polyps,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Nasal polyps,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Nasal polyps,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Nasal polyps,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Organising pneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Organising pneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Organising pneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Organising pneumonia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Pneumothorax,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pneumothorax,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pneumothorax,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pneumothorax,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pulmonary embolism,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Pulmonary embolism,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pulmonary embolism,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pulmonary embolism,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Erythema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Erythema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",5,Erythema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Erythema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pruritus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pruritus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",4,Pruritus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Pruritus,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Urticaria,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urticaria,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urticaria,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urticaria,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aortic stenosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aortic stenosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Aortic stenosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aortic stenosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aortic thrombosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aortic thrombosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Aortic thrombosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Aortic thrombosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Deep vein thrombosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Deep vein thrombosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Deep vein thrombosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Deep vein thrombosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,serious,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Peripheral artery stenosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,serious,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Peripheral artery stenosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,serious,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Peripheral artery stenosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Peripheral artery stenosis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Tachycardia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Tachycardia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Tachycardia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Tachycardia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypoacusis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypoacusis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypoacusis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hypoacusis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Vision blurred,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",4,Vision blurred,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Vision blurred,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Vision blurred,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,6,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",16,Constipation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,6,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",6,Constipation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,9,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",10,Constipation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Constipation,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,8,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",8,Diarrhoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,7,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",7,Diarrhoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,11,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",15,Diarrhoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Diarrhoea,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,9,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",11,Vomiting,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,9,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",11,Vomiting,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,10,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",12,Vomiting,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,3,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Vomiting,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Catheter site haematoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Catheter site haematoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Catheter site haematoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Catheter site haematoma,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,17,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",23,Nasopharyngitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,18,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",24,Nasopharyngitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,28,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",44,Nasopharyngitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Nasopharyngitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,5,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",16,Sinusitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,3,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Sinusitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,3,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",5,Sinusitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",12,Sinusitis,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,15,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",17,Urinary tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,13,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",17,Urinary tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,9,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",13,Urinary tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Urinary tract infection,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,6,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",7,Contusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,8,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",10,Contusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Contusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Contusion,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,18,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",25,Fall,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,16,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",18,Fall,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,18,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",26,Fall,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Fall,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,5,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",5,Blood pressure increased,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,5,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",9,Blood pressure increased,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,6,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",7,Blood pressure increased,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Blood pressure increased,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypophagia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypophagia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypophagia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",4,Hypophagia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,6,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",15,Arthralgia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,5,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",17,Arthralgia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,6,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",9,Arthralgia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",5,Arthralgia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Musculoskeletal stiffness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Musculoskeletal stiffness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Musculoskeletal stiffness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Musculoskeletal stiffness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Aphasia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,2,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",4,Aphasia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",6,Aphasia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Aphasia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,2,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Ataxia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Ataxia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Ataxia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Ataxia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Balance disorder,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Balance disorder,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Balance disorder,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Balance disorder,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,11,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",13,Cerebral microhaemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,22,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",41,Cerebral microhaemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,9,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",21,Cerebral microhaemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",9,Cerebral microhaemorrhage,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Disturbance in attention,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Disturbance in attention,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Disturbance in attention,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Disturbance in attention,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,8,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",8,Dizziness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,7,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",20,Dizziness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,16,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",17,Dizziness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",5,Dizziness,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dizziness postural,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Dizziness postural,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,1,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Dizziness postural,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Dizziness postural,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Exertional headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Exertional headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Exertional headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Exertional headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,17,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",19,Headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,15,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",36,Headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,29,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",36,Headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",9,Headache,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hyporeflexia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hyporeflexia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hyporeflexia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hyporeflexia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Mental impairment,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Mental impairment,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Mental impairment,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",5,Mental impairment,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Paraesthesia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Paraesthesia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Paraesthesia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Paraesthesia,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Parkinson's disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Parkinson's disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Parkinson's disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",5,Parkinson's disease,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,7,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",16,Vasogenic cerebral oedema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,20,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",43,Vasogenic cerebral oedema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",7,Vasogenic cerebral oedema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Vasogenic cerebral oedema,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,4,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",4,Confusional state,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,3,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",5,Confusional state,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,6,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",6,Confusional state,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",3,Confusional state,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,13,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",25,Depression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,11,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",21,Depression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,9,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",24,Depression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",9,Depression,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,2,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Hallucination,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,2,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Hallucination,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,2,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Hallucination,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hallucination,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Psychotic disorder,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Psychotic disorder,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Psychotic disorder,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",2,Psychotic disorder,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,0,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Petechiae,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,0,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Petechiae,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Petechiae,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Petechiae,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,8,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",8,Hypertension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,10,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",12,Hypertension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,9,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",16,Hypertension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",9,Hypertension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG000,4 years,other,NA,NA,1,267,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hypotension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG001,4 years,other,NA,NA,1,263,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hypotension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG002,4 years,other,NA,NA,0,344,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",0,Hypotension,5,MedDRA 15.0,Systematic Assessment
NCT00667810,EG003,4 years,other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",1,Hypotension,5,MedDRA 15.0,Systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Anaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Anaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Bone marrow failure,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Bone marrow failure,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Leukocytosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Leukocytosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Acute myocardial infarction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Acute myocardial infarction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Angina pectoris,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Angina pectoris,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Angina unstable,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Angina unstable,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Atrial fibrillation,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Atrial fibrillation,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Atrioventricular block complete,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Atrioventricular block complete,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Atrioventricular block second degree,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Atrioventricular block second degree,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Bradycardia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Bradycardia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cardiac arrest,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cardiac arrest,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cardiovascular insufficiency,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cardiovascular insufficiency,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hypertensive heart disease,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Hypertensive heart disease,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Myocardial infarction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Myocardial infarction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Myocardial ischaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Myocardial ischaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Sinus bradycardia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Sinus bradycardia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Supraventricular tachycardia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Supraventricular tachycardia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Tachycardia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Tachycardia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cataract,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Cataract,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Vitreous haemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Vitreous haemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Abdominal pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Abdominal pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Abdominal pain upper,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Abdominal pain upper,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Anal haemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Anal haemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Colonic polyp,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Colonic polyp,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Diarrhoea,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Diarrhoea,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Duodenal ulcer perforation,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Duodenal ulcer perforation,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Gastric ulcer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Gastric ulcer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Gastrointestinal ulcer haemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Gastrointestinal ulcer haemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Haematemesis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Haematemesis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Ileus,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Ileus,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Inguinal hernia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Inguinal hernia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,"Inguinal hernia, obstructive",5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,"Inguinal hernia, obstructive",5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Intestinal obstruction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Intestinal obstruction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Nausea,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Nausea,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Oesophageal ulcer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Oesophageal ulcer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Pancreatitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pancreatitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Pancreatitis acute,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pancreatitis acute,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Vomiting,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Vomiting,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Chest discomfort,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Chest discomfort,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Chest pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Chest pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Device occlusion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Device occlusion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Fibrosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Fibrosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,General physical health deterioration,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,General physical health deterioration,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Malaise,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Malaise,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Non-cardiac chest pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Non-cardiac chest pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Pyrexia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Pyrexia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Bile duct stone,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Bile duct stone,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cholangitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cholangitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cholecystitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cholecystitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cholelithiasis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cholelithiasis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Gallbladder disorder,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Gallbladder disorder,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Hepatic function abnormal,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hepatic function abnormal,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Jaundice,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Jaundice,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Hypersensitivity,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hypersensitivity,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Abdominal abscess,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Abdominal abscess,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Abscess,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Abscess,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Appendicitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Appendicitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Bacterial Sepsis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Bacterial Sepsis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Bronchitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Bronchitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cellulitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cellulitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Gastroenteritis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Gastroenteritis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Herpes zoster,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Herpes zoster,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Infected skin ulcer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Infected skin ulcer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Kidney infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Kidney infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Lower respiratory tract infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Lower respiratory tract infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Meningitis cryptococcal,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Meningitis cryptococcal,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Osteomyelitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Osteomyelitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Paronychia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Paronychia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,3,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Pneumonia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,6,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",6,Pneumonia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pseudomembranous colitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Pseudomembranous colitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pyelonephritis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Pyelonephritis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,3,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",4,Sepsis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Sepsis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Toxic shock syndrome,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Toxic shock syndrome,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Urinary tract infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Urinary tract infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Urosepsis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Urosepsis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Vaginitis bacterial,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Vaginitis bacterial,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Viral upper respiratory tract infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Viral upper respiratory tract infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Accidental overdose,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Accidental overdose,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Ankle fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Ankle fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Contusion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Contusion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Drug administration error,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Drug administration error,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Excoriation,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Excoriation,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Eye injury,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Eye injury,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Fall,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Fall,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Femoral neck fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",5,Femoral neck fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Femur fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,3,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Femur fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Head injury,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Head injury,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",5,Hip fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hip fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Humerus fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Humerus fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Post lumbar puncture syndrome,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Post lumbar puncture syndrome,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Pubis fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pubis fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Radius fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Radius fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Rib fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Rib fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",7,Spinal compression fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Spinal compression fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Stab wound,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Stab wound,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Subdural haematoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Subdural haematoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Upper limb fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Upper limb fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",5,Wrist fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Wrist fracture,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Blood pressure increased,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Blood pressure increased,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Fibrin D dimer increased,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Fibrin D dimer increased,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Heart rate increased,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Heart rate increased,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Streptococcus test positive,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Streptococcus test positive,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Dehydration,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,3,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",4,Dehydration,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hypoglycaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Hypoglycaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Hypokalaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hypokalaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Hyponatraemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Hyponatraemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Arthralgia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Arthralgia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Arthritis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Arthritis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Back pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Back pain,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Intervertebral disc protrusion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Intervertebral disc protrusion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Lumbar spinal stenosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Lumbar spinal stenosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Osteoarthritis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Osteoarthritis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Polymyalgia rheumatica,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Polymyalgia rheumatica,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Rhabdomyolysis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Rhabdomyolysis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Spinal column stenosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Spinal column stenosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Adenocarcinoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Adenocarcinoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Basal cell carcinoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Basal cell carcinoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Bladder cancer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Bladder cancer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Breast cancer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Breast cancer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Breast neoplasm,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Breast neoplasm,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hepatic neoplasm,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Hepatic neoplasm,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Leiomyosarcoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Leiomyosarcoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Lentigo maligna,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Lentigo maligna,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Metastatic neoplasm,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Metastatic neoplasm,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Neoplasm prostate,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Neoplasm prostate,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Oesophageal carcinoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Oesophageal carcinoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,4,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",5,Prostate cancer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Prostate cancer,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,3,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Squamous cell carcinoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Squamous cell carcinoma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Amyotrophic lateral sclerosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",5,Amyotrophic lateral sclerosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Aphasia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Aphasia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Brain stem ischaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Brain stem ischaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cerebral haemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,3,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Cerebral haemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cerebral haemosiderin deposition,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cerebral haemosiderin deposition,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cerebral infarction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cerebral infarction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cerebral ischaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Cerebral ischaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cerebral microhaemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,4,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",4,Cerebral microhaemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Cerebrovascular accident,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Cerebrovascular accident,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Convulsion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,3,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Convulsion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Dizziness,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Dizziness,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Epilepsy,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Epilepsy,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Grand mal convulsion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Grand mal convulsion,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Haemorrhagic stroke,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Haemorrhagic stroke,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Hydrocephalus,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hydrocephalus,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Ischaemic stroke,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Ischaemic stroke,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",4,Lacunar infarction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Lacunar infarction,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Lethargy,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Lethargy,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Loss of consciousness,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Loss of consciousness,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Mental impairment,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Mental impairment,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Paraesthesia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Paraesthesia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Presyncope,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Presyncope,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Syncope,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,4,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",4,Syncope,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Transient ischaemic attack,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Transient ischaemic attack,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,4,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",5,Vasogenic cerebral oedema,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,40,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",61,Vasogenic cerebral oedema,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Visual field defect,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Visual field defect,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Abnormal behaviour,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Abnormal behaviour,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Aggression,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Aggression,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Agitation,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Agitation,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Completed suicide,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Completed suicide,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Confusional state,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,3,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Confusional state,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Delirium,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Delirium,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Depression,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Depression,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hallucination,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Hallucination,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Mental status changes,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,3,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Mental status changes,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Restlessness,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Restlessness,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Suicide attempt,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Suicide attempt,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Acute prerenal failure,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Acute prerenal failure,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Haematuria,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Haematuria,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Pollakiuria,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pollakiuria,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Renal failure acute,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,2,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Renal failure acute,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Benign prostatic hyperplasia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Benign prostatic hyperplasia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Breast mass,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Breast mass,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Rectocele,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Rectocele,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Asthma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Asthma,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Paranasal cyst,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Paranasal cyst,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Pneumonia aspiration,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pneumonia aspiration,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,2,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",2,Pulmonary embolism,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,3,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Pulmonary embolism,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Pulmonary oedema,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,3,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",3,Pulmonary oedema,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Respiratory failure,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Respiratory failure,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Social problem,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Social problem,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Thyroidectomy,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Thyroidectomy,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Arteriosclerosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,0,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Arteriosclerosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,1,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Deep vein thrombosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,5,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",5,Deep vein thrombosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Ischaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Ischaemia,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,serious,NA,NA,0,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",0,Peripheral artery stenosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,serious,NA,NA,1,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",1,Peripheral artery stenosis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,23,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",30,Diarrhoea,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,34,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",38,Diarrhoea,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,34,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",40,Nasopharyngitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,45,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",66,Nasopharyngitis,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,24,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",37,Urinary tract infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,30,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",34,Urinary tract infection,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,27,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",36,Fall,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,39,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",47,Fall,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,16,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",38,Cerebral microhaemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,76,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",218,Cerebral microhaemorrhage,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,23,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",32,Dizziness,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,20,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",26,Dizziness,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,44,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",98,Headache,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,45,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",66,Headache,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,5,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",5,Vasogenic cerebral oedema,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,74,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",123,Vasogenic cerebral oedema,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,26,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",29,Anxiety,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,30,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",61,Anxiety,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,27,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",73,Depression,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,35,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",95,Depression,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG000,4 years,other,NA,NA,22,439,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",50,Hypertension,5,MedDRA v15.0,Non-systematic Assessment
NCT00676143,EG001,4 years,other,NA,NA,18,654,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",48,Hypertension,5,MedDRA v15.0,Non-systematic Assessment
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,101,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,213,Worsening heart failure,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,93,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,181,Worsening heart failure,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,27,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,34,Atrial arrhythmia,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,25,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,35,Atrial arrhythmia,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,26,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,36,Ventricular arrhythmia,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,22,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,29,Ventricular arrhythmia,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,16,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,31,Chest pain,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,21,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,26,Chest pain,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,18,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,21,Other cardiovascular,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,17,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,20,Other cardiovascular,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,16,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,16,Dyspnea,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,11,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,12,Dyspnea,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,13,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,13,Coronary artery disease,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,10,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,11,Coronary artery disease,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,58,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,77,Infection,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,45,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,54,Infection,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,43,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,68,Gastrointestinal disorder,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,28,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,41,Gastrointestinal disorder,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,40,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,54,Other noncardiovascular,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,36,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,55,Other noncardiovascular,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,14,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,27,Respiratory disorder,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,22,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,38,Respiratory disorder,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,28,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,38,Renal disorder,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,16,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,19,Renal disorder,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,25,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,32,Musculoskeletal disorder,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,15,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,18,Musculoskeletal disorder,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,13,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,16,Nervous system disorder,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,5,Nervous system disorder,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,23,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,26,ICD lead,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,13,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,13,ICD lead,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,18,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,21,Lead for right atrial pacing,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,5,Lead for right atrial pacing,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,18,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,21,Lead for left ventricular pacing,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,4,Lead for left ventricular pacing,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,17,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,19,Implantation related,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,16,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,18,Implantation related,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,11,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,14,Hypotension,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,9,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,9,Hypotension,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,7,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,8,Angina,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,12,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,13,Angina,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,6,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,8,Peripheral vascular disease,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,10,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,12,Peripheral vascular disease,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,8,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,8,Syncope,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,7,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,9,Syncope,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,11,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,13,Cardiac arrest,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,3,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Cardiac arrest,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,6,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,6,Myocardial infarction,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,6,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,8,Myocardial infarction,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,9,Anemia,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,4,Anemia,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,6,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,7,Stroke,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,6,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,6,Stroke,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,5,Pulmonary embolism,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,7,Pulmonary embolism,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,6,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,6,Transischemic attack,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,4,Transischemic attack,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,3,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Thrombosis,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,6,Thrombosis,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,7,Fluid accumulation,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Fluid accumulation,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,5,Pulmonary edema,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,2,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Pulmonary edema,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,5,Cardiac catheterization,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,2,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,2,Cardiac catheterization,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,3,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Cardiovascular medication related,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,4,Cardiovascular medication related,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,4,Dizziness,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,3,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Dizziness,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,4,Pleural effusion,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,2,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,2,Pleural effusion,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,5,Valvular heart disease,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Valvular heart disease,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,3,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Abdominal Aortic Aneurysm,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,2,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,2,Abdominal Aortic Aneurysm,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Edema,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,3,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Edema,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,2,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Increased INR,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Increased INR,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Palpitations,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,2,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,2,Palpitations,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Bradycardia,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Bradycardia,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Dilated cardiomyopathy,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Dilated cardiomyopathy,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Hypertension,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Hypertension,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Ischemic cardiomyopathy,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Ischemic cardiomyopathy,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,2,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,2,Weight gain,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,0,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,0,Weight gain,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,1,Fatigue,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,0,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,0,Fatigue,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,12,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,13,Endocrine,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,6,Endocrine,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,5,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,5,Cancer,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,10,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,13,Cancer,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,11,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,12,Traumatic injury,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,4,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,4,Traumatic injury,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,0,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,0,Headache,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,3,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,4,Headache,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,1,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,2,Hepatic,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,2,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,2,Hepatic,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,3,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,3,Fatigue,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,0,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,0,Fatigue,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,6,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,6,Device related,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",serious,NA,NA,9,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,10,Device related,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,29,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,32,Worsening heart failure,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,29,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,34,Worsening heart failure,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,39,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,44,Atrial arrhythmia,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,35,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,43,Atrial arrhythmia,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,33,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,39,Ventricular arrhythmia,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,25,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,29,Ventricular arrhythmia,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,20,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,21,Chest pain,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,29,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,32,Chest pain,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,20,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,27,Dyspnea,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,30,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,32,Dyspnea,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,27,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,28,Hypotension,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,27,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,30,Hypotension,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,21,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,25,Dizziness,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,14,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,15,Dizziness,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,21,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,23,Edema,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,15,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,16,Edema,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,203,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,602,Non-cardiovascular,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,201,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,548,Non-cardiovascular,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,31,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,33,Implant Procedure,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,41,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,46,Implant Procedure,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,28,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,34,ICD lead,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,6,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,6,ICD lead,5,NA,NA
NCT00683696,EG000,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,49,404,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,55,Lead for left ventricular pacing,5,NA,NA
NCT00683696,EG001,"Study duration from date of implant to date of study exit, with a mean implant duration of 1.7 years",other,NA,NA,10,405,Subjects could have more than one event. Other adverse event data includes data from non-serious adverse events.,11,Lead for left ventricular pacing,5,NA,NA
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,serious,NA,NA,2,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Muscular weakness,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,serious,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Muscular weakness,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,serious,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Muscular weakness,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,2,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Muscular weakness,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Muscular weakness,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Muscular weakness,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,1,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Flatulence,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Flatulence,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Flatulence,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,1,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Abdominal pain upper,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Abdominal pain upper,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Abdominal pain upper,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,3,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Alanine aminotransferase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Alanine aminotransferase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Alanine aminotransferase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,3,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Aspartate aminotransferase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Aspartate aminotransferase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Aspartate aminotransferase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,3,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Blood creatine phosphokinase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Blood creatine phosphokinase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Blood creatine phosphokinase increased,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,2,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Fall,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Fall,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Fall,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,1,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Dysphagia,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Dysphagia,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Dysphagia,5,Uncoded,Systematic Assessment
NCT00688597,EG000,Day 1 (after dosing) through end of follow up.,other,NA,NA,1,3,"Due to the discontinuation of the study, AEs were not encoded.",NA,Joint injury,5,Uncoded,Systematic Assessment
NCT00688597,EG001,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Joint injury,5,Uncoded,Systematic Assessment
NCT00688597,EG002,Day 1 (after dosing) through end of follow up.,other,NA,NA,0,0,"Due to the discontinuation of the study, AEs were not encoded.",NA,Joint injury,5,Uncoded,Systematic Assessment
NCT00708942,EG000,NA,serious,NA,NA,1,47,NA,1,Jaw fracture,4,NA,NA
NCT00708942,EG001,NA,serious,NA,NA,0,12,NA,0,Jaw fracture,4,NA,NA
NCT00708942,EG002,NA,serious,NA,NA,0,11,NA,0,Jaw fracture,4,NA,NA
NCT00708942,EG003,NA,serious,NA,NA,0,10,NA,0,Jaw fracture,4,NA,NA
NCT00708942,EG004,NA,serious,NA,NA,0,3,NA,0,Jaw fracture,4,NA,NA
NCT00708942,EG000,NA,serious,NA,NA,1,47,NA,1,Schizophrenia,4,NA,NA
NCT00708942,EG001,NA,serious,NA,NA,0,12,NA,0,Schizophrenia,4,NA,NA
NCT00708942,EG002,NA,serious,NA,NA,0,11,NA,0,Schizophrenia,4,NA,NA
NCT00708942,EG003,NA,serious,NA,NA,0,10,NA,0,Schizophrenia,4,NA,NA
NCT00708942,EG004,NA,serious,NA,NA,0,3,NA,0,Schizophrenia,4,NA,NA
NCT00708942,EG000,NA,serious,NA,NA,1,47,NA,1,Concomitant disease aggravated,4,NA,NA
NCT00708942,EG001,NA,serious,NA,NA,0,12,NA,0,Concomitant disease aggravated,4,NA,NA
NCT00708942,EG002,NA,serious,NA,NA,0,11,NA,0,Concomitant disease aggravated,4,NA,NA
NCT00708942,EG003,NA,serious,NA,NA,0,10,NA,0,Concomitant disease aggravated,4,NA,NA
NCT00708942,EG004,NA,serious,NA,NA,0,3,NA,0,Concomitant disease aggravated,4,NA,NA
NCT00708942,EG000,NA,serious,NA,NA,0,47,NA,0,Depression,4,NA,NA
NCT00708942,EG001,NA,serious,NA,NA,0,12,NA,0,Depression,4,NA,NA
NCT00708942,EG002,NA,serious,NA,NA,1,11,NA,1,Depression,4,NA,NA
NCT00708942,EG003,NA,serious,NA,NA,0,10,NA,0,Depression,4,NA,NA
NCT00708942,EG004,NA,serious,NA,NA,0,3,NA,0,Depression,4,NA,NA
NCT00708942,EG000,NA,other,NA,NA,2,47,NA,2,Uterine pain,4,MedDRA 14.1,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,1,12,NA,1,Uterine pain,4,MedDRA 14.1,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Uterine pain,4,MedDRA 14.1,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Uterine pain,4,MedDRA 14.1,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Uterine pain,4,MedDRA 14.1,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,2,47,NA,2,Pain,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Pain,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Pain,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Pain,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Pain,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,2,47,NA,2,Vaginal infection,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Vaginal infection,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Vaginal infection,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Vaginal infection,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Vaginal infection,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,3,47,NA,4,Muscle spasms,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Muscle spasms,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Muscle spasms,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Muscle spasms,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Muscle spasms,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,2,47,NA,2,Haemorrhage,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Haemorrhage,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Haemorrhage,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Haemorrhage,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Haemorrhage,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Influenza,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,1,12,NA,1,Influenza,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Influenza,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,1,10,NA,1,Influenza,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Influenza,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,2,47,NA,3,Headache,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,1,12,NA,1,Headache,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Headache,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,1,10,NA,1,Headache,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,1,3,NA,1,Headache,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Urinary tract infection,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,1,12,NA,1,Urinary tract infection,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Urinary tract infection,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Urinary tract infection,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Urinary tract infection,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Hypertension,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Hypertension,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,1,11,NA,1,Hypertension,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Hypertension,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Hypertension,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,2,47,NA,2,Dysmenorrhoea,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Dysmenorrhoea,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Dysmenorrhoea,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Dysmenorrhoea,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Dysmenorrhoea,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,2,47,NA,2,Seasonal allergy,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Seasonal allergy,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Seasonal allergy,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Seasonal allergy,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Seasonal allergy,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Discomfort,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Discomfort,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Discomfort,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,1,10,NA,1,Discomfort,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Discomfort,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Back pain,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Back pain,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Back pain,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,2,10,NA,2,Back pain,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Back pain,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Diarrhoea,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Diarrhoea,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Diarrhoea,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Diarrhoea,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,1,3,NA,1,Diarrhoea,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Vomiting,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Vomiting,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Vomiting,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,0,10,NA,0,Vomiting,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,1,3,NA,1,Vomiting,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,1,47,NA,1,Vaginal discharge,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Vaginal discharge,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Vaginal discharge,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,1,10,NA,1,Vaginal discharge,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Vaginal discharge,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Pelvic pain,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Pelvic pain,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Pelvic pain,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,1,10,NA,1,Pelvic pain,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Pelvic pain,4,NA,Systematic Assessment
NCT00708942,EG000,NA,other,NA,NA,0,47,NA,0,Pneumonia,4,NA,Systematic Assessment
NCT00708942,EG001,NA,other,NA,NA,0,12,NA,0,Pneumonia,4,NA,Systematic Assessment
NCT00708942,EG002,NA,other,NA,NA,0,11,NA,0,Pneumonia,4,NA,Systematic Assessment
NCT00708942,EG003,NA,other,NA,NA,1,10,NA,1,Pneumonia,4,NA,Systematic Assessment
NCT00708942,EG004,NA,other,NA,NA,0,3,NA,0,Pneumonia,4,NA,Systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Anaemia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,6,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Anaemia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Leukopenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Leukopenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Thrombocytopenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,5,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",7,Thrombocytopenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Neutropenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Neutropenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Pancytopenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Pancytopenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Febrile neutropenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Febrile neutropenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Intestinal obstruction,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,3,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Intestinal obstruction,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Diarrhoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Diarrhoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Ileus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,2,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Ileus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Abdominal pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Abdominal pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Ascites,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Ascites,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Constipation,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Constipation,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Abdominal Pain Upper,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Abdominal Pain Upper,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Abdominal pain lower,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Abdominal pain lower,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Vomiting,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Vomiting,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Gastrointestinal Hypomotility,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Gastrointestinal Hypomotility,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Nausea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Nausea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Subileus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Subileus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Faecaloma,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Faecaloma,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Intestinal infarction,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Intestinal infarction,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,General Physical health deterioration,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,5,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",5,General Physical health deterioration,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,non cardiac chest pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,non cardiac chest pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Asthenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Asthenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Viral infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Viral infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Gastroenteritis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Gastroenteritis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Device related infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,3,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Device related infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Tracheobronchitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Tracheobronchitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Hepatitis C,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Hepatitis C,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Neutropenic infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,2,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Neutropenic infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Bacterial infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Bacterial infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Streptococcal bacteraemia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Streptococcal bacteraemia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Abdominal abscess,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Abdominal abscess,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Neutropenic sepsis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Neutropenic sepsis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Infected lymphocele,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Infected lymphocele,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Respiratory tract infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Respiratory tract infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Urinary tract infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Urinary tract infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Pneumonia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Pneumonia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Femoral neck fracture,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Femoral neck fracture,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Anastomotic leak,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Anastomotic leak,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Seroma,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Seroma,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Muscle spasms,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Muscle spasms,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Arthralgia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Arthralgia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Bone pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Bone pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Rheumatoid arthritis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Rheumatoid arthritis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,3,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Dyspnoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Dyspnoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Pulmonary embolism,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Pulmonary embolism,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Epistaxis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Epistaxis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Lung disorder,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Lung disorder,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Lymphocele,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Lymphocele,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Aortic aneurysm,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Aortic aneurysm,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Subclavian vein thrombosis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Subclavian vein thrombosis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Hypocalcaemia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Hypocalcaemia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Diabetes melitus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Diabetes melitus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Deafness neurosensory,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Deafness neurosensory,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Convulsion,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Convulsion,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Haemorrhage intracranial,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Haemorrhage intracranial,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Syncope,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Syncope,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Nervous system disorder,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Nervous system disorder,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Dizziness,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Dizziness,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Cholestasis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Cholestasis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Female genital tract fistula,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Female genital tract fistula,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Vaginal haemorrhage,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Vaginal haemorrhage,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Mental status changes,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Mental status changes,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Rash maculo papular,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Rash maculo papular,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Petechiae,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Petechiae,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Cardiac failure,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Cardiac failure,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,0,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Postoperative Wound Infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,serious,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Postoperative Wound Infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Tinnitus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,3,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Tinnitus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Vertigo,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,8,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",8,Vertigo,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Vision blurred,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Vision blurred,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,28,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",33,Constipation,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,28,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",32,Constipation,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,6,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Dry mouth,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,11,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",13,Dry mouth,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,17,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",19,Stomatitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,24,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",25,Stomatitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Chills,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,10,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",12,Chills,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,46,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",55,Fatigue,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,49,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",55,Fatigue,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,8,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",8,Oedema peripheral,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",5,Oedema peripheral,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,9,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",10,Pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,11,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",11,Pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,13,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",15,Pyrexia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,9,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",12,Pyrexia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,10,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",14,Hypersensitivity,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,8,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",10,Hypersensitivity,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",5,Bronchitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,2,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Bronchitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",9,Cystitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,2,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Cystitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,12,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",13,Nasopharyngitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,7,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",10,Nasopharyngitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Weight increased,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Weight increased,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,16,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",17,Decreased appetite,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,12,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",14,Decreased appetite,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Hypomagnesaemia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",5,Hypomagnesaemia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,14,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",16,Back pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,8,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",8,Back pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Musculoskeletal chest pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,0,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",0,Musculoskeletal chest pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Musculoskeletal pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,3,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Musculoskeletal pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,20,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",26,Myalgia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,27,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",33,Myalgia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,16,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",17,Pain in extremity,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,11,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",13,Pain in extremity,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,15,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",17,Dysgueusia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,15,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",16,Dysgueusia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,17,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",20,Headache,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,23,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",30,Headache,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,15,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",17,Neuropathy peripheral,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,24,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",25,Neuropathy peripheral,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,7,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",9,Paraesthesia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,3,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Paraesthesia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,32,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",35,Peripheral sensory neuropathy,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,27,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",31,Peripheral sensory neuropathy,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,11,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",11,Polyneuropathy,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,8,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",8,Polyneuropathy,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Anxiety,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,2,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Anxiety,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,6,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Depression,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,2,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Depression,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,6,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Insomnia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,7,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",7,Insomnia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,7,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",7,Cough,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,9,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",9,Cough,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",5,Oropharyngeal pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Oropharyngeal pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Rhinorrhoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,3,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Rhinorrhoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,1,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Acne,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Acne,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,68,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",68,Alopecia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,66,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",66,Alopecia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,3,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Dry skin,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",5,Dry skin,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Nail disorder,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,8,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",8,Nail disorder,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,11,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",15,Pruritus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,11,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",12,Pruritus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,13,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",13,Hot flush,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,7,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",8,Hot flush,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,3,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",3,Hypertension,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,6,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Hypertension,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,16,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",16,Abdominal Pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,18,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",22,Abdominal Pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,14,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",16,Abdominal Pain Upper,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,6,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Abdominal Pain Upper,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,24,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",32,Diarrhoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,37,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",45,Diarrhoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,51,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",67,Nausea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,46,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",53,Nausea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,31,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",38,Vomiting,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,29,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",32,Vomiting,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,9,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",17,Asthenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,5,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Asthenia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,11,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",15,Urinary Tract Infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,7,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",8,Urinary Tract Infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,24,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",39,Arthralgia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,30,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",34,Arthralgia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,13,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",15,Bone Pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,18,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",21,Bone Pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,2,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",2,Muscle Spasms,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,6,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Muscle Spasms,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,15,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",16,Dizziness,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,9,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",9,Dizziness,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,4,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",4,Syncope,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,1,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",1,Syncope,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,15,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",15,Dyspnoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,12,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",12,Dyspnoea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,6,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",6,Epistaxis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,12,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",13,Epistaxis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG000,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,17,77,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",22,Rash,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00718523,EG001,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,other,NA,NA,24,88,"For participant flow module it is based on Intent To Treat so the patients are counted according to their ""randomization group"".For ""participants at risk"" the patients are grouped by the ""actual treatment"" 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.",28,Rash,5,MedDRA (Unspecified),Non-systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Grand mal convulsion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Grand mal convulsion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Nervous system disorder,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Nervous system disorder,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Partial seizures,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Partial seizures,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Meningitis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Meningitis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Neoplasm progression,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Neoplasm progression,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Pancytopenia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Pancytopenia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Haematemesis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Haematemesis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Device malfunction,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Device malfunction,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Device occlusion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Device occlusion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Acute respiratory failure,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Acute respiratory failure,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Pulmonary embolism,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Pulmonary embolism,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Neurosurgery,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",serious,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Neurosurgery,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,7,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",7,Headache,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Headache,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,4,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",4,Partial seizures,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Partial seizures,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,3,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",3,Brain oedema,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Brain oedema,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Dizziness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Dizziness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Hemiparesis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Hemiparesis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Convulsion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Convulsion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Epilepsy,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Epilepsy,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Facial palsy,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Facial palsy,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Grand mal convulsion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Grand mal convulsion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Memory impairment,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Memory impairment,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Somnolence,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",NA,Somnolence,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Speech disorder,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Speech disorder,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Acquired epileptic aphasia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Acquired epileptic aphasia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Aphasia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Aphasia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Burning sensation,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Burning sensation,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Complex partial seizures,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Complex partial seizures,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Dysgeusia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Dysgeusia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Hydrocephalus,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Hydrocephalus,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Hyperaesthesia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Hyperaesthesia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Hypoaesthesia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Hypoaesthesia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Loss of consciousness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Loss of consciousness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Monoplegia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Monoplegia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Nervous system disorder,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Nervous system disorder,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Paralysis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Paralysis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Simple partial seizures,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Simple partial seizures,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Tremor,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Tremor,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Asthenia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,3,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",3,Asthenia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,5,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",5,Pyrexia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Pyrexia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,3,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",3,Chills,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Chills,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Device occlusion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Device occlusion,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Fatigue,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Fatigue,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Gait disturbance,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Gait disturbance,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Administration site reaction,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Administration site reaction,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Device alarm issue,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Device alarm issue,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Device malfunction,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Device malfunction,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Medical device pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Medical device pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Medical device site reaction,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Medical device site reaction,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Vessel puncture site haemorrhage,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Vessel puncture site haemorrhage,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,3,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",3,Nausea,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Nausea,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Diarrhoea,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Diarrhoea,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Vomiting,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Vomiting,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Abdominal pain upper,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Abdominal pain upper,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Constipation,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Constipation,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Dyspepsia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Dyspepsia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Abdominal distention,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Abdominal distention,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Abdominal tenderness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Abdominal tenderness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Gastrointestinal haemorrhage,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Gastrointestinal haemorrhage,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Haematemesis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Haematemesis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,White blood cell count decreased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,4,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",4,White blood cell count decreased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Platelet count decreased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,3,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",3,Platelet count decreased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Neutrophil count,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Neutrophil count,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,White blood cell count,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,White blood cell count,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Alanine aminotransferase increased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Alanine aminotransferase increased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,CSF protein increased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,CSF protein increased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Haemoglobin,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Haemoglobin,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Pseudomonas test positive,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Pseudomonas test positive,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Staphylococcus test postivie,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Staphylococcus test postivie,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Weight increased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Weight increased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,White blood cell count increased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,White blood cell count increased,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Meningitis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Meningitis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Bronchitis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Bronchitis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Nasopharyngitis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Nasopharyngitis,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Oral herpes,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Oral herpes,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Pneumonia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Pneumonia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Skin bacterial infection,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Skin bacterial infection,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Urinary tract infection,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Urinary tract infection,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Depression,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Depression,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Confusional state,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Confusional state,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Disorientation,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Disorientation,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Insomnia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Insomnia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Restlessness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Restlessness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Rash,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Rash,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Scar pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Scar pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Acne,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Acne,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Dermatitis contact,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Dermatitis contact,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Dry skin,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Dry skin,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Rash pruritic,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Rash pruritic,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Hiccups,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Hiccups,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Acute respiratory failure,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Acute respiratory failure,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Cough,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Cough,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Pulmonary embolism,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Pulmonary embolism,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Incorrect dose administered,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Incorrect dose administered,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Meningitis chemical,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Meningitis chemical,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Overdose,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Overdose,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Blepharospasm,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Blepharospasm,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Hippus,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Hippus,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Decreased appetite,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Decreased appetite,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Arthralgia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Arthralgia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Back pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Back pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Muscular weakness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Muscular weakness,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,2,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",2,Neoplasm progression,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Neoplasm progression,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Metastases to spine,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Metastases to spine,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Urethral pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Urethral pain,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Urinary retention,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Urinary retention,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Hypotension,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Hypotension,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Varicose veins,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Varicose veins,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Pancytopenia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Pancytopenia,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Ear discomfort,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Ear discomfort,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG000,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,1,13,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",1,Neurosurgery,5,MedDRA (13.0),Systematic Assessment
NCT00761280,EG001,"Safety monitoring (including adverse events) started from the signature of the informed consent and continued until 28 days after the last administration of study drug, up to 24 months.",other,NA,NA,0,11,"Only treatment-emergent adverse events are listed, defined as any AE whose onset occurred or intensity worsened after undertaking the first study procedure or first dose of study drug (whichever occurred first) but less than 28 days after medication/procedures had stopped. Adverse events (including lab tests) were assessed at study visits.",0,Neurosurgery,5,MedDRA (13.0),Systematic Assessment
NCT00831233,EG000,12 weeks.,serious,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Hepatic failure,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,serious,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Hepatic failure,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,serious,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Prostate cancer,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,serious,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Prostate cancer,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,serious,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Renal failure,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,serious,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Renal failure,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,serious,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Prostatic obstruction,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,serious,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Prostatic obstruction,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,2,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,2,Anaemia,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,0,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Anaemia,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Leukocytosis,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Leukocytosis,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,2,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,2,"Reproductive tract hypoplasia, male",5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,0,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,"Reproductive tract hypoplasia, male",5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,3,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,3,Constipation,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,0,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Constipation,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,6,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,16,Injection site pain,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,0,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Injection site pain,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,3,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,5,Injection site erythema,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,0,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Injection site erythema,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,2,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,2,Fatigue,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,0,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Fatigue,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,1,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Pyrexia,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Pyrexia,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Hepatic failure,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Hepatic failure,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,3,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,4,Cystitis,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,2,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,2,Cystitis,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,1,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Urinary tract infection,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,2,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,2,Urinary tract infection,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,3,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,3,Weight decreased,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,0,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Weight decreased,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,1,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Metastases to bone,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,2,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,2,Metastases to bone,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Prostate cancer,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Prostate cancer,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Renal cyst,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Renal cyst,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Renal failure,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Renal failure,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Urinary retention,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,2,Urinary retention,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,0,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,0,Prostatic obstruction,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,1,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,1,Prostatic obstruction,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG000,12 weeks.,other,NA,NA,5,27,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,5,Hot flush,5,MedDRA (10.1),Systematic Assessment
NCT00831233,EG001,12 weeks.,other,NA,NA,2,13,Each participant's condition was monitored throughout the trial from the time of signing the informed consent until the end of the follow-up period. The investigator was to record all adverse events (AEs) in the AE log of the participant's Case Report Form.,2,Hot flush,5,MedDRA (10.1),Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,serious,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,NA,Femur fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,serious,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,NA,Femur fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,serious,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,NA,Femur fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,serious,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,NA,Femur fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,serious,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,NA,Hypertension,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,serious,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,NA,Hypertension,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,serious,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,NA,Hypertension,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,serious,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,NA,Hypertension,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Lymphadenopathy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Lymphadenopathy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Lymphadenopathy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Lymphadenopathy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Anaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Anaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Anaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Anaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Microcytic anaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Microcytic anaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Microcytic anaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Microcytic anaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Neutropenia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Neutropenia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Neutropenia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Neutropenia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dilatation ventricular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dilatation ventricular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dilatation ventricular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Dilatation ventricular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Arrhythmia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Arrhythmia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Arrhythmia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Arrhythmia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Cardiomyopathy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Cardiomyopathy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cardiomyopathy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cardiomyopathy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Left ventricular hypertrophy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Left ventricular hypertrophy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Left ventricular hypertrophy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Left ventricular hypertrophy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tachycardia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tachycardia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tachycardia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tachycardia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Kidney malformation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Kidney malformation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Kidney malformation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Kidney malformation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Deafness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Deafness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Deafness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Deafness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Ear pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Ear pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Ear pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Ear pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tympanic membrane hyperaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tympanic membrane hyperaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tympanic membrane hyperaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tympanic membrane hyperaemia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Vertigo,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Vertigo,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Vertigo,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Vertigo,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cushingoid,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Cushingoid,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Cushingoid,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cushingoid,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cataract,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Cataract,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cataract,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Cataract,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Myopia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Myopia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Myopia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Myopia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abnormal sensation in eye,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abnormal sensation in eye,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Abnormal sensation in eye,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Abnormal sensation in eye,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Conjunctivitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Conjunctivitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Conjunctivitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Conjunctivitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypermetropia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypermetropia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypermetropia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypermetropia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Photophobia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Photophobia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Photophobia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Photophobia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Strabismus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Strabismus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Strabismus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Strabismus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Vision blurred,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Vision blurred,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Vision blurred,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Vision blurred,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,11,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,16,Vomiting,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,12,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,23,Vomiting,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,20,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,33,Vomiting,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,43,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,72,Vomiting,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Diarrhoea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,11,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,13,Diarrhoea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,8,Diarrhoea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,20,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,25,Diarrhoea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,10,Abdominal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Abdominal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,7,Abdominal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,16,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,21,Abdominal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Abdominal pain upper,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,9,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,11,Abdominal pain upper,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Abdominal pain upper,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,15,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,18,Abdominal pain upper,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,7,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,7,Flatulence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Flatulence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Flatulence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,14,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,14,Flatulence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Nausea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Nausea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Nausea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,11,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,12,Nausea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dyspepsia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Dyspepsia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Dyspepsia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Dyspepsia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Constipation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Constipation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Constipation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Constipation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Stomach discomfort,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Stomach discomfort,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Stomach discomfort,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Stomach discomfort,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Aerophagia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Aerophagia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Aerophagia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Aerophagia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gastrooesophageal reflux disease,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gastrooesophageal reflux disease,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gastrooesophageal reflux disease,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Gastrooesophageal reflux disease,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abdominal discomfort,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abdominal discomfort,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Abdominal discomfort,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Abdominal discomfort,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abdominal pain lower,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abdominal pain lower,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Abdominal pain lower,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Abdominal pain lower,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Abdominal tenderness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abdominal tenderness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abdominal tenderness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Abdominal tenderness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abnormal faeces,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abnormal faeces,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Abnormal faeces,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Abnormal faeces,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Aphthous stomatitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Aphthous stomatitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Aphthous stomatitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Aphthous stomatitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Chapped lips,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Chapped lips,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Chapped lips,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Chapped lips,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Duodenogastric reflux,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Duodenogastric reflux,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Duodenogastric reflux,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Duodenogastric reflux,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Eructation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Eructation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Eructation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Eructation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Faecal incontinence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Faecal incontinence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Faecal incontinence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Faecal incontinence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gastritis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gastritis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gastritis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gastritis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gastrointestinal sounds abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gastrointestinal sounds abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gastrointestinal sounds abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gastrointestinal sounds abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gingivitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gingivitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gingivitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gingivitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oral pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Oral pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Oral pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oral pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tongue disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tongue disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tongue disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tongue disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,9,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,9,Disease progression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,7,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,7,Disease progression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Disease progression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,19,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,19,Disease progression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Asthenia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Asthenia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Asthenia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,9,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,10,Asthenia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Gait disturbance,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Gait disturbance,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Gait disturbance,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,9,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,9,Gait disturbance,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Pyrexia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Pyrexia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Pyrexia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,9,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,11,Pyrexia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Fatigue,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Fatigue,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Fatigue,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Fatigue,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Malaise,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Malaise,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Malaise,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Malaise,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Oedema peripheral,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oedema peripheral,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Oedema peripheral,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oedema peripheral,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypersensitivity,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypersensitivity,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypersensitivity,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Hypersensitivity,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,7,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,7,Influenza,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Influenza,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Influenza,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,18,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,18,Influenza,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Nasopharyngitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,8,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,10,Nasopharyngitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Nasopharyngitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,16,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,19,Nasopharyngitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,8,Upper respiratory tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Upper respiratory tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Upper respiratory tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,14,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,17,Upper respiratory tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Ear infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Ear infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Ear infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,8,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,10,Ear infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Gastroenteritis viral,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Gastroenteritis viral,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Gastroenteritis viral,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,7,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,8,Gastroenteritis viral,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Gastroenteritis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gastroenteritis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Gastroenteritis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Gastroenteritis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Otitis media,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Otitis media,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Otitis media,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Otitis media,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rhinitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rhinitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Rhinitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Rhinitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Bronchitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Bronchitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Bronchitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Bronchitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Croup infectious,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Croup infectious,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Croup infectious,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Croup infectious,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Lower respiratory tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Lower respiratory tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Lower respiratory tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Lower respiratory tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Paronychia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Paronychia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Paronychia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Paronychia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Sinusitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Sinusitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Sinusitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Sinusitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Urinary tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Urinary tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Urinary tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Urinary tract infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Viral infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Viral infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Viral infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Viral infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Enterobiasis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Enterobiasis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Enterobiasis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Enterobiasis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Gastrointestinal infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Gastrointestinal infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Gastrointestinal infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Gastrointestinal infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Molluscum contagiosum,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Molluscum contagiosum,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Molluscum contagiosum,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Molluscum contagiosum,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pharyngitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pharyngitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pharyngitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Pharyngitis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Pharyngitis streptococcal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pharyngitis streptococcal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pharyngitis streptococcal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Pharyngitis streptococcal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tinea pedis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tinea pedis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Tinea pedis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Tinea pedis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Conjunctivitis infective,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Conjunctivitis infective,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Conjunctivitis infective,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Conjunctivitis infective,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Helicobacter infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Helicobacter infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Helicobacter infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Helicobacter infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Localised infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Localised infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Localised infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Localised infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Lung infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Lung infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Lung infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Lung infection,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Onychomycosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Onychomycosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Onychomycosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Onychomycosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Oral herpes,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Oral herpes,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oral herpes,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oral herpes,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Otitis externa,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Otitis externa,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Otitis externa,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Otitis externa,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pneumonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pneumonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pneumonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pneumonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Scarlet fever,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Scarlet fever,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Scarlet fever,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Scarlet fever,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Fall,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Fall,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Fall,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,14,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,15,Fall,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Contusion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Contusion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Contusion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Contusion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Iliotibial band syndrome,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Iliotibial band syndrome,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Iliotibial band syndrome,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Iliotibial band syndrome,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Joint sprain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Joint sprain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Joint sprain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Joint sprain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Arthropod bite,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Arthropod bite,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Arthropod bite,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Arthropod bite,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Femur fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Femur fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Femur fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Femur fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Limb injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Limb injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Limb injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Limb injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Lower limb fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Lower limb fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Lower limb fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Lower limb fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Arthropod sting,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Arthropod sting,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Arthropod sting,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Arthropod sting,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Excoriation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Excoriation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Excoriation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Excoriation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Facial bones fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Facial bones fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Facial bones fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Facial bones fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Foot fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Foot fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Foot fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Foot fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Head injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Head injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Head injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Head injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Humerus fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Humerus fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Humerus fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Humerus fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Incision site erythema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Incision site erythema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Incision site erythema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Incision site erythema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Lumbar vertebral fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Lumbar vertebral fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Lumbar vertebral fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Lumbar vertebral fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Mouth injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Mouth injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Mouth injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Mouth injury,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Muscle strain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Muscle strain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Muscle strain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Muscle strain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Overdose,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Overdose,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Overdose,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Overdose,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Procedural pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Procedural pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Procedural pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Procedural pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin laceration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin laceration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin laceration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin laceration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Spinal compression fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Spinal compression fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Spinal compression fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Spinal compression fracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Wound,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Wound,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Wound,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Wound,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Wound dehiscence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Wound dehiscence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Wound dehiscence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Wound dehiscence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Blood sodium increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Blood sodium increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Blood sodium increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Blood sodium increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Weight decreased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Weight decreased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Weight decreased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Weight decreased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Blood bicarbonate decreased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Blood bicarbonate decreased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Blood bicarbonate decreased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Blood bicarbonate decreased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Blood triglycerides increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Blood triglycerides increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Blood triglycerides increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Blood triglycerides increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Breath sounds abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Breath sounds abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Breath sounds abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Breath sounds abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Weight increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Weight increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Weight increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Weight increased,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Decreased appetite,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Decreased appetite,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Decreased appetite,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Decreased appetite,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dehydration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dehydration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dehydration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dehydration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypovitaminosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypovitaminosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypovitaminosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypovitaminosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Insulin resistance,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Insulin resistance,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Insulin resistance,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Insulin resistance,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Iron deficiency,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Iron deficiency,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Iron deficiency,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Iron deficiency,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,11,Back pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Back pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,7,Back pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,11,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,21,Back pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Muscular weakness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Muscular weakness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Muscular weakness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,11,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,12,Muscular weakness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,8,Pain in extremity,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Pain in extremity,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pain in extremity,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,10,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,14,Pain in extremity,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Joint contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,8,Joint contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Joint contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,9,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,13,Joint contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Arthralgia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Arthralgia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Arthralgia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,7,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,7,Arthralgia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Muscle tightness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Muscle tightness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Muscle tightness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Muscle tightness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Lordosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Lordosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Lordosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Lordosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Musculoskeletal chest pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Musculoskeletal chest pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Musculoskeletal chest pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Musculoskeletal chest pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Myalgia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Myalgia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Myalgia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Myalgia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Muscle spasms,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Muscle spasms,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Muscle spasms,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Muscle spasms,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Osteoporosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Osteoporosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Osteoporosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Osteoporosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tendinous contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Tendinous contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tendinous contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Tendinous contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Muscle atrophy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Muscle atrophy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Muscle atrophy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Muscle atrophy,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Scoliosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Scoliosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Scoliosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Scoliosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tendon disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tendon disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tendon disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Tendon disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Coccydynia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Coccydynia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Coccydynia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Coccydynia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Groin pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Groin pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Groin pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Groin pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Growth retardation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Growth retardation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Growth retardation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Growth retardation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Joint instability,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Joint instability,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Joint instability,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Joint instability,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Muscle contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Muscle contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Muscle contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Muscle contracture,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Musculoskeletal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Musculoskeletal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Musculoskeletal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Musculoskeletal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Neck pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Neck pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Neck pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Neck pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Musculoskeletal stiffness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Musculoskeletal stiffness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Musculoskeletal stiffness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Musculoskeletal stiffness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin papilloma,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Skin papilloma,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin papilloma,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,7,Skin papilloma,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Melanocytic naevus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Melanocytic naevus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Melanocytic naevus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Melanocytic naevus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,48,Headache,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,15,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,48,Headache,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,14,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,17,Headache,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,34,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,113,Headache,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Migraine,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Migraine,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Migraine,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Migraine,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Areflexia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Areflexia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Areflexia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Areflexia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dizziness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dizziness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dizziness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dizziness,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypertonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypertonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypertonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypertonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypotonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypotonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypotonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hypotonia,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Memory impairment,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Memory impairment,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Memory impairment,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Memory impairment,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Partial seizures,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Partial seizures,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Partial seizures,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Partial seizures,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Sedation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Sedation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Sedation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Sedation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Sinus headache,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Sinus headache,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Sinus headache,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Sinus headache,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Attention deficit/hyperactivity disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Attention deficit/hyperactivity disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Attention deficit/hyperactivity disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,5,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Attention deficit/hyperactivity disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abnormal behaviour,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Abnormal behaviour,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Abnormal behaviour,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Abnormal behaviour,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Aggression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Aggression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Aggression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Aggression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Obsessive-compulsive disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Obsessive-compulsive disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Obsessive-compulsive disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Obsessive-compulsive disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Tic,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Tic,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Tic,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Tic,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Depression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Depression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Depression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Depression,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Frustration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Frustration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Frustration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Frustration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Oppositional defiant disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Oppositional defiant disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oppositional defiant disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oppositional defiant disorder,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Enuresis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Enuresis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Enuresis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Enuresis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Urine abnormality,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Urine abnormality,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Urine abnormality,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Urine abnormality,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pollakiuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pollakiuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pollakiuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Pollakiuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Urinary incontinence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Urinary incontinence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Urinary incontinence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Urinary incontinence,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dysuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dysuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dysuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dysuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Haematuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Haematuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Haematuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Haematuria,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Kidney enlargement,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Kidney enlargement,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Kidney enlargement,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Kidney enlargement,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Micturition urgency,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Micturition urgency,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Micturition urgency,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Micturition urgency,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pyelocaliectasis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pyelocaliectasis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pyelocaliectasis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pyelocaliectasis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Renal cyst,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Renal cyst,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Renal cyst,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Renal cyst,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Ureteric dilatation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Ureteric dilatation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Ureteric dilatation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Ureteric dilatation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hot flush,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Hot flush,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hot flush,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Hot flush,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hypertension,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Hypertension,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Hypertension,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,4,Hypertension,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Rash,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rash,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Rash,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Rash,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dry skin,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dry skin,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Dry skin,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Dry skin,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Ecchymosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Ecchymosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Ecchymosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Ecchymosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Eczema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Eczema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Eczema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Eczema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pruritus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pruritus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pruritus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Pruritus,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Acne,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Acne,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Acne,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Acne,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Cold sweat,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cold sweat,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Cold sweat,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cold sweat,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hyperkeratosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hyperkeratosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Hyperkeratosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Hyperkeratosis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Keratosis pilaris,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Keratosis pilaris,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Keratosis pilaris,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Keratosis pilaris,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Petechiae,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Petechiae,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Petechiae,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Petechiae,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pityriasis rosea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pityriasis rosea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pityriasis rosea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pityriasis rosea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Rash maculo-papular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rash maculo-papular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Rash maculo-papular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rash maculo-papular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rash papular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Rash papular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Rash papular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rash papular,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin chapped,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin chapped,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin chapped,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin chapped,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin depigmentation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin depigmentation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin depigmentation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin depigmentation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin discolouration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin discolouration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin discolouration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin discolouration,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin exfoliation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin exfoliation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin exfoliation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin exfoliation,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin odour abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin odour abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Skin odour abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Skin odour abnormal,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Swelling face,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Swelling face,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Swelling face,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Swelling face,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Cough,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Cough,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Cough,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,13,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,13,Cough,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Oropharyngeal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Oropharyngeal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Oropharyngeal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,7,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,9,Oropharyngeal pain,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Nasal congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Nasal congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Nasal congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,6,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,6,Nasal congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,3,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,3,Epistaxis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Epistaxis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Epistaxis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,4,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,5,Epistaxis,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Wheezing,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Wheezing,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Wheezing,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,2,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,2,Wheezing,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Asthma,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Asthma,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Asthma,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Asthma,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dyspnoea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dyspnoea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Dyspnoea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Dyspnoea,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pharyngeal erythema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pharyngeal erythema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Pharyngeal erythema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Pharyngeal erythema,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Postnasal drip,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Postnasal drip,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Postnasal drip,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Postnasal drip,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Productive cough,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Productive cough,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Productive cough,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Productive cough,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Respiratory tract congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Respiratory tract congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Respiratory tract congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Respiratory tract congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Rhinitis allergic,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rhinitis allergic,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Rhinitis allergic,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Rhinitis allergic,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Sinus congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Sinus congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Sinus congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Sinus congestion,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG000,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,59,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Snoring,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG001,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,0,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,0,Snoring,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG002,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,57,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Snoring,0,MedDRA 11.0,Systematic Assessment
NCT00847379,EG003,Baseline (Week 48 of Study 007) up to Week 102,other,NA,NA,1,173,As-treated population included all participants who completed Study 007 and received ≥1 dose of ataluren in Study 007e.,1,Snoring,0,MedDRA 11.0,Systematic Assessment
NCT00850499,EG000,NA,serious,NA,NA,1,4,NA,NA,Abdominal pain,5,NA,Systematic Assessment
NCT00850499,EG001,NA,serious,NA,NA,0,8,NA,NA,Abdominal pain,5,NA,Systematic Assessment
NCT00850499,EG000,NA,serious,NA,NA,1,4,NA,NA,Anaemia,5,NA,Systematic Assessment
NCT00850499,EG001,NA,serious,NA,NA,0,8,NA,NA,Anaemia,5,NA,Systematic Assessment
NCT00850499,EG000,NA,serious,NA,NA,1,4,NA,NA,Small Intestinal Obstruction,5,NA,Systematic Assessment
NCT00850499,EG001,NA,serious,NA,NA,0,8,NA,NA,Small Intestinal Obstruction,5,NA,Systematic Assessment
NCT00850499,EG000,NA,serious,NA,NA,0,4,NA,NA,Dypnoea,5,NA,Systematic Assessment
NCT00850499,EG001,NA,serious,NA,NA,1,8,NA,NA,Dypnoea,5,NA,Systematic Assessment
NCT00850499,EG000,NA,serious,NA,NA,0,4,NA,NA,Febrile neutropenia,5,NA,Systematic Assessment
NCT00850499,EG001,NA,serious,NA,NA,1,8,NA,NA,Febrile neutropenia,5,NA,Systematic Assessment
NCT00850499,EG000,NA,serious,NA,NA,0,4,NA,NA,General physical health deterioration,5,NA,Systematic Assessment
NCT00850499,EG001,NA,serious,NA,NA,1,8,NA,NA,General physical health deterioration,5,NA,Systematic Assessment
NCT00850499,EG000,NA,serious,NA,NA,0,4,NA,NA,Pyrexia,5,NA,Systematic Assessment
NCT00850499,EG001,NA,serious,NA,NA,1,8,NA,NA,Pyrexia,5,NA,Systematic Assessment
NCT00850499,EG000,NA,serious,NA,NA,0,4,NA,NA,Respiratory gas exchange disorder,5,NA,Systematic Assessment
NCT00850499,EG001,NA,serious,NA,NA,1,8,NA,NA,Respiratory gas exchange disorder,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Leukopenia,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,2,8,NA,NA,Leukopenia,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Lymphopenia,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,2,8,NA,NA,Lymphopenia,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Neutropenia,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,4,8,NA,NA,Neutropenia,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Thrombocytopenia,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,3,8,NA,NA,Thrombocytopenia,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Blepharitis,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Blepharitis,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,2,4,NA,NA,Constipation,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Constipation,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Diarrhoea,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Diarrhoea,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Gastrointestinal pain,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Gastrointestinal pain,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Nausea,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Nausea,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Asthenia,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,3,8,NA,NA,Asthenia,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Fatigue,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,2,8,NA,NA,Fatigue,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Oedema peripheral,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Oedema peripheral,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Performance status decreased,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Performance status decreased,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Nasopharyngitis,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Nasopharyngitis,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Pharyngitis,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Pharyngitis,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Tinea infection,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Tinea infection,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Decreased appetite,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Decreased appetite,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Back pain,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Back pain,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Bone pain,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Bone pain,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Osteoarthritis,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Osteoarthritis,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Peripheral sensory neuropathy,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Peripheral sensory neuropathy,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Conversion disorder,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Conversion disorder,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Depression,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,0,8,NA,NA,Depression,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Chronic obstructive pulmonary disease,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Chronic obstructive pulmonary disease,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,1,4,NA,NA,Cough,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Cough,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Rash,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Rash,5,NA,Systematic Assessment
NCT00850499,EG000,NA,other,NA,NA,0,4,NA,NA,Skin reaction,5,NA,Systematic Assessment
NCT00850499,EG001,NA,other,NA,NA,1,8,NA,NA,Skin reaction,5,NA,Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Anaemia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Anaemia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Atrioventricular block complete,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Atrioventricular block complete,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Bradycardia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Bradycardia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal pain lower,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal pain lower,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pneumonia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pneumonia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Respiratory tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Respiratory tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Procedural complication,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Procedural complication,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Electrocardiogram T wave inversion,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Electrocardiogram T wave inversion,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hyperkalaemia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hyperkalaemia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Groin pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Groin pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Breast cancer,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Breast cancer,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Renal failure,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Renal failure,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,3,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Idiopathic pulmonary fibrosis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Idiopathic pulmonary fibrosis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dyspnoea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dyspnoea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hypoxia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hypoxia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Acute respiratory failure,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Acute respiratory failure,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Haemoptysis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Haemoptysis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Interstitial lung disease,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Interstitial lung disease,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pulmonary fibrosis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pulmonary fibrosis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,serious,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Respiratory failure,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,serious,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Respiratory failure,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,4,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Constipation,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Constipation,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal distension,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal distension,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal pain upper,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal pain upper,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal discomfort,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal discomfort,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Abdominal pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Diarrhoea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,2,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Diarrhoea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dry mouth,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dry mouth,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dyspepsia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dyspepsia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Nausea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,2,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Nausea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Vomiting,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Vomiting,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,5,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Oedema peripheral,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,3,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Oedema peripheral,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pyrexia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pyrexia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Fatigue,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,4,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Fatigue,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Anaemia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Anaemia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Myocardial infarction,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Myocardial infarction,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Palpitations,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Palpitations,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hyperparathyroidism secondary,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hyperparathyroidism secondary,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,4,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Upper respiratory tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Upper respiratory tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pneumonia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pneumonia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Respiratory tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Respiratory tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Sinusitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Sinusitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Bronchitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Bronchitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Diverticulitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,2,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Diverticulitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Influenza,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Influenza,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Lower respiratory tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,2,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Lower respiratory tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Nasopharyngitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Nasopharyngitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Rhinitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Rhinitis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Urinary tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,3,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Urinary tract infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Viral infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Viral infection,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Joint sprain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Joint sprain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Cardiac murmur,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Cardiac murmur,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Eosinophil count increased,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Eosinophil count increased,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Decreased appetite,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Decreased appetite,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hypercalcaemia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hypercalcaemia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Back pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,3,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Back pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Muscle spasms,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Muscle spasms,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Musculoskeletal chest pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Musculoskeletal chest pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Neck pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Neck pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pain in extremity,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Pain in extremity,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,5,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Headache,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,3,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Headache,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dizziness,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,2,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dizziness,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Neuropathy peripheral,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Neuropathy peripheral,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Syncope,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Syncope,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Anxiety,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Anxiety,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Proteinuria,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Proteinuria,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,6,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dyspnoea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,5,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Dyspnoea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,6,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Nasal congestion,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Nasal congestion,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,3,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Cough,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,2,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Cough,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hypoxia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hypoxia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Orthopnoea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Orthopnoea,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,2,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hyperhidrosis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,0,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Hyperhidrosis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Alopecia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Alopecia,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Ecchymosis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Ecchymosis,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,1,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Flushing,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,2,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Flushing,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Chest discomfort,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Chest discomfort,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Chest pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Chest pain,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG000,Baseline to end of treatment,other,NA,NA,0,25,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Malaise,5,MedDRA (13.1),Systematic Assessment
NCT00879229,EG001,Baseline to end of treatment,other,NA,NA,1,15,Adverse events were collected based on the randomization group and not with regards to the specific treatment received.,NA,Malaise,5,MedDRA (13.1),Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Acute left ventricular failure,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Acute left ventricular failure,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Acute left ventricular failure,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Acute left ventricular failure,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Acute left ventricular failure,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina pectoris,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina pectoris,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina pectoris,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina pectoris,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina pectoris,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina unstable,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina unstable,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina unstable,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina unstable,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Angina unstable,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Atrial fibrillation,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Atrial fibrillation,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Atrial fibrillation,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Atrial fibrillation,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Atrial fibrillation,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cardiac failure congestive,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cardiac failure congestive,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cardiac failure congestive,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cardiac failure congestive,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cardiac failure congestive,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Coronary artery disease,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Coronary artery disease,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Coronary artery disease,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Coronary artery disease,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Coronary artery disease,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Myocardial infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Myocardial infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Myocardial infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Myocardial infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Myocardial infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Colonic polyp,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Colonic polyp,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Colonic polyp,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Colonic polyp,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Colonic polyp,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Inguinal hernia,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Inguinal hernia,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Inguinal hernia,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Inguinal hernia,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Inguinal hernia,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Oedema peripheral,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cholecystitis,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cholecystitis,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cholecystitis,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cholecystitis,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cholecystitis,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Breast abscess,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Breast abscess,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Breast abscess,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Breast abscess,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Breast abscess,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cellulitis,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cellulitis,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cellulitis,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cellulitis,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Cellulitis,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis bacterial,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis bacterial,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis bacterial,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis bacterial,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Gastroenteritis bacterial,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Graft infection,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Graft infection,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Graft infection,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Graft infection,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Graft infection,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Pneumonia,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Pneumonia,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Pneumonia,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Pneumonia,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Pneumonia,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urosepsis,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urosepsis,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urosepsis,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urosepsis,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urosepsis,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Multiple fractures,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Multiple fractures,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Multiple fractures,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Multiple fractures,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Multiple fractures,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hepatic enzyme increased,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hepatic enzyme increased,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hepatic enzyme increased,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hepatic enzyme increased,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hepatic enzyme increased,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Dehydration,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Dehydration,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Dehydration,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Dehydration,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Dehydration,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hyperglycaemia,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hyperglycaemia,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hyperglycaemia,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hyperglycaemia,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Hyperglycaemia,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Osteoarthritis,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Osteoarthritis,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Osteoarthritis,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Osteoarthritis,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Osteoarthritis,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Rotator cuff syndrome,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Rotator cuff syndrome,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Rotator cuff syndrome,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Rotator cuff syndrome,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Rotator cuff syndrome,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Basal cell carcinoma,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Basal cell carcinoma,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Basal cell carcinoma,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Basal cell carcinoma,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Basal cell carcinoma,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Haemorrhagic stroke,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Haemorrhagic stroke,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Haemorrhagic stroke,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Haemorrhagic stroke,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Haemorrhagic stroke,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Ischaemic cerebral infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Ischaemic cerebral infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Ischaemic cerebral infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Ischaemic cerebral infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Ischaemic cerebral infarction,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus ureteric,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus ureteric,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus ureteric,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus ureteric,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus ureteric,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus urinary,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus urinary,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus urinary,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus urinary,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Calculus urinary,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal failure acute,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal failure acute,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal failure acute,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal failure acute,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal failure acute,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal mass,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal mass,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal mass,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal mass,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Renal mass,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,1,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Benign prostatic hyperplasia,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Benign prostatic hyperplasia,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Benign prostatic hyperplasia,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Benign prostatic hyperplasia,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),serious,NA,NA,0,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Benign prostatic hyperplasia,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,2,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Diarrhoea,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,2,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Diarrhoea,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,5,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Diarrhoea,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,0,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Diarrhoea,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,3,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Diarrhoea,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,5,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Nasopharyngitis,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,4,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Nasopharyngitis,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,9,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Nasopharyngitis,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,4,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Nasopharyngitis,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,15,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Nasopharyngitis,5,MedDRA,Systematic Assessment
NCT00900146,EG000,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,3,93,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urinary tract infection,5,MedDRA,Systematic Assessment
NCT00900146,EG001,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,4,95,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urinary tract infection,5,MedDRA,Systematic Assessment
NCT00900146,EG002,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,5,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urinary tract infection,5,MedDRA,Systematic Assessment
NCT00900146,EG003,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,5,92,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urinary tract infection,5,MedDRA,Systematic Assessment
NCT00900146,EG004,Patients have been exposed up to 15 months (median exposure however was at about 6 months),other,NA,NA,11,179,The data reported below in the safety tables are from the pooled Phase II and Phase III data.,NA,Urinary tract infection,5,MedDRA,Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Acute Respiratory Distress Syndrome,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,2,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Acute Respiratory Distress Syndrome,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,2,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Chronic Obstructive Pulmonary Disease,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,2,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Chronic Obstructive Pulmonary Disease,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Acute Respiratory Failure,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Acute Respiratory Failure,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Dyspnoea,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Dyspnoea,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Respiratory Arrest,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Respiratory Arrest,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,2,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Pneumonia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,2,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Pneumonia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Klebsiella Bacteraemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Klebsiella Bacteraemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Sinusitis Bacterial,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Sinusitis Bacterial,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,2,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Cellulitis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Cellulitis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Echinococciasis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Echinococciasis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Influenza,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Influenza,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Respiratory Tract Infection Viral,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Respiratory Tract Infection Viral,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Septic Shock,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Septic Shock,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Viral Myositis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Viral Myositis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Cardiac Failure Congestive,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,2,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Cardiac Failure Congestive,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Neuroleptic Malignant Syndrome,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Neuroleptic Malignant Syndrome,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Presyncope,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Presyncope,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Confusional State,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Confusional State,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Delirium,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Delirium,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Chest Pain,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Chest Pain,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Multi-organ Disorder,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Multi-organ Disorder,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Diabetic Ketoacidosis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Diabetic Ketoacidosis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Musculoskeletal Chest Pain,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Musculoskeletal Chest Pain,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Back Pain,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Back Pain,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Haematemesis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Haematemesis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Accidental Needle Stick,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Accidental Needle Stick,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Haemodynamic Instability,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,serious,NA,NA,0,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Haemodynamic Instability,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,10,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Diarrhoea,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,12,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Diarrhoea,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,10,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Nausea,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,10,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Nausea,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,7,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Constipation,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,6,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Constipation,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,5,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Vomiting,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,3,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Vomiting,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Insomnia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,10,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Insomnia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,3,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Anxiety,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,5,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Anxiety,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,5,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Alanine Aminotransferase Increased,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,7,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Alanine Aminotransferase Increased,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Blood Creatine Phosphokinase Increased,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,7,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Blood Creatine Phosphokinase Increased,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,3,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Aspartate Aminotransferase Increased,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,6,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Aspartate Aminotransferase Increased,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,3,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Blood Glucose Increased,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,5,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Blood Glucose Increased,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,5,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Hypokalaemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,8,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Hypokalaemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,3,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Hypophosphataemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,2,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Hypophosphataemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,3,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Dehydration,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Dehydration,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,4,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Hypomagnesaemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Hypomagnesaemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,2,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Headache,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,7,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Headache,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,3,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Dizziness,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,1,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Dizziness,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,1,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Hypertension,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,7,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Hypertension,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,3,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Anaemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,5,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Anaemia,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG000,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,4,134,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Epistaxis,2,MedDRA (12.1),Systematic Assessment
NCT00958776,EG001,Adverse events were recorded at least once daily during the period of study drug administration in the hospital and at each follow-up visit until the study completion visit at Day 14 or later.,other,NA,NA,4,264,"For subjects who experienced the same coded event more than once, only one event is presented. Seven of the 405 subjects who were randomized did not receive study drug; safety analyses included 398 subjects (134 in the Placebo+SOC arm and 264 in the Peramivir+SOC arm).",NA,Epistaxis,2,MedDRA (12.1),Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,3,40,NA,NA,Acute graft versus host disease,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Chronic graft versus host disease,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Bacterial sepsis,5,NA,NA
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Encephalitis,5,NA,NA
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,JC virus infection,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Urinary tract infection,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Viral infection,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Abdominal pain,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Ascites,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Diarrhoea,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Nausea,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Hepatitis failure,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Hepatitis toxic,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Febrile neutropenia,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Pain,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Pyrexia,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Rash,5,NA,Systematic Assessment
NCT00967343,EG000,NA,serious,NA,NA,1,40,NA,NA,Dyspnoea,5,NA,Systematic Assessment
NCT00967343,EG000,NA,other,NA,NA,4,40,NA,NA,Acute graft versus host disease,5,NA,Systematic Assessment
NCT00967343,EG000,NA,other,NA,NA,2,40,NA,NA,Cytomegalovirus infection,5,NA,Systematic Assessment
NCT00967343,EG000,NA,other,NA,NA,2,40,NA,NA,abdominal pain,5,NA,Systematic Assessment
NCT00967343,EG000,NA,other,NA,NA,4,40,NA,NA,Diarrhoea,5,NA,Systematic Assessment
NCT00967343,EG000,NA,other,NA,NA,3,40,NA,NA,Vomiting,5,NA,Systematic Assessment
NCT00967343,EG000,NA,other,NA,NA,3,40,NA,NA,Nausea,5,NA,Systematic Assessment
NCT00967343,EG000,NA,other,NA,NA,2,40,NA,NA,Dry mouth,5,NA,Systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Cardiac failure,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Myocardial infarction,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Trachycardia,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Abdominal pain,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Chest pain,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,2,125,NA,NA,Drug withdrawal syndrome,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Oedema,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,pneumonia,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Intervertebral disc protrusion,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Bladder cancer,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Headache,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Subarachnoid haemorrhage,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Calculus urinary,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Nephrolithiasis,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Haematoma,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",serious,NA,NA,1,125,NA,NA,Hypertension,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,7,125,NA,NA,Abdominal pain upper,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,15,125,NA,NA,Constipation,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,13,125,NA,NA,Diarrhoea,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,8,125,NA,NA,Dry mouth,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,19,125,NA,NA,Nausea,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,26,125,NA,NA,Drug Withdrawal Syndrome,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,13,125,NA,NA,Fatigue,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,16,125,NA,NA,Dizziness,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,18,125,NA,NA,Headache,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,16,125,NA,NA,Insomnia,5,MedDRA 13.1,Non-systematic Assessment
NCT00986258,EG000,"In total, subjects were to be treated for up to 12 weeks with tapentadol.",other,NA,NA,10,125,NA,NA,Hyperhidrosis,5,MedDRA 13.1,Non-systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,3,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Anaemia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Anaemia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Abdominal pain,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,2,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Abdominal pain,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Gastrointestinal necrosis,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,1,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Gastrointestinal necrosis,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,1,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Ileus,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Ileus,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Intestinal obstruction,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,1,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Intestinal obstruction,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Intra-abdominal haemorrhage,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,1,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Intra-abdominal haemorrhage,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Peritonitis,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,1,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Peritonitis,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,1,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Generalised oedema,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Generalised oedema,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,1,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Purpura,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",serious,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Purpura,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,15,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Anaemia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Anaemia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Tachycardia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Tachycardia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,4,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Abdominal pain,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,9,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Abdominal pain,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,2,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Abdominal pain upper,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Abdominal pain upper,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Constipation,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,4,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Constipation,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,2,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Diarrhoea,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,7,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Diarrhoea,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,5,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Nausea,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,5,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Nausea,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,0,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Proctalgia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,4,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Proctalgia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,10,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Asthenia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,2,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Asthenia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,4,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Face oedema,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,1,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Face oedema,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,11,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Fatigue,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,6,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Fatigue,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Localised oedema,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Localised oedema,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Oedema,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,1,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Oedema,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,17,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Oedema peripheral,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,2,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Oedema peripheral,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,2,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Pyrexia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Pyrexia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,21,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Weight increased,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,5,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Weight increased,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,2,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Decreased appetite,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Decreased appetite,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,5,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Fluid retention,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,2,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Fluid retention,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,1,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Myalgia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,4,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Myalgia,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Dizziness,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,1,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Dizziness,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,1,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Cough,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Cough,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,11,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Dyspnoea,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Dyspnoea,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG000,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,3,41,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Pleural effusion,5,MedDRA (13.0),Systematic Assessment
NCT00986440,EG001,"Treatment-emergent adverse events (TEAEs) were collected from baseline up to 30 days after last dose, up to 3 years 3 months in the Safety Analysis Set.",other,NA,NA,0,42,"A TEAE was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment. If relationship is missing, the AE is also considered to be related to the drug.",NA,Pleural effusion,5,MedDRA (13.0),Systematic Assessment
NCT01018953,EG000,Up to week 26,serious,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Neoplasm progression,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,2,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",2,Injection site erythema,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Fatigue,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Injection site inflammation,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",3,Injection site pain,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Injection site pruritus,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Injection site reaction,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Oedema,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,3,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",3,Nausea,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,2,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",2,Abdominal pain,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,2,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",2,Constipation,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,2,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",3,Vomiting,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Abdominal distension,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Diarrhoea,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Dyspepsia,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Mucous stools,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,2,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",2,Dizziness,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Headache,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Lethargy,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Nasopharyngitis,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Sinusitis,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,2,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",3,Decreased appetite,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Hypoalbuminaemia,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Metastases to liver,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Metastases to peripheral vascular system,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Breast pain,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Pelvic floor muscle weakness,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Vulvovaginal dryness,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Vision blurred,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Procedural pain,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Groin pain,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Systemic lupus erythematosus,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Anxiety,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Dyspnoea,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Dry skin,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Erythema,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Night sweats,0,MedDRA 13.0,Systematic Assessment
NCT01018953,EG000,Up to week 26,other,NA,NA,1,8,"Dose received prior to AE onset.

Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",1,Flushing,0,MedDRA 13.0,Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",serious,NA,NA,1,4,NA,NA,Squamous cell carcinoma,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",serious,NA,NA,0,5,NA,NA,Squamous cell carcinoma,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Herpes zoster,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Herpes zoster,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Herpes zoster ophthalmic,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Herpes zoster ophthalmic,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,4,NA,NA,Nasopharyngitis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,5,NA,NA,Nasopharyngitis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,4,NA,NA,Rhinitis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,5,NA,NA,Rhinitis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Viral rash,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Viral rash,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Thrombocytopenia,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,5,NA,NA,Thrombocytopenia,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Neutropenia,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Neutropenia,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Constipation,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,5,NA,NA,Constipation,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Abdominal pain upper,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Abdominal pain upper,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Diarrhoea,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Diarrhoea,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Dry mouth,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Dry mouth,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Flatulence,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Flatulence,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Stomatitis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Stomatitis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,4,NA,NA,Asthemia,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,5,NA,NA,Asthemia,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Chills,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Chills,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Oedema peripheral,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Oedema peripheral,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Dysgeusia,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Dysgeusia,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,4,NA,NA,Headache,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,5,NA,NA,Headache,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Peripheral sensory neuropathy,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Peripheral sensory neuropathy,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Eczema,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Eczema,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,4,NA,NA,Pruritis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,5,NA,NA,Pruritis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Rash,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Rash,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Conjunctivitis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Conjunctivitis,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Muscle spasms,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Muscle spasms,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Neck pain,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Neck pain,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Basal cell carcinoma,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Basal cell carcinoma,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Malignant melanoma,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Malignant melanoma,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Libido decrease,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Libido decrease,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG000,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,1,4,NA,NA,Erectile dysfunction,0,MedDRA (10.0),Systematic Assessment
NCT01021423,EG001,"Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.",other,NA,NA,0,5,NA,NA,Erectile dysfunction,0,MedDRA (10.0),Systematic Assessment
NCT01023269,EG000,"Adverse event reporting started at enrollment until study completion and/or study exit, an average of 14 months, whatever applies.",serious,NA,NA,1,17,NA,1,Infection of the device stimulator,0,NA,Systematic Assessment
NCT01023269,EG000,"Adverse event reporting started at enrollment until study completion and/or study exit, an average of 14 months, whatever applies.",other,NA,NA,4,17,NA,6,URINARY INFECTION,0,NA,Systematic Assessment
NCT01023269,EG000,"Adverse event reporting started at enrollment until study completion and/or study exit, an average of 14 months, whatever applies.",other,NA,NA,1,17,NA,2,pain after surgery,0,NA,Systematic Assessment
NCT01023269,EG000,"Adverse event reporting started at enrollment until study completion and/or study exit, an average of 14 months, whatever applies.",other,NA,NA,1,17,NA,1,Bronchitis,0,NA,Systematic Assessment
NCT01023269,EG000,"Adverse event reporting started at enrollment until study completion and/or study exit, an average of 14 months, whatever applies.",other,NA,NA,1,17,NA,1,Battery empty at 07h30 and return of symptoms,0,NA,Systematic Assessment
NCT01023269,EG000,"Adverse event reporting started at enrollment until study completion and/or study exit, an average of 14 months, whatever applies.",other,NA,NA,1,17,NA,1,Lead cut by the nurse,0,NA,Systematic Assessment
NCT01030666,EG000,NA,other,NA,NA,1,28,NA,1,head ache,5,NA,Systematic Assessment
NCT01030666,EG001,NA,other,NA,NA,4,33,NA,4,head ache,5,NA,Systematic Assessment
NCT01030666,EG000,NA,other,NA,NA,3,28,NA,3,Nausea,5,NA,Systematic Assessment
NCT01030666,EG001,NA,other,NA,NA,1,33,NA,1,Nausea,5,NA,Systematic Assessment
NCT01030666,EG000,NA,other,NA,NA,0,28,NA,0,tiredness,5,NA,Systematic Assessment
NCT01030666,EG001,NA,other,NA,NA,2,33,NA,2,tiredness,5,NA,Systematic Assessment
NCT01030666,EG000,NA,other,NA,NA,2,28,NA,2,tooth discomfort/pain,5,NA,Systematic Assessment
NCT01030666,EG001,NA,other,NA,NA,0,33,NA,0,tooth discomfort/pain,5,NA,Systematic Assessment
NCT01030666,EG000,NA,other,NA,NA,2,28,NA,2,mucosal/skin lesions,5,NA,Systematic Assessment
NCT01030666,EG001,NA,other,NA,NA,2,33,NA,2,mucosal/skin lesions,5,NA,Systematic Assessment
NCT01058369,EG000,NA,serious,NA,NA,1,2,NA,1,Pneumonia,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,serious,NA,NA,1,2,NA,1,acute myeloid leukaemia,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,back pain,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,petechiae,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,haematoma,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,thrombophlebitis,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,2,2,NA,2,fatigue,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,dyspnea,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,depression,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,wound,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,nausea,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,dyspepsia,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,abdominal pain upper,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,hypertension,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,emotional distress,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,pain in extremity,0,MedDRA (Unspecified),NA
NCT01058369,EG000,NA,other,NA,NA,1,2,NA,1,gingival bleeding,0,MedDRA (Unspecified),NA
NCT01083472,EG000,NA,serious,NA,NA,0,18,NA,0,Ileus,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,1,Ileus,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,1,18,NA,1,Diarrhea,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,0,19,NA,0,Diarrhea,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,1,18,NA,2,Pyrexia,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,0,19,NA,0,Pyrexia,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,1,18,NA,1,Bacterial Sepsis,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,0,19,NA,0,Bacterial Sepsis,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,0,18,NA,0,Infectious Peritonitis,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,1,Infectious Peritonitis,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,1,18,NA,1,Post Operative Wound Infection,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,0,19,NA,0,Post Operative Wound Infection,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,0,18,NA,0,Sepsis,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,1,Sepsis,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,3,18,NA,3,Wound Infection,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,1,Wound Infection,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,0,18,NA,0,Incisional Hernia,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,1,Incisional Hernia,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,1,18,NA,1,Seroma,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,0,19,NA,0,Seroma,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,3,18,NA,3,Wound Dehiscence,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,7,19,NA,8,Wound Dehiscence,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,2,18,NA,2,Wound Necrosis,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,1,Wound Necrosis,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,0,18,NA,0,Wound Secretion,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,1,Wound Secretion,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,1,18,NA,1,Female Genital Tract Fistula,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,0,19,NA,0,Female Genital Tract Fistula,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,0,18,NA,0,Pleural Effusion,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,2,Pleural Effusion,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,1,18,NA,1,Pulmonary Embolism,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,0,19,NA,0,Pulmonary Embolism,5,NA,NA
NCT01083472,EG000,NA,serious,NA,NA,0,18,NA,0,Circulatory Collapse,5,NA,NA
NCT01083472,EG001,NA,serious,NA,NA,1,19,NA,1,Circulatory Collapse,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,0,18,NA,0,Blood and Lymphatic System Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,3,19,NA,3,Blood and Lymphatic System Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,1,18,NA,1,Cardiac Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,1,19,NA,1,Cardiac Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,1,18,NA,1,Endocrine Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,0,19,NA,0,Endocrine Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,5,18,NA,5,Gastrointestinal Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,7,19,NA,7,Gastrointestinal Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,3,18,NA,3,General Disorders Administration Site Conditions,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,4,19,NA,4,General Disorders Administration Site Conditions,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,11,18,NA,11,Infections and Infestations,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,9,19,NA,9,Infections and Infestations,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,9,18,NA,9,"Injury, Poisoning and Procedural Complications",5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,12,19,NA,12,"Injury, Poisoning and Procedural Complications",5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,2,18,NA,2,Metabolism and Nutrition Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,1,19,NA,1,Metabolism and Nutrition Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,1,18,NA,1,Musculoskeletal and Connective Tissue Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,1,19,NA,1,Musculoskeletal and Connective Tissue Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,2,18,NA,2,Nervous System Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,0,19,NA,0,Nervous System Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,1,18,NA,1,Renal and Urinary Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,1,19,NA,1,Renal and Urinary Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,1,18,NA,1,Reproductive System and Breast Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,0,19,NA,0,Reproductive System and Breast Disorders,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,2,18,NA,2,"Respiratory, Thoracic and Mediastinal Disorders",5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,4,19,NA,4,"Respiratory, Thoracic and Mediastinal Disorders",5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,1,18,NA,1,Surgical and Medical Procedures,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,0,19,NA,0,Surgical and Medical Procedures,5,NA,NA
NCT01083472,EG000,NA,other,NA,NA,1,18,NA,1,Vascular Disorders,5,NA,NA
NCT01083472,EG001,NA,other,NA,NA,2,19,NA,2,Vascular Disorders,5,NA,NA
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Tonsilitis,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Tonsilitis,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Fall,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Fall,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,2,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Convulsion,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,5,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",5,Convulsion,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Rash,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Rash,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Adenoidectomy,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Adenoidectomy,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Upper respiratory tract infection,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Upper respiratory tract infection,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Wound infection,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Wound infection,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Fracture,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Fracture,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Injury,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Injury,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Somnolence,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Somnolence,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Status epilepticus,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,2,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Status epilepticus,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Stevens Johnson Syndrome,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Stevens Johnson Syndrome,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Hospitalization,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,3,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",3,Hospitalization,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Investigation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Investigation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Medical device removal,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Medical device removal,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Surgery,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Surgery,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),serious,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Tonsillectomy,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),serious,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Tonsillectomy,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Neutropenia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Neutropenia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,External ear disorder,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,External ear disorder,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Vision blurred,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Vision blurred,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Abdonimal pain,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Abdonimal pain,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Constipation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Constipation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Vomiting,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,2,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Vomiting,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Fatigue,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Fatigue,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Localised oedema,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Localised oedema,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Medical device pain,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Medical device pain,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Influenza,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Influenza,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Viral infection,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Viral infection,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,2,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Wound infection,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Wound infection,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Fall,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Fall,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Thermal burn,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Thermal burn,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Wrist fracture,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Wrist fracture,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Weight decreased,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Weight decreased,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,2,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Decreased appetite,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,2,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Decreased appetite,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Muscle spasms,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Muscle spasms,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Neck pain,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Neck pain,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,2,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Convulsion,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,4,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",4,Convulsion,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Dizziness,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Dizziness,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Dysarthia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Dysarthia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Grand mal convulsion,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Grand mal convulsion,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Headache,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Headache,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Myoclonus,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Myoclonus,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,2,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Psychomotor hyperactivity,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Psychomotor hyperactivity,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Sedation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,2,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Sedation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Somnolence,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Somnolence,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Speech disorder,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Speech disorder,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Abnormal behavior,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,3,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",3,Abnormal behavior,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Breath holding,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Breath holding,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Depressed mood,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Depressed mood,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Insomnia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Insomnia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Sleep disorder,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Sleep disorder,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Suicidal ideation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Suicidal ideation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Asthma,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Asthma,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,2,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",2,Cough,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Cough,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Dysphonia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Dysphonia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Stridor,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Stridor,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Throat irritation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Throat irritation,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Alopecia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Alopecia,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,1,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Rash pruritic,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,0,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Rash pruritic,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG000,0-52 Weeks (1-Year),other,NA,NA,0,66,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",0,Skin nodule,1,MedDRA 14.0,Systematic Assessment
NCT01118455,EG001,0-52 Weeks (1-Year),other,NA,NA,1,69,"The safety population consists of 66 VNS implanted patients and the AED safety population includes 69 patients who are randomized to the AED arm.

Please note one patient in the VNS safety population who was implanted but never received stimulation was excluded from the ITT population.",1,Skin nodule,1,MedDRA 14.0,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,2,11,All randomized participants who received at least 1 dose of study drug.,NA,Glomerular vascular disorder,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,2,11,All randomized participants who received at least 1 dose of study drug.,NA,Hypercreatininaemia,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Hypertransaminasaemia,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Hypercalcaemia,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Hypercholesterolaemia,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Gastroenteritis,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,2,11,All randomized participants who received at least 1 dose of study drug.,NA,Abdominal pain,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Rhinorrhoea,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,2,11,All randomized participants who received at least 1 dose of study drug.,NA,Hypertriglyceridaemia,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Haematoma,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,4,11,All randomized participants who received at least 1 dose of study drug.,NA,Vomiting,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,2,11,All randomized participants who received at least 1 dose of study drug.,NA,Diarrhoea,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Muscle spasms,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Muscle strain,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Skin discolouration,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Convulsion,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,4,11,All randomized participants who received at least 1 dose of study drug.,NA,Nasopharyngitis,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Pyrexia,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Cough,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Flatulence,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Rash,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Headache,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Scoliosis,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Hypoglycaemia,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Hypernatraemia,0,MedDRA 11.1,Systematic Assessment
NCT01141075,EG000,Baseline up to Day 112 (end of study follow-up),other,NA,NA,1,11,All randomized participants who received at least 1 dose of study drug.,NA,Hyperuricaemia,0,MedDRA 11.1,Systematic Assessment
NCT01143272,EG000,NA,serious,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Duodenal perforation,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Duodenal perforation,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Duodenal ulcer haemorrhage,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Duodenal ulcer haemorrhage,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Upper gastrointestinal haemorrhage,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Upper gastrointestinal haemorrhage,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Sudden cardiac death,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Sudden cardiac death,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Cholecystitis acute,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Cholecystitis acute,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,2,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",2,Sepsis,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Sepsis,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Renal failure,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Renal failure,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Pulmonary empyema,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Pulmonary empyema,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,0,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Hepatic cirrhosis,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Hepatic cirrhosis,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,serious,NA,NA,0,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Bronchial carcinoma,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,serious,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Bronchial carcinoma,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Gastrointestinal pain,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Gastrointestinal pain,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,0,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Gastrointestinal sounds abnormal,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Gastrointestinal sounds abnormal,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Diarrhoea,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Diarrhoea,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Nausea,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,2,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",2,Nausea,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Vomiting,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Vomiting,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Faecal incontinence,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Faecal incontinence,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Flatulence,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Flatulence,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Glossodynia,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Glossodynia,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Ileus paralytic,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Ileus paralytic,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Malaise,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Malaise,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Blood pressure increased,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Blood pressure increased,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Decreased appetite,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Decreased appetite,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Neoplasm malignant,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Neoplasm malignant,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Bronchospasm,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Bronchospasm,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Cough,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Cough,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,2,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",2,Drug eruption,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Drug eruption,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,1,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Erythema,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,0,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Erythema,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,0,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Oral candidiasis,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Oral candidiasis,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,0,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Body temperature increased,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Body temperature increased,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,0,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Dermatitis allergic,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Dermatitis allergic,0,MedDRA 10.0,NA
NCT01143272,EG000,NA,other,NA,NA,0,245,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",0,Erythema,0,MedDRA 10.0,NA
NCT01143272,EG001,NA,other,NA,NA,1,222,"Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.",1,Erythema,0,MedDRA 10.0,NA
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Acute myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Acute myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Acute myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Acute myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Acute myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Acute myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Angina pectoris,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Angina pectoris,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Angina pectoris,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Angina pectoris,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Angina pectoris,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Angina pectoris,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac arrest,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac arrest,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac arrest,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac arrest,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac arrest,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac arrest,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure congestive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure congestive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure congestive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure congestive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure congestive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cardiac failure congestive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Myocardial infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastrointestinal haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastrointestinal haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastrointestinal haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastrointestinal haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastrointestinal haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastrointestinal haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematochezia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematochezia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematochezia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematochezia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematochezia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematochezia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ileus paralytic,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ileus paralytic,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ileus paralytic,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ileus paralytic,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ileus paralytic,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ileus paralytic,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Intestinal obstruction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Intestinal obstruction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Intestinal obstruction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Intestinal obstruction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Intestinal obstruction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Intestinal obstruction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Condition aggravated,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Condition aggravated,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Condition aggravated,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Condition aggravated,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Condition aggravated,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Condition aggravated,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Death,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Death,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Death,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Death,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Death,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Death,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cholangitis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cholangitis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cholangitis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cholangitis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cholangitis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cholangitis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urosepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urosepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urosepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urosepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urosepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urosepsis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Concussion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Concussion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Concussion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Concussion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Concussion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Concussion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Femur fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Femur fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Femur fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Femur fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Femur fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Femur fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Electrocardiogram ST-T change,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Electrocardiogram ST-T change,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Electrocardiogram ST-T change,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Electrocardiogram ST-T change,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Electrocardiogram ST-T change,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Electrocardiogram ST-T change,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hyperglycaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hyperglycaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hyperglycaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hyperglycaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hyperglycaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hyperglycaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Metastases to bone,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Metastases to bone,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Metastases to bone,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Metastases to bone,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Metastases to bone,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Metastases to bone,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Brain oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Brain oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Brain oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Brain oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Brain oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Brain oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebrovascular accident,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebrovascular accident,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebrovascular accident,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebrovascular accident,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebrovascular accident,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cerebrovascular accident,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Epilepsy,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Epilepsy,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Epilepsy,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Epilepsy,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Epilepsy,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Epilepsy,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhage intracranial,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhage intracranial,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhage intracranial,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhage intracranial,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhage intracranial,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhage intracranial,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic cerebral infarction,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Ischaemic stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Subarachnoid haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Subarachnoid haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Subarachnoid haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Subarachnoid haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Subarachnoid haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Subarachnoid haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Disorientation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Disorientation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Disorientation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Disorientation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Disorientation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Disorientation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Asphyxia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Asphyxia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Asphyxia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Asphyxia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Asphyxia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Asphyxia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia aspiration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia aspiration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia aspiration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia aspiration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia aspiration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pneumonia aspiration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,3,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",serious,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Anaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Leukocytosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Leukocytosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Leukocytosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Leukocytosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Leukocytosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Leukocytosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Neutrophilia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Neutrophilia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Neutrophilia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Neutrophilia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Neutrophilia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Neutrophilia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Thrombocytopenia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Thrombocytopenia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Thrombocytopenia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Thrombocytopenia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Thrombocytopenia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Thrombocytopenia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial fibrillation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bradycardia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bradycardia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bradycardia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bradycardia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bradycardia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bradycardia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Coronary artery occlusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Coronary artery occlusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Coronary artery occlusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Coronary artery occlusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Coronary artery occlusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Coronary artery occlusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Supraventricular extrasystoles,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Supraventricular extrasystoles,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Supraventricular extrasystoles,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Supraventricular extrasystoles,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Supraventricular extrasystoles,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Supraventricular extrasystoles,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial septal defect,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial septal defect,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial septal defect,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial septal defect,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial septal defect,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atrial septal defect,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vertigo,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vertigo,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vertigo,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vertigo,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vertigo,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vertigo,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Conjunctival hyperaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Conjunctival hyperaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Conjunctival hyperaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Conjunctival hyperaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Conjunctival hyperaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Conjunctival hyperaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Eye disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Eye disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Eye disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Eye disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Eye disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Eye disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal distension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal distension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal distension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal distension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal distension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal distension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal pain upper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal pain upper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal pain upper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal pain upper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal pain upper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Abdominal pain upper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Constipation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Constipation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Constipation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Constipation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,8,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Constipation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,14,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Constipation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,9,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,10,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspepsia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspepsia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspepsia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspepsia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspepsia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspepsia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gastritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Nausea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Nausea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Nausea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Nausea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Nausea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Nausea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vomiting,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vomiting,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vomiting,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vomiting,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vomiting,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Vomiting,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Face oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Face oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Face oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Face oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Face oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Face oedema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Feeling cold,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Feeling cold,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Feeling cold,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Feeling cold,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Feeling cold,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Feeling cold,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Oedema peripheral,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Oedema peripheral,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Oedema peripheral,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Oedema peripheral,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Oedema peripheral,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Oedema peripheral,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pyrexia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pyrexia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pyrexia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pyrexia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,7,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pyrexia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,6,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pyrexia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Genitourinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Genitourinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Genitourinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Genitourinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Genitourinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Genitourinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Herpes zoster,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Herpes zoster,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Herpes zoster,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Herpes zoster,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Herpes zoster,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Herpes zoster,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Upper respiratory tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Upper respiratory tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Upper respiratory tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Upper respiratory tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Upper respiratory tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Upper respiratory tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,8,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,8,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary tract infection,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Contusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Contusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Contusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Contusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Contusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Contusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Excoriation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Excoriation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Excoriation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Excoriation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Excoriation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Excoriation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fall,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Joint dislocation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Joint dislocation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Joint dislocation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Joint dislocation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Joint dislocation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Joint dislocation,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Laceration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Laceration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Laceration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Laceration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Laceration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Laceration,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Limb injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Limb injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Limb injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Limb injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Limb injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Limb injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Lip injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Lip injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Lip injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Lip injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Lip injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Lip injury,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Alanine aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aspartate aminotransferase increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood bilirubin abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood bilirubin abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood bilirubin abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood bilirubin abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood bilirubin abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood bilirubin abnormal,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood potassium decreased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood potassium decreased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood potassium decreased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood potassium decreased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood potassium decreased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood potassium decreased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood pressure increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood pressure increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood pressure increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood pressure increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood pressure increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Blood pressure increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Red blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Red blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Red blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Red blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Red blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Red blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Transaminases increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Transaminases increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Transaminases increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Transaminases increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Transaminases increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Transaminases increased,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,White blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,White blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,White blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,White blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,White blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,White blood cells urine positive,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Decreased appetite,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Decreased appetite,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Decreased appetite,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Decreased appetite,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Decreased appetite,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Decreased appetite,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fluid imbalance,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fluid imbalance,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fluid imbalance,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fluid imbalance,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fluid imbalance,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Fluid imbalance,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypokalaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypokalaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypokalaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypokalaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,7,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypokalaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypokalaemia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Arthralgia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Arthralgia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Arthralgia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Arthralgia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Arthralgia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Arthralgia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Back pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Back pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Back pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Back pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Back pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Back pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gouty arthritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gouty arthritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gouty arthritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gouty arthritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gouty arthritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Gouty arthritis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Muscular weakness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Muscular weakness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Muscular weakness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Muscular weakness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Muscular weakness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Muscular weakness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Musculoskeletal pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Musculoskeletal pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Musculoskeletal pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Musculoskeletal pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Musculoskeletal pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Musculoskeletal pain,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pain in extremity,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pain in extremity,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pain in extremity,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pain in extremity,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,9,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pain in extremity,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pain in extremity,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dementia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dementia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dementia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dementia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dementia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dementia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dizziness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dizziness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dizziness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dizziness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dizziness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dizziness,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhagic transformation stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhagic transformation stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhagic transformation stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhagic transformation stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhagic transformation stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haemorrhagic transformation stroke,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Headache,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Headache,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Headache,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Headache,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,5,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Headache,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,7,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Headache,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Somnolence,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Somnolence,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Somnolence,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Somnolence,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Somnolence,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Somnolence,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Syncope,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Syncope,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Syncope,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Syncope,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Syncope,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Syncope,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depressed mood,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depressed mood,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depressed mood,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depressed mood,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,5,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depressed mood,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depressed mood,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Insomnia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Insomnia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Insomnia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Insomnia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,7,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Insomnia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Insomnia,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep disorder,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Albuminuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Albuminuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Albuminuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Albuminuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Albuminuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Albuminuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dysuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dysuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dysuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dysuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,5,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dysuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dysuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,7,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal cyst,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal cyst,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal cyst,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal cyst,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal cyst,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal cyst,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal failure acute,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal failure acute,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal failure acute,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal failure acute,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal failure acute,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Renal failure acute,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urethral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urethral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urethral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urethral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urethral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urethral haemorrhage,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary retention,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary retention,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary retention,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary retention,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary retention,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Urinary retention,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atelectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atelectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atelectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atelectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atelectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Atelectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bronchiectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bronchiectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bronchiectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bronchiectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bronchiectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Bronchiectasis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cough,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cough,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cough,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cough,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cough,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Cough,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspnoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspnoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspnoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspnoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspnoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dyspnoea,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pleural effusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pleural effusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pleural effusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pleural effusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pleural effusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pleural effusion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary congestion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary congestion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary congestion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary congestion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary congestion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary congestion,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep apnoea syndrome,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep apnoea syndrome,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep apnoea syndrome,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep apnoea syndrome,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep apnoea syndrome,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Sleep apnoea syndrome,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis contact,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis contact,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis contact,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis contact,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis contact,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis contact,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis diaper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis diaper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis diaper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis diaper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis diaper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Dermatitis diaper,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Erythema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Erythema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Erythema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Erythema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,5,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Erythema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Erythema,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pruritus,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pruritus,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pruritus,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pruritus,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pruritus,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Pruritus,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aortic aneurysm,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aortic aneurysm,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aortic aneurysm,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aortic aneurysm,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aortic aneurysm,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Aortic aneurysm,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Deep vein thrombosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Deep vein thrombosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Deep vein thrombosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Deep vein thrombosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Deep vein thrombosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Deep vein thrombosis,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematoma,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematoma,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematoma,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematoma,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematoma,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Haematoma,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypertension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypertension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypertension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypertension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,3,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypertension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,2,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypertension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG000,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypotension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG001,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,9,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypotension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG002,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,0,11,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypotension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG003,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,1,10,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypotension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG004,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,4,70,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypotension,5,MedDRA 16.1,Non-systematic Assessment
NCT01208233,EG005,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.",other,NA,NA,7,67,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",NA,Hypotension,5,MedDRA 16.1,Non-systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Cholecystitis,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Appendicitis,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,2,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,2,Pneumonia,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Ankle fracture,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Injury,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Cervical spinal stenosis,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,2,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,2,Systemic lupus erythematosus,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Cerebrovascular accident,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Convulsion,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Myelitis transverse,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Syncope,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,serious,NA,NA,1,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,1,Pleurisy,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,10,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,17,Diarrhoea,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,10,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,12,Nausea,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,8,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,9,Bronchitis,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,11,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,13,Nasopharyngitis,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,10,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,10,Sinusitis,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,20,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,25,Upper respiratory tract infection,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,10,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,11,Urinary tract infection,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,12,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,15,Arthralgia,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,15,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,18,Arthritis,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,7,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,10,Pain in extremity,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,18,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,26,Systemic lupus erythematosus,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,10,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,16,Headache,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,7,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,7,Anxiety,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,7,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,7,Oropharyngeal pain,5,MedDRA 13.0,Systematic Assessment
NCT01240694,EG000,Baseline up to Week 72,other,NA,NA,16,136,Safety analysis set included all enrolled participants who took at least 1 dose of study drug.,17,Systemic lupus erythematosus rash,5,MedDRA 13.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Iron deficiency anaemia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Iron deficiency anaemia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Myocardial infarction,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Myocardial infarction,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pericarditis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pericarditis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Abdominal pain,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Abdominal pain,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anal fistula,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anal fistula,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anal haemorrhage,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anal haemorrhage,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Colitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Colitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Enterocolitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Enterocolitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hiatus hernia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hiatus hernia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Chest pain,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Chest pain,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hernia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hernia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cholecystitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cholecystitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cholecystitis acute,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cholecystitis acute,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cholelithiasis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cholelithiasis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Acute hepatitis C,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Acute hepatitis C,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anal abscess,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anal abscess,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cerebral toxoplasmosis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cerebral toxoplasmosis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Chronic sinusitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Chronic sinusitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Eye infection syphilitic,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Eye infection syphilitic,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Gastroenteritis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Gastroenteritis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hepatitis A,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hepatitis A,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Lymph node abscess,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Lymph node abscess,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Neurosyphilis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Neurosyphilis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pharyngotonsillitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pharyngotonsillitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pneumonia bacterial,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pneumonia bacterial,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pneumonia viral,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pneumonia viral,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pyelonephritis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pyelonephritis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Viral infection,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Viral infection,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Patella fracture,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Patella fracture,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Toxicity to various agents,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Toxicity to various agents,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Amylase increased,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Amylase increased,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hepatic enzyme increased,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Abnormal loss of weight,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Abnormal loss of weight,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Dehydration,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Dehydration,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Intervertebral disc protrusion,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Intervertebral disc protrusion,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Rhabdomyolysis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Rhabdomyolysis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hodgkin's disease,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Hodgkin's disease,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Kaposi's sarcoma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Kaposi's sarcoma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Lung adenocarcinoma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Lung adenocarcinoma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Lymphoma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Lymphoma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Castleman's disease,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Castleman's disease,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Testis cancer,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Testis cancer,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Uterine leiomyoma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Uterine leiomyoma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Loss of consciousness,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Loss of consciousness,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Syncope,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Syncope,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Ectopic pregnancy,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Ectopic pregnancy,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anxiety disorder,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anxiety disorder,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Bipolar I disorder,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Bipolar I disorder,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Drug abuse,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Drug abuse,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Drug dependence,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Drug dependence,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Mania,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Mania,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Stress,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Stress,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Suicidal ideation,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Suicidal ideation,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Suicide attempt,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Suicide attempt,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Haematuria,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Priapism,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Priapism,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Dyspnoea,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Dyspnoea,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pulmonary embolism,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Rash,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Rash,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Drug rehabilitation,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Drug rehabilitation,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Papilloma excision,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Papilloma excision,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Deep vein thrombosis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Deep vein thrombosis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Proctitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Proctitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Proctitis ulcerative,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Proctitis ulcerative,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anaphylactic reaction,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anaphylactic reaction,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Amoebic dysentery,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Amoebic dysentery,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Epididymitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Epididymitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pneumonia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Pneumonia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Shigella infection,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Shigella infection,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Concussion,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Concussion,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Radius fracture,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Osteoarthritis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Osteoarthritis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Presyncope,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Presyncope,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Alcohol withdrawal syndrome,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Alcohol withdrawal syndrome,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Major depression,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,2,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Major depression,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Mental disorder,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Mental disorder,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Schizophrenia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Schizophrenia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Asthma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Asthma,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Chronic obstructive pulmonary disease,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Chronic obstructive pulmonary disease,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anal lesion excision,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Anal lesion excision,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,"THROMBUS, AORTIC HEPATIC ARTERY",5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,"THROMBUS, AORTIC HEPATIC ARTERY",5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Gastrointestinal necrosis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Gastrointestinal necrosis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,1,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Herpes zoster infection neurological,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,serious,NA,NA,0,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Herpes zoster infection neurological,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,88,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,135,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Diarrhoea,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,34,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Nausea,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,45,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Nausea,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,27,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Fatigue,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,46,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Fatigue,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,25,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Bronchitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,24,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Bronchitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,23,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Gastroenteritis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,16,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Gastroenteritis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,48,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Nasopharyngitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,55,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Nasopharyngitis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,40,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Upper respiratory tract infection,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,45,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Upper respiratory tract infection,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,22,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Back pain,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,23,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Back pain,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,27,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Headache,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,47,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Headache,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,26,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,29,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Depression,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,15,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Insomnia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,25,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Insomnia,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,27,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cough,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,30,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Cough,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,37,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Rash,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,30,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Rash,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,9,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Abdominal distension,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,22,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Abdominal distension,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,22,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Influenza,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,20,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Influenza,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,15,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Syphilis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,23,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Syphilis,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,22,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Blood cholesterol increased,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,10,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Blood cholesterol increased,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG000,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,22,396,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Low density lipoprotein increased,5,MedDRA v17.0,Systematic Assessment
NCT01345630,EG001,From the day the first dose of the study drug was administered to 28 days after the last dose of the study drug was administered.,other,NA,NA,11,401,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",NA,Low density lipoprotein increased,5,MedDRA v17.0,Systematic Assessment
NCT01370863,EG000,NA,other,NA,NA,13,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Diarrhea,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,2,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Diarrhea,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,3,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Abdominal pain,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,2,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Abdominal pain,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,3,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Nausea,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,2,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Nausea,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,2,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Abdominal pain upper,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,0,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Abdominal pain upper,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,2,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Dyspepsia,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,1,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Dyspepsia,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,0,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Abdominal distension,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,2,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Abdominal distension,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,12,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Headache,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,4,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Headache,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,2,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Dizziness,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,2,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Dizziness,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,1,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Influenza,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,2,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Influenza,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,3,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Nasopharyngitis,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,1,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Nasopharyngitis,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,0,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Pharyngitis,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,2,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Pharyngitis,5,NA,NA
NCT01370863,EG000,NA,other,NA,NA,0,34,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Edema peripheral,5,NA,NA
NCT01370863,EG001,NA,other,NA,NA,2,31,The Safety Population was defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).,NA,Edema peripheral,5,NA,NA
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,1,13,NA,NA,HEPATITIS,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,0,8,NA,NA,HEPATITIS,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,1,13,NA,NA,METABOLIC ACIDOSIS,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,0,8,NA,NA,METABOLIC ACIDOSIS,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,1,13,NA,NA,HYPERCAPNIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,0,8,NA,NA,HYPERCAPNIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,0,13,NA,NA,PNEUMOTHORAX,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,2,8,NA,NA,PNEUMOTHORAX,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,1,13,NA,NA,CIRCULATORY COLLAPSE,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,0,8,NA,NA,CIRCULATORY COLLAPSE,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,0,13,NA,NA,SEPSIS,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",serious,NA,NA,1,8,NA,NA,SEPSIS,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,3,13,NA,NA,ANAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,8,NA,NA,ANAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,3,13,NA,NA,GENERALISED OEDEMA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,GENERALISED OEDEMA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,COAGULOPATHY,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,8,NA,NA,COAGULOPATHY,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,2,13,NA,NA,VOMITING,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,VOMITING,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,BILIRUBIN CONJUGATED INCREASED,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,BILIRUBIN CONJUGATED INCREASED,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,BODY TEMPERATURE INCREASED,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,BODY TEMPERATURE INCREASED,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,C-REACTIVE PROTEIN INCREASED,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,C-REACTIVE PROTEIN INCREASED,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,DYSPHONIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,DYSPHONIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,ENDOTRACHEAL INTUBATION COMPLICATION,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,ENDOTRACHEAL INTUBATION COMPLICATION,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,GASTRIC HAEMORRHAGE,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,GASTRIC HAEMORRHAGE,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,13,NA,NA,HYPOGLYCAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,8,NA,NA,HYPOGLYCAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,13,NA,NA,HYPOKALAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,8,NA,NA,HYPOKALAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,13,NA,NA,HYPOPHOSPHATAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,8,NA,NA,HYPOPHOSPHATAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,INFECTIOUS DISEASE CARRIER,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,INFECTIOUS DISEASE CARRIER,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,13,NA,NA,METABOLIC ACIDOSIS,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,8,NA,NA,METABOLIC ACIDOSIS,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,METHAEMOGLOBINAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,METHAEMOGLOBINAEMIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,MITRAL VALVE INCOMPETENCE,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,MITRAL VALVE INCOMPETENCE,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,PNEUMOMEDIASTINUM,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,PNEUMOMEDIASTINUM,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,PNEUMOTHORAX,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,PNEUMOTHORAX,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,PROCEDURAL COMPLICATION,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,PROCEDURAL COMPLICATION,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG000,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,1,13,NA,NA,THROMBOCYTOPENIA,5,MedDRA version 16.0,Systematic Assessment
NCT01389856,EG001,"Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events",other,NA,NA,0,8,NA,NA,THROMBOCYTOPENIA,5,MedDRA version 16.0,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Febrile neutropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Febrile neutropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Febrile neutropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pancytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pancytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pancytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Acute myocardial infarction,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Acute myocardial infarction,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Acute myocardial infarction,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Atrial fibrillation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Atrial fibrillation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Atrial fibrillation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Coronary artery disease,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Coronary artery disease,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Coronary artery disease,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myocardial infarction,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myocardial infarction,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myocardial infarction,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinnitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinnitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinnitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nausea,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nausea,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nausea,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Stomatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Stomatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Stomatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vomiting,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vomiting,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vomiting,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,General physical health deterioration,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,General physical health deterioration,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,General physical health deterioration,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pyrexia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pyrexia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pyrexia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abscess limb,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abscess limb,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abscess limb,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bacteraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bacteraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bacteraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pneumonia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pneumonia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pneumonia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pseudomonas infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pseudomonas infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pseudomonas infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Accidental overdose,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Accidental overdose,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Accidental overdose,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheostomy malfunction,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheostomy malfunction,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheostomy malfunction,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alanine aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alanine aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alanine aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aspartate aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aspartate aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aspartate aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood phosphorous decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood phosphorous decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood phosphorous decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram ST segment depression,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram ST segment depression,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram ST segment depression,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Troponin increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Troponin increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Troponin increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dehydration,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dehydration,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dehydration,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cerebrovascular accident,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cerebrovascular accident,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cerebrovascular accident,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal failure acute,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal failure acute,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal failure acute,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal impairment,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal impairment,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal impairment,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoxia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoxia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoxia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Obstructive airway disorder,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Obstructive airway disorder,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Obstructive airway disorder,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pharyngeal haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pharyngeal haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pharyngeal haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pneumonitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pneumonitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pneumonitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pulmonary embolism,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pulmonary embolism,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pulmonary embolism,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,serious,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheal fistula,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,serious,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheal fistula,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,serious,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheal fistula,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,4,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Anaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,10,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Anaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,4,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Anaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Disseminated intravascular coagulation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Disseminated intravascular coagulation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Disseminated intravascular coagulation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erythropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erythropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erythropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,7,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Leukopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,13,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Leukopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,6,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Leukopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphadenopathy,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphadenopathy,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphadenopathy,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphatic obstruction,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphatic obstruction,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphatic obstruction,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,3,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neutropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,10,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neutropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,5,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neutropenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pancytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pancytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pancytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombocytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,9,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombocytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,7,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombocytopenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Atrial fibrillation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Atrial fibrillation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Atrial fibrillation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bundle branch block left,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bundle branch block left,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bundle branch block left,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tachycardia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tachycardia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tachycardia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Deafness,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Deafness,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Deafness,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ear discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ear discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ear discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ear pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,5,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ear pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,3,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ear pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperacusis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperacusis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperacusis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoacusis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoacusis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoacusis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,4,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinnitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinnitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinnitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vertigo,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vertigo,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vertigo,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperthyroidism,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperthyroidism,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperthyroidism,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Periorbital oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Periorbital oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Periorbital oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abdominal pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abdominal pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abdominal pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abdominal pain upper,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abdominal pain upper,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Abdominal pain upper,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Breath odor,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Breath odor,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Breath odor,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,13,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Constipation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,22,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Constipation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,9,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Constipation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,10,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diarrhoea,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,7,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diarrhoea,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,3,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diarrhoea,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,10,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dry mouth,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,11,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dry mouth,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,5,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dry mouth,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,3,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dyspepsia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,4,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dyspepsia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dyspepsia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,6,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,12,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphagia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Epigastric discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Epigastric discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Epigastric discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gastritis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gastritis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gastritis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gastrooesophageal reflux disease,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,5,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gastrooesophageal reflux disease,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gastrooesophageal reflux disease,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Glossitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Glossitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Glossitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Glossodynia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Glossodynia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,3,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Glossodynia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemorrhoids,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemorrhoids,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemorrhoids,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mouth ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mouth ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mouth ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,14,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nausea,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,20,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nausea,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,14,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nausea,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,5,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Odynophagia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,5,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Odynophagia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,4,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Odynophagia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral mucosal erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral mucosal erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral mucosal erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,9,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,7,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Regurgitation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Regurgitation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Regurgitation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Saliva altered,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Saliva altered,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Saliva altered,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Salivary hypersecretion,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Salivary hypersecretion,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Salivary hypersecretion,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Stomatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Stomatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Stomatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Swollen tongue,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Swollen tongue,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Swollen tongue,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,9,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vomiting,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,12,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vomiting,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,10,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Vomiting,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,3,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Asthenia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,4,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Asthenia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,4,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Asthenia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site haemorrhage,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site inflammation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site inflammation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site inflammation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Catheter site pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug intolerance,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug intolerance,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug intolerance,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Face oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Face oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Face oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,8,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Fatigue,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,7,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Fatigue,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,5,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Fatigue,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperthermia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperthermia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperthermia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Infusion site erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Infusion site erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Infusion site erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Local swelling,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Local swelling,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Local swelling,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Localized oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Localized oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Localized oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Malaise,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Malaise,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Malaise,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oedema peripheral,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oedema peripheral,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oedema peripheral,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pyrexia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pyrexia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pyrexia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperbilirubinemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperbilirubinemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperbilirubinemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug hypersensitivity,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug hypersensitivity,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug hypersensitivity,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bronchitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bronchitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Bronchitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diverticulitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diverticulitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diverticulitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erysipelas,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erysipelas,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erysipelas,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Febrile infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Febrile infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Febrile infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hand-foot-and-mouth disease,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hand-foot-and-mouth disease,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hand-foot-and-mouth disease,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Herpes simplex,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Herpes simplex,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Herpes simplex,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Infective glossitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Infective glossitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Infective glossitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Laryngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Laryngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Laryngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection fungal,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection fungal,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lower respiratory tract infection fungal,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,4,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nasopharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nasopharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,3,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nasopharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,11,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral candidiasis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,18,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral candidiasis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,8,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oral candidiasis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oropharyngeal candidiasis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oropharyngeal candidiasis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oropharyngeal candidiasis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural cellulitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural cellulitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural cellulitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Postoperative wound infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Postoperative wound infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Postoperative wound infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pseudomonas infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pseudomonas infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pseudomonas infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Staphylococcal infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Staphylococcal infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Staphylococcal infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Staphylococcal pharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Staphylococcal pharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Staphylococcal pharyngitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinea cruris,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinea cruris,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tinea cruris,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheostomy infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheostomy infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheostomy infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Upper respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Upper respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Upper respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Urinary tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Urinary tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Urinary tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Viral infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Viral infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Viral infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Viral upper respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Viral upper respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Viral upper respiratory tract infection,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Accidental overdose,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Accidental overdose,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Accidental overdose,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural haematoma,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural haematoma,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural haematoma,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Post procedural oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Radiation fibrosis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Radiation fibrosis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Radiation fibrosis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,7,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Radiation skin injury,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,8,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Radiation skin injury,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,5,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Radiation skin injury,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Suture related complication,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Suture related complication,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Suture related complication,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheal obstruction,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheal obstruction,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tracheal obstruction,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alanine aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,4,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alanine aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alanine aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aspartate aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aspartate aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,3,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aspartate aminotransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood alkaline phosphotase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood alkaline phosphotase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood alkaline phosphotase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood bicarbonate decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood bicarbonate decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood bicarbonate decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood bilirubin increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood bilirubin increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood bilirubin increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood calcium decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood calcium decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood calcium decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood chloride decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood chloride decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood chloride decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood cholesterol increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood cholesterol increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood cholesterol increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood creatinine increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,5,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood creatinine increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood creatinine increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood glucose increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood glucose increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood glucose increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood potassium decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood potassium decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood potassium decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood pressure diastolic increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood pressure diastolic increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood pressure diastolic increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood pressure increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood pressure increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood pressure increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood triglycerides increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood triglycerides increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood triglycerides increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood urea increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood urea increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Blood urea increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,C-reactive protein increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,C-reactive protein increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,C-reactive protein increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Creatinine renal clearance decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Creatinine renal clearance decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Creatinine renal clearance decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram QT prolonged,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram QT prolonged,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram QT prolonged,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram change,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram change,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrocardiogram change,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gamma-glutamyltransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gamma-glutamyltransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gamma-glutamyltransferase increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Globulins decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Globulins decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Globulins decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haematocrit decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haematocrit decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haematocrit decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemoglobin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemoglobin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemoglobin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphocyte count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphocyte count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphocyte count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell haemoglobin concentration decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell haemoglobin concentration decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell haemoglobin concentration decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell haemoglobin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell haemoglobin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell haemoglobin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell volume decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell volume decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Mean cell volume decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neutrophil count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neutrophil count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,6,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neutrophil count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Platelet count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,7,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Platelet count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,8,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Platelet count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Prealbumin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Prealbumin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Prealbumin decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Red blood cell count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Red blood cell count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Red blood cell count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal function test abnormal,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal function test abnormal,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal function test abnormal,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Reticulocyte count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Reticulocyte count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Reticulocyte count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,7,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Weight decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,11,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Weight decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,11,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Weight decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,White blood cell count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,White blood cell count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,9,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,White blood cell count decreased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,5,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Decreased appetite,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,4,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Decreased appetite,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Decreased appetite,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dehydration,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,5,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dehydration,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dehydration,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diabetes mellitus inadequate control,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diabetes mellitus inadequate control,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Diabetes mellitus inadequate control,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrolyte imbalance,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrolyte imbalance,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Electrolyte imbalance,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gout,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gout,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Gout,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperglycaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperglycaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperglycaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperkalaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperkalaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperkalaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypernatraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypernatraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypernatraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypertriglyceridaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypertriglyceridaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypertriglyceridaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperuricaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperuricaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperuricaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypocalcaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypocalcaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,4,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypocalcaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypokalaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,5,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypokalaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,4,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypokalaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypomagnesaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypomagnesaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypomagnesaemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyponatraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyponatraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyponatraemia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypophagia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypophagia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypophagia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Arthralgia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Arthralgia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Arthralgia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Back pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Back pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Back pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Muscle twitching,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Muscle twitching,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Muscle twitching,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Musculoskeletal chest pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Musculoskeletal chest pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Musculoskeletal chest pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Musculoskeletal discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Musculoskeletal discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Musculoskeletal discomfort,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myalgia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myalgia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myalgia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neck pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neck pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Neck pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pain in extremity,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pain in extremity,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pain in extremity,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pain in jaw,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pain in jaw,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pain in jaw,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tumour ulceration,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ageusia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ageusia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ageusia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphasia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphasia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphasia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphonia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphonia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aphonia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cognitive disorder,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cognitive disorder,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cognitive disorder,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dizziness,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,7,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dizziness,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dizziness,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drooling,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drooling,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drooling,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,12,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysgeusia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,11,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysgeusia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,5,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysgeusia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,8,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Headache,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,6,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Headache,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,3,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Headache,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypogeusia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypogeusia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypogeusia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lethargy,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lethargy,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lethargy,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myoclonus,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myoclonus,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Myoclonus,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Polyneuropathy,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Polyneuropathy,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Polyneuropathy,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue biting,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue biting,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue biting,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue paralysis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue paralysis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Tongue paralysis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Agitation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Agitation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Agitation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Anxiety,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,4,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Anxiety,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,4,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Anxiety,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Confusional state,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Confusional state,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Confusional state,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Depressed mood,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Depressed mood,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Depressed mood,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Depression,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Depression,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Depression,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug dependence,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug dependence,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Drug dependence,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,4,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Insomnia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,6,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Insomnia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Insomnia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Chromaturia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Chromaturia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Chromaturia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nocturia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nocturia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Nocturia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oliguria,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oliguria,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oliguria,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Polyuria,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Polyuria,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Polyuria,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Proteinuria,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Proteinuria,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Proteinuria,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal failure,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal failure,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Renal failure,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Urinary retention,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Urinary retention,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Urinary retention,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cough,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cough,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,7,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Cough,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,3,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphonia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,3,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphonia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,3,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dysphonia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dyspnoea,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dyspnoea,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dyspnoea,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Epiglottic oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Epiglottic oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Epiglottic oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemoptysis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,4,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemoptysis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Haemoptysis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hiccups,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hiccups,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hiccups,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoxia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoxia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypoxia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,4,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Increased upper airway secretion,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,4,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Increased upper airway secretion,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Increased upper airway secretion,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Laryngeal oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Laryngeal oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Laryngeal oedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,4,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oropharyngeal pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,8,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oropharyngeal pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,6,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Oropharyngeal pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pleuritic pain,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pleuritic pain,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pleuritic pain,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Productive cough,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Productive cough,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Productive cough,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rhinorrhoea,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rhinorrhoea,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rhinorrhoea,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Sputum discolored,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Sputum discolored,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Sputum discolored,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Sputum increased,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Sputum increased,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Sputum increased,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Upper-airway cough syndrome,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Upper-airway cough syndrome,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Upper-airway cough syndrome,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alopecia,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alopecia,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Alopecia,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,3,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dermatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dermatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Dermatitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ecchymosis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ecchymosis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Ecchymosis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Erythema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperhidrosis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperhidrosis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hyperhidrosis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Photodermatosis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Photodermatosis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Photodermatosis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pruritis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pruritis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Pruritis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Psoriasis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Psoriasis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Psoriasis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash macular,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash macular,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash macular,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash pruritic,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash pruritic,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Rash pruritic,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Skin discoloration,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Skin discoloration,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Skin discoloration,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Skin exfoliation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Skin exfoliation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Skin exfoliation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aortic dilatation,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aortic dilatation,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Aortic dilatation,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Deep vein thrombosis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Deep vein thrombosis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Deep vein thrombosis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypertension,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypertension,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypertension,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,2,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypotension,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,2,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypotension,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,2,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Hypotension,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphoedema,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphoedema,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Lymphoedema,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Orthostatic hypotension,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,1,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Orthostatic hypotension,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Orthostatic hypotension,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,1,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombophlebitis,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombophlebitis,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,0,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombophlebitis,0,MedDRA,Systematic Assessment
NCT01403064,EG000,Up to 15 months for each participant,other,NA,NA,0,23,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombophlebitis superficial,0,MedDRA,Systematic Assessment
NCT01403064,EG001,Up to 15 months for each participant,other,NA,NA,0,32,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombophlebitis superficial,0,MedDRA,Systematic Assessment
NCT01403064,EG002,Up to 15 months for each participant,other,NA,NA,1,21,"Safety Population (SP) defined as any subject who received at least 1 dose of ALD518 or placebo. Subjects were analyzed based on the treatment they received. As pre-specified, the two treatment groups that received 160 mg were combined into one 160 mg group.",NA,Thrombophlebitis superficial,0,MedDRA,Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,1,7,NA,NA,Haemorrhagic anaemia,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,0,8,NA,NA,Haemorrhagic anaemia,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Haemorrhagic anaemia,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,0,10,NA,NA,Haemorrhagic anaemia,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Haemorrhagic anaemia,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Haemorrhagic anaemia,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Cardiac tamponade,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,1,8,NA,NA,Cardiac tamponade,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Cardiac tamponade,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,0,10,NA,NA,Cardiac tamponade,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Cardiac tamponade,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Cardiac tamponade,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Coronary artery occlusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,1,8,NA,NA,Coronary artery occlusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Coronary artery occlusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,0,10,NA,NA,Coronary artery occlusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Coronary artery occlusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Coronary artery occlusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Low cardiac output syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,1,8,NA,NA,Low cardiac output syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,1,7,NA,NA,Low cardiac output syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,0,10,NA,NA,Low cardiac output syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Low cardiac output syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Low cardiac output syndrome,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,1,7,NA,NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,0,8,NA,NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,0,10,NA,NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Ischaemic stroke,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Vascular graft thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,0,8,NA,NA,Vascular graft thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Vascular graft thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,1,10,NA,NA,Vascular graft thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Vascular graft thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Vascular graft thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,1,7,NA,NA,Renal failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,0,8,NA,NA,Renal failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Renal failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,0,10,NA,NA,Renal failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Renal failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Renal failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,1,7,NA,NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,0,8,NA,NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,0,10,NA,NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Respiratory failure,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Arterial thrombosis limb,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,0,8,NA,NA,Arterial thrombosis limb,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Arterial thrombosis limb,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,1,10,NA,NA,Arterial thrombosis limb,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Arterial thrombosis limb,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Arterial thrombosis limb,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,1,7,NA,NA,Extremity necrosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,0,8,NA,NA,Extremity necrosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Extremity necrosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,0,10,NA,NA,Extremity necrosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Extremity necrosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Extremity necrosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Jugular vein thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,serious,NA,NA,0,8,NA,NA,Jugular vein thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,serious,NA,NA,0,7,NA,NA,Jugular vein thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,serious,NA,NA,1,10,NA,NA,Jugular vein thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Jugular vein thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,serious,NA,NA,0,6,NA,NA,Jugular vein thrombosis,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,other,NA,NA,3,7,NA,NA,Pleural effusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,other,NA,NA,2,8,NA,NA,Pleural effusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,other,NA,NA,1,7,NA,NA,Pleural effusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,other,NA,NA,1,10,NA,NA,Pleural effusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,other,NA,NA,1,6,NA,NA,Pleural effusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,Pleural effusion,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,other,NA,NA,1,7,NA,NA,Atrial fibrillation,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,other,NA,NA,2,8,NA,NA,Atrial fibrillation,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,other,NA,NA,1,7,NA,NA,Atrial fibrillation,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,other,NA,NA,2,10,NA,NA,Atrial fibrillation,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,other,NA,NA,1,6,NA,NA,Atrial fibrillation,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,other,NA,NA,2,6,NA,NA,Atrial fibrillation,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,other,NA,NA,1,7,NA,NA,Troponin T increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,other,NA,NA,2,8,NA,NA,Troponin T increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,other,NA,NA,1,7,NA,NA,Troponin T increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,other,NA,NA,1,10,NA,NA,Troponin T increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,Troponin T increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,Troponin T increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,other,NA,NA,2,7,NA,NA,Nausea,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,other,NA,NA,1,8,NA,NA,Nausea,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,other,NA,NA,0,7,NA,NA,Nausea,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,other,NA,NA,1,10,NA,NA,Nausea,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,other,NA,NA,2,6,NA,NA,Nausea,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,Nausea,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,other,NA,NA,0,7,NA,NA,Urinary tract infection,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,other,NA,NA,0,8,NA,NA,Urinary tract infection,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,other,NA,NA,1,7,NA,NA,Urinary tract infection,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,other,NA,NA,2,10,NA,NA,Urinary tract infection,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,other,NA,NA,2,6,NA,NA,Urinary tract infection,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,Urinary tract infection,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,other,NA,NA,0,7,NA,NA,Pneumothorax,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,other,NA,NA,2,8,NA,NA,Pneumothorax,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,other,NA,NA,1,7,NA,NA,Pneumothorax,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,other,NA,NA,0,10,NA,NA,Pneumothorax,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,Pneumothorax,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,Pneumothorax,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,other,NA,NA,0,7,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,other,NA,NA,2,8,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,other,NA,NA,0,7,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,other,NA,NA,0,10,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG000,30 (+5) days post treatment,other,NA,NA,0,7,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG001,30 (+5) days post treatment,other,NA,NA,0,8,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG002,30 (+5) days post treatment,other,NA,NA,0,7,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG003,30 (+5) days post treatment,other,NA,NA,0,10,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG004,30 (+5) days post treatment,other,NA,NA,0,6,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01530399,EG005,30 (+5) days post treatment,other,NA,NA,2,6,NA,NA,AST increased,5,MedDRA (Unspecified),Systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,squamous cell carcinoma,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,squamous cell carcinoma,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,anemia,5,medDRA,Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,2,160,NA,2,anemia,5,medDRA,Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,atrial fibrillation,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,atrial fibrillation,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,myocardial infarction,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,2,160,NA,2,myocardial infarction,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,0,81,NA,0,abdominal pain upper,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,2,160,NA,2,abdominal pain upper,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,diarrhea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,3,160,NA,3,diarrhea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,chest pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,2,160,NA,2,chest pain,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,2,81,NA,2,biliary sepsis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,0,160,NA,0,biliary sepsis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,2,81,NA,2,diverticulitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,diverticulitis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,erysipelas,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,erysipelas,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,0,81,NA,0,gastroenteritis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,3,160,NA,3,gastroenteritis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,gastroenteritis norovirus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,gastroenteritis norovirus,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,herpes zoster,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,2,160,NA,2,herpes zoster,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,2,81,NA,2,influenza,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,influenza,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,5,81,NA,5,pneumonia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,5,160,NA,5,pneumonia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,2,81,NA,2,respiratory tract infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,0,160,NA,0,respiratory tract infection,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,septic shock,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,septic shock,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,0,81,NA,0,complications of transplanted kidney,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,2,160,NA,2,complications of transplanted kidney,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,2,81,NA,2,forced expiratory volume decreased,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,forced expiratory volume decreased,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,2,81,NA,2,dehydration,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,0,160,NA,0,dehydration,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,2,81,NA,2,osteoarthritis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,osteoarthritis,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,0,81,NA,0,metastases to liver,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,2,160,NA,2,metastases to liver,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,syncope,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,syncope,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,dyspnea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,1,160,NA,1,dyspnea,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,serious,NA,NA,1,81,NA,1,peripheral arterial occlusive disease,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,serious,NA,NA,2,160,NA,2,peripheral arterial occlusive disease,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,other,NA,NA,5,81,NA,5,pneumonia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG001,NA,other,NA,NA,7,160,NA,7,pneumonia,5,MedDRA (Unspecified),Non-systematic Assessment
NCT01532453,EG000,NA,other,NA,NA,7,81,NA,7,hypertension,5,medDRA,Non-systematic Assessment
NCT01532453,EG001,NA,other,NA,NA,4,160,NA,4,hypertension,5,medDRA,Non-systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,18,NA,NA,Cardiovascular insufficiency,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,33,NA,NA,Cardiovascular insufficiency,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,18,NA,NA,Convulsion,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,33,NA,NA,Convulsion,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,18,NA,NA,Epilepsy,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,33,NA,NA,Epilepsy,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,18,NA,NA,Pancreatitis,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,33,NA,NA,Pancreatitis,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,18,NA,NA,Renal failure,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,33,NA,NA,Renal failure,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,18,NA,NA,Rib fracture,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,33,NA,NA,Rib fracture,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,18,NA,NA,Status epilepticus,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,33,NA,NA,Status epilepticus,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,18,NA,NA,Sudden Death,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,33,NA,NA,Sudden Death,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,0,18,NA,NA,Vertebrobasilar insuffficiency,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",serious,NA,NA,1,33,NA,NA,Vertebrobasilar insuffficiency,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Anxiety,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,33,NA,NA,Anxiety,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Arthralgia,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,33,NA,NA,Arthralgia,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Asparatate aminotransferase increased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Asparatate aminotransferase increased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,18,NA,NA,Asthenia,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,2,33,NA,NA,Asthenia,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Blood creatine phosphokinase increased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Blood creatine phosphokinase increased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Blood pressure decreased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Blood pressure decreased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Confusional state,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Confusional state,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,18,NA,NA,Constipation,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,2,33,NA,NA,Constipation,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Depression,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Depression,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,18,NA,NA,Diplopia,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,2,33,NA,NA,Diplopia,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,2,18,NA,NA,Dizziness,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,5,33,NA,NA,Dizziness,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Epistaxis,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Epistaxis,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Gamma-glutamyltransferase increased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Gamma-glutamyltransferase increased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Gastritis,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Gastritis,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,18,NA,NA,Headache,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,4,33,NA,NA,Headache,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,2,18,NA,NA,Hypertension,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,33,NA,NA,Hypertension,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,18,NA,NA,Nasopharyngitis,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,2,33,NA,NA,Nasopharyngitis,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Palpitations,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Palpitations,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Pruritus,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,3,33,NA,NA,Pruritus,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Radicular syndrome,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Radicular syndrome,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Sciatica,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Sciatica,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,18,NA,NA,Somnolence,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,5,33,NA,NA,Somnolence,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Upper respiratory tract infection,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Upper respiratory tract infection,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Vertigo,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,33,NA,NA,Vertigo,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,18,NA,NA,Vomiting,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,3,33,NA,NA,Vomiting,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG000,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,1,18,NA,NA,Alanine aminotransferase increased,5,MedDRA v.13.1,Systematic Assessment
NCT01546688,EG001,"Treatment-Emergent Adverse Events (TEAE) were collected, and includes all Adverse Events (AE) with a start date on or after Day 1 and within 15 Days of last dose, including AEs with missing start dates. Participants were followed for up to 27 weeks.",other,NA,NA,0,33,NA,NA,Alanine aminotransferase increased,5,MedDRA v.13.1,Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,2,Cardiac Failure,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Gallstone ileus,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,2,117,NA,3,Ileal stenosis,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Death,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,2,117,NA,2,Impaired healing,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,2,117,NA,2,Oedema peripheral,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Renal failure,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Graft infection,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Infection,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Pneumonia,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,8,117,NA,8,Wound infection,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Post procedural haematoma,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,3,117,NA,3,Seroma,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Transplant failure,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,15,117,NA,24,Vascular graft occlusion,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Wound secretion,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Pain in extremity,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Bronchial carcinoma,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Angioplasty,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Aortic aneurysm repair,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Peripheral endarterectomy,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Surgery,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,2,117,NA,3,Aortic stenosis,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Intermittent claudication,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,4,117,NA,4,Haematoma,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Leriche syndrome,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Peripheral arterial occlusive disease,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,2,117,NA,2,Peripheral ischemia,5,MedDRA (10.0),Systematic Assessment
NCT01601496,EG000,Through 12 months follow up,serious,NA,NA,1,117,NA,1,Vasculitis,5,MedDRA (10.0),Systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,FEBRILE NEUTROPENIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,LEUKOPENIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,NEUTROPENIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,CARDIAC ARREST,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CARDIO-RESPIRATORY ARREST,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,STRESS CARDIOMYOPATHY,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,VENTRICULAR FIBRILLATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,COLITIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CONSTIPATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,16,616,NA,NA,DYSPHAGIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,FAECALOMA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,GASTROINTESTINAL HAEMORRHAGE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,DEATH,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,EUTHANASIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,GENERAL PHYSICAL HEALTH DETERIORATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,HAEMORRHOIDS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,PYREXIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CHOLECYSTITIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,BRONCHITIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CATHETER SITE INFECTION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CLOSTRIDIUM DIFFICILE COLITIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,ENTEROCOCCAL INFECTION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,ENTEROCOCCAL SEPSIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,ENTEROCOLITIS INFECTIOUS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,GASTROENTERITIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,HERPES ZOSTER OTICUS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,LOWER RESPIRATORY TRACT INFECTION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,ORAL INFECTION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,15,616,NA,NA,PNEUMONIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,PNEUMONIA PNEUMOCOCCAL,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,PSEUDOMONAL BACTERAEMIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,RESPIRATORY TRACT INFECTION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,UROSEPSIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CAPNOTHORAX,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CERVICAL VERTEBRAL FRACTURE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,3,616,NA,NA,FALL,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,FEMUR FRACTURE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,HIP FRACTURE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,BLOOD GLUCOSE INCREASED,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,LIVER FUNCTION TEST ABNORMAL,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,SLEEP STUDY,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,WEIGHT DECREASED,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,HYPOKALAEMIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,HYPONATRAEMIA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,JOINT SWELLING,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,BRONCHIAL CARCINOMA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,16,616,NA,NA,AMYOTROPHIC LATERAL SCLEROSIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,ANXIETY,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CONFUSIONAL STATE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,HALLUCINATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CALCULUS URETERIC,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,HYDRONEPHROSIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,URINARY RETENTION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,ACUTE RESPIRATORY FAILURE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,ASPIRATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,CHRONIC RESPIRATORY FAILURE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,COUGH,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,4,616,NA,NA,DYSPNOEA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,FOREIGN BODY ASPIRATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,HYPOVENTILATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,LARYNGOSPASM,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,NASAL SEPTUM DEVIATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,5,616,NA,NA,PNEUMONIA ASPIRATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,PNEUMOTHORAX,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,3,616,NA,NA,PULMONARY EMBOLISM,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,RESPIRATORY ARREST,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,RESPIRATORY DISORDER,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,RESPIRATORY DISTRESS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,50,616,NA,NA,RESPIRATORY FAILURE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,RESPIRATORY MUSCLE WEAKNESS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,ANGIOEDEMA,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,RASH GENERALISED,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,RESPITE CARE,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,GASTROSTOMY TUBE INSERTION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,INTESTINAL RESECTION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,MECHANICAL VENTILATION,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,TRACHEOSTOMY,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,2,616,NA,NA,DEEP VEIN THROMBOSIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,SHOCK,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",serious,NA,NA,1,616,NA,NA,THROMBOSIS,5,MedDRA 15.0,Non-systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",other,NA,NA,31,616,NA,NA,URINARY TRACT INFECTION,5,MedDRA 15.0,Systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",other,NA,NA,52,616,NA,NA,RESPIRATORY FAILURE,5,MedDRA 15.0,Systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",other,NA,NA,49,616,NA,NA,CONSTIPATION,5,MedDRA 15.0,Systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",other,NA,NA,33,616,NA,NA,NAUSEA,5,MedDRA 15.0,Systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",other,NA,NA,31,616,NA,NA,OEDEMA PERIPHERAL,5,MedDRA 15.0,Systematic Assessment
NCT01622088,EG000,"Adverse events were collected between the time of the first dose of study treatment and the last study visit for each enrolled subject. In this study, the maximum subject duration was a maximum 226 days: approximately 32.2 weeks.",other,NA,NA,68,616,NA,NA,FALL,5,MedDRA 15.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,154,NA,2,ACUTE MYOCARDIAL INFARCTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,ACUTE MYOCARDIAL INFARCTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,154,NA,2,ANGINA PECTORIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,ANGINA PECTORIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,3,154,NA,3,ATRIAL FIBRILLATION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,ATRIAL FIBRILLATION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,CARDIAC ARREST,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,CARDIAC ARREST,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,154,NA,4,CARDIAC FAILURE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,CARDIAC FAILURE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,CORONARY ARTERY DISEASE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,CORONARY ARTERY DISEASE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,MYOPERICARDITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,MYOPERICARDITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,PERICARDIAL EFFUSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PERICARDIAL EFFUSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,VERTIGO POSITIONAL,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,VERTIGO POSITIONAL,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,EYE PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,EYE PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,PHOTOPHOBIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PHOTOPHOBIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,RETINAL VEIN THROMBOSIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,RETINAL VEIN THROMBOSIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,154,NA,3,ABDOMINAL PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,ABDOMINAL PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,NAUSEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,NAUSEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,5,154,NA,5,PANCREATITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PANCREATITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,SMALL INTESTINAL OBSTRUCTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,SMALL INTESTINAL OBSTRUCTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,VOMITING,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,VOMITING,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,NON-CARDIAC CHEST PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,NON-CARDIAC CHEST PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,OEDEMA PERIPHERAL,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,2,OEDEMA PERIPHERAL,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,154,NA,2,PYREXIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,PYREXIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,CHOLECYSTITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,CHOLECYSTITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,HEPATITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,HEPATITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,BACTERIAL PYELONEPHRITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,BACTERIAL PYELONEPHRITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,CERVICITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,CERVICITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,DISSEMINATED TUBERCULOSIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,DISSEMINATED TUBERCULOSIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,DIVERTICULITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,DIVERTICULITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,HEPATITIS B,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,HEPATITIS B,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,HERPES ZOSTER,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,HERPES ZOSTER,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,LUNG INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,LUNG INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,PARAINFLUENZAE VIRUS INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PARAINFLUENZAE VIRUS INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,PARASPINAL ABSCESS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,PARASPINAL ABSCESS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,PERICOLIC ABSCESS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PERICOLIC ABSCESS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,154,NA,3,PNEUMONIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,PNEUMONIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,PYELONEPHRITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PYELONEPHRITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,RESPIRATORY TRACT INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,RESPIRATORY TRACT INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,SEPSIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,SEPSIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,VESTIBULAR NEURONITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,VESTIBULAR NEURONITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,VIRAL UPPER RESPIRATORY TRACT INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,VIRAL UPPER RESPIRATORY TRACT INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,COMPRESSION FRACTURE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,COMPRESSION FRACTURE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,PERIORBITAL CONTUSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PERIORBITAL CONTUSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,SPLENIC RUPTURE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,SPLENIC RUPTURE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,ALANINE AMINOTRANSFERASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,ALANINE AMINOTRANSFERASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,AMYLASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,AMYLASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,C-REACTIVE PROTEIN INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,C-REACTIVE PROTEIN INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,3,154,NA,3,PLATELET COUNT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PLATELET COUNT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,DECREASED APPETITE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,DECREASED APPETITE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,FAILURE TO THRIVE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,FAILURE TO THRIVE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,HYPONATRAEMIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,HYPONATRAEMIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,BACK PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,BACK PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,BONE PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,BONE PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,MUSCULOSKELETAL CHEST PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,MUSCULOSKELETAL CHEST PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,NECK PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,NECK PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,POLYARTHRITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,POLYARTHRITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,SACROILIITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,SACROILIITIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,ANGIOMYOLIPOMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,ANGIOMYOLIPOMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,BLAST CRISIS IN MYELOGENOUS LEUKAEMIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,152,NA,2,BLAST CRISIS IN MYELOGENOUS LEUKAEMIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,CHLOROMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,CHLOROMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,CLEAR CELL RENAL CELL CARCINOMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,CLEAR CELL RENAL CELL CARCINOMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,CEREBROVASCULAR ACCIDENT,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,CEREBROVASCULAR ACCIDENT,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,DYSARTHRIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,DYSARTHRIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,HEADACHE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,HEADACHE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,HYPOXIC-ISCHAEMIC ENCEPHALOPATHY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,HYPOXIC-ISCHAEMIC ENCEPHALOPATHY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,LOSS OF CONSCIOUSNESS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,LOSS OF CONSCIOUSNESS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,POLYNEUROPATHY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,POLYNEUROPATHY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,PRESYNCOPE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,PRESYNCOPE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,RADICULITIS CERVICAL,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,RADICULITIS CERVICAL,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,TRANSIENT ISCHAEMIC ATTACK,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,TRANSIENT ISCHAEMIC ATTACK,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,BENIGN PROSTATIC HYPERPLASIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,BENIGN PROSTATIC HYPERPLASIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,DYSPNOEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,DYSPNOEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,PLEURAL EFFUSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,152,NA,2,PLEURAL EFFUSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,154,NA,0,PULMONARY OEDEMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,152,NA,1,PULMONARY OEDEMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,RESPIRATORY FAILURE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,RESPIRATORY FAILURE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,HYPERTENSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,HYPERTENSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,2,154,NA,2,PERIPHERAL ARTERIAL OCCLUSIVE DISEASE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PERIPHERAL ARTERIAL OCCLUSIVE DISEASE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,1,154,NA,1,PERIPHERAL ARTERY THROMBOSIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",serious,NA,NA,0,152,NA,0,PERIPHERAL ARTERY THROMBOSIS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,13,154,NA,15,ANAEMIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,12,152,NA,14,ANAEMIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,10,154,NA,10,DRY EYE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,3,152,NA,3,DRY EYE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,1,154,NA,1,EYELID OEDEMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,13,152,NA,13,EYELID OEDEMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,1,154,NA,1,PERIORBITAL OEDEMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,33,152,NA,37,PERIORBITAL OEDEMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,10,154,NA,11,ABDOMINAL DISCOMFORT,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,152,NA,5,ABDOMINAL DISCOMFORT,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,54,154,NA,69,ABDOMINAL PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,15,152,NA,15,ABDOMINAL PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,41,154,NA,48,CONSTIPATION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,3,152,NA,3,CONSTIPATION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,20,154,NA,28,DIARRHOEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,41,152,NA,54,DIARRHOEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,11,154,NA,11,DRY MOUTH,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,152,NA,5,DRY MOUTH,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,7,154,NA,7,DYSPEPSIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,9,152,NA,10,DYSPEPSIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,34,154,NA,44,NAUSEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,52,152,NA,58,NAUSEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,17,154,NA,18,VOMITING,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,28,152,NA,30,VOMITING,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,6,154,NA,6,ASTHENIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,12,152,NA,14,ASTHENIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,10,154,NA,12,CHILLS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,6,152,NA,6,CHILLS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,32,154,NA,37,FATIGUE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,30,152,NA,35,FATIGUE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,14,154,NA,15,OEDEMA PERIPHERAL,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,22,152,NA,24,OEDEMA PERIPHERAL,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,9,154,NA,10,PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,2,152,NA,2,PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,26,154,NA,31,PYREXIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,6,152,NA,8,PYREXIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,154,NA,5,UPPER RESPIRATORY TRACT INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,13,152,NA,16,UPPER RESPIRATORY TRACT INFECTION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,20,154,NA,29,ALANINE AMINOTRANSFERASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,2,152,NA,3,ALANINE AMINOTRANSFERASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,14,154,NA,20,AMYLASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,1,152,NA,1,AMYLASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,18,154,NA,24,ASPARTATE AMINOTRANSFERASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,6,152,NA,7,ASPARTATE AMINOTRANSFERASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,14,154,NA,20,BLOOD ALKALINE PHOSPHATASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,152,NA,5,BLOOD ALKALINE PHOSPHATASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,41,154,NA,68,LIPASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,11,152,NA,13,LIPASE INCREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,8,154,NA,15,NEUTROPHIL COUNT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,17,152,NA,34,NEUTROPHIL COUNT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,36,154,NA,65,PLATELET COUNT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,21,152,NA,37,PLATELET COUNT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,9,154,NA,11,WEIGHT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,2,152,NA,2,WEIGHT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,154,NA,5,WHITE BLOOD CELL COUNT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,9,152,NA,11,WHITE BLOOD CELL COUNT DECREASED,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,18,154,NA,20,DECREASED APPETITE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,7,152,NA,8,DECREASED APPETITE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,13,154,NA,14,HYPERTRIGLYCERIDAEMIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,7,152,NA,8,HYPERTRIGLYCERIDAEMIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,29,154,NA,33,ARTHRALGIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,23,152,NA,29,ARTHRALGIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,11,154,NA,13,BACK PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,6,152,NA,7,BACK PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,13,154,NA,19,BONE PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,12,152,NA,16,BONE PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,11,154,NA,12,MUSCLE SPASMS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,52,152,NA,62,MUSCLE SPASMS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,10,154,NA,11,MUSCULOSKELETAL PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,4,152,NA,4,MUSCULOSKELETAL PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,40,154,NA,44,MYALGIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,27,152,NA,31,MYALGIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,19,154,NA,19,PAIN IN EXTREMITY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,12,152,NA,15,PAIN IN EXTREMITY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,15,154,NA,21,DIZZINESS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,9,152,NA,11,DIZZINESS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,50,154,NA,61,HEADACHE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,20,152,NA,27,HEADACHE,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,3,154,NA,3,LETHARGY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,10,152,NA,12,LETHARGY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,8,154,NA,8,ANXIETY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,152,NA,5,ANXIETY,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,8,154,NA,8,DEPRESSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,152,NA,5,DEPRESSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,16,154,NA,17,INSOMNIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,4,152,NA,4,INSOMNIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,8,154,NA,9,COUGH,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,8,152,NA,8,COUGH,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,13,154,NA,18,DYSPNOEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,152,NA,5,DYSPNOEA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,10,154,NA,10,OROPHARYNGEAL PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,3,152,NA,3,OROPHARYNGEAL PAIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,17,154,NA,17,ALOPECIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,8,152,NA,8,ALOPECIA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,27,154,NA,29,DRY SKIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,5,152,NA,5,DRY SKIN,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,11,154,NA,12,ERYTHEMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,2,152,NA,3,ERYTHEMA,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,7,154,NA,7,NIGHT SWEATS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,9,152,NA,10,NIGHT SWEATS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,18,154,NA,20,PRURITUS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,11,152,NA,15,PRURITUS,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,58,154,NA,100,RASH,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,25,152,NA,41,RASH,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,6,154,NA,8,RASH PRURITIC,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,11,152,NA,14,RASH PRURITIC,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG000,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,27,154,NA,37,HYPERTENSION,5,MedDRA 16.0,Systematic Assessment
NCT01650805,EG001,"Patients were followed-up for AEs from the time of informed consent until 30 days after the close of the trial. The median follow-up was 4.97 months (range: 0.03, 17.57) for ponatinib patients, and 5.32 months (range: 0.49, 14.05) for imatinib patients.",other,NA,NA,3,152,NA,4,HYPERTENSION,5,MedDRA 16.0,Systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,1,3,NA,1,Progression of disease (fatal),5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,0,6,NA,0,Progression of disease (fatal),5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,1,3,NA,1,"thrombocytopenia, anaemia, hypokaliemia",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,0,6,NA,0,"thrombocytopenia, anaemia, hypokaliemia",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,1,3,NA,1,worsening of pleural effusion,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,0,6,NA,0,worsening of pleural effusion,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,pulmonary embolism,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,pulmonary embolism,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,liver failure,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,liver failure,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,diarrhea,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,diarrhea,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,"diarrhea, hypokaliemia",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,"diarrhea, hypokaliemia",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,"sepsis, chronic kidney disease (worsening), platelet count decreased, worsening of anemia, diarrhea",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,"sepsis, chronic kidney disease (worsening), platelet count decreased, worsening of anemia, diarrhea",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,"Infection unknown origin, platelet count decreased",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,"Infection unknown origin, platelet count decreased",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,"""infection unknown origin, worsening of chronic kidney disease, platelet count decreased, leukocytop",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,"""infection unknown origin, worsening of chronic kidney disease, platelet count decreased, leukocytop",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,Biliary tract infection,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,Biliary tract infection,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,serious,NA,NA,0,3,NA,0,"infection, unknown origin, pulmonary embolism both sides, deep vein thrombosis both leg",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,serious,NA,NA,1,6,NA,1,"infection, unknown origin, pulmonary embolism both sides, deep vein thrombosis both leg",5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,3,3,NA,11,fatigue,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,6,6,NA,19,fatigue,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,3,3,NA,5,nausea,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,5,6,NA,9,nausea,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,2,3,NA,4,diarrhoea,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,5,6,NA,25,diarrhoea,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,3,3,NA,7,rash,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,4,6,NA,10,rash,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,3,3,NA,6,stomatitis,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,4,6,NA,8,stomatitis,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,3,3,NA,7,anemia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,4,6,NA,8,anemia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,1,3,NA,2,weight loss,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,6,6,NA,9,weight loss,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,2,3,NA,3,epistaxis,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,2,6,NA,2,epistaxis,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,2,3,NA,11,neutropenia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,3,6,NA,9,neutropenia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,3,3,NA,17,thrombocytopenia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,3,6,NA,20,thrombocytopenia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,2,3,NA,4,hypokalemia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,3,6,NA,6,hypokalemia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,1,3,NA,1,paresthesia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,4,6,NA,9,paresthesia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG000,NA,other,NA,NA,1,3,NA,1,paronychia,5,MedDRA (11.0),Non-systematic Assessment
NCT01679405,EG001,NA,other,NA,NA,4,6,NA,4,paronychia,5,MedDRA (11.0),Non-systematic Assessment
NCT01808950,EG000,NA,serious,NA,NA,0,1,NA,0,Mutlilocular BCC right had Prox.,0,NA,Non-systematic Assessment
NCT01808950,EG001,NA,serious,NA,NA,1,3,NA,1,Mutlilocular BCC right had Prox.,0,NA,Non-systematic Assessment
NCT01808950,EG002,NA,serious,NA,NA,0,0,NA,0,Mutlilocular BCC right had Prox.,0,NA,Non-systematic Assessment
NCT01808950,EG000,NA,serious,NA,NA,0,1,NA,0,Nodular BCC arm left,0,NA,Non-systematic Assessment
NCT01808950,EG001,NA,serious,NA,NA,1,3,NA,1,Nodular BCC arm left,0,NA,Non-systematic Assessment
NCT01808950,EG002,NA,serious,NA,NA,0,0,NA,0,Nodular BCC arm left,0,NA,Non-systematic Assessment
NCT01808950,EG000,NA,serious,NA,NA,0,1,NA,0,superficial BCC submammary,0,NA,Non-systematic Assessment
NCT01808950,EG001,NA,serious,NA,NA,1,3,NA,1,superficial BCC submammary,0,NA,Non-systematic Assessment
NCT01808950,EG002,NA,serious,NA,NA,0,0,NA,0,superficial BCC submammary,0,NA,Non-systematic Assessment
NCT01808950,EG000,NA,other,NA,NA,1,1,NA,1,exertional dyspnoea,0,NA,Systematic Assessment
NCT01808950,EG001,NA,other,NA,NA,0,3,NA,0,exertional dyspnoea,0,NA,Systematic Assessment
NCT01808950,EG002,NA,other,NA,NA,0,0,NA,0,exertional dyspnoea,0,NA,Systematic Assessment
NCT01808950,EG000,NA,other,NA,NA,0,1,NA,0,cornu cutaneum,0,NA,Non-systematic Assessment
NCT01808950,EG001,NA,other,NA,NA,1,3,NA,1,cornu cutaneum,0,NA,Non-systematic Assessment
NCT01808950,EG002,NA,other,NA,NA,0,0,NA,0,cornu cutaneum,0,NA,Non-systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Atrial fibrillation,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,2,3,NA,3,Biliary anastomosis complication,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Liver function test abnormal,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Liver transplant rejection,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Papilla of Vater stenosis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Wound dehiscence,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Post procedural bile leak,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Subcutaneous abscess,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Gastroenteritis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Myoclonus,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,serious,NA,NA,1,3,NA,1,Subcutaneous haematoma,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Abdominal distension,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,2,Abdominal pain upper,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Abnormal faeces,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Acidosis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,5,Agitation,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Bile duct stenosis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Cholangitis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Cholestasis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,3,3,NA,4,Constipation,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Cough,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Cytomegalovirus infection,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Dermatitis contact,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Diarrhoea,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,3,3,NA,3,Dyspepsia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Dysphemia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Fatigue,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Flatulence,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Haemorrhage,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Hypercapnia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,3,Hyperglycaemia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Hyperkalaemia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Hyperlipidaemia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Hypertension,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Hyperthyroidism,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Hypertrichosis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,2,Hypomagnesaemia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Ileus,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,2,Impaired healing,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Incisional hernia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,2,Increased bronchial secretion,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Infection,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,2,Leukopenia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,2,Liver function test abnormal,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Myopia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,4,Nasopharyngitis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Night sweats,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,2,Oedema,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,2,Oedema peripheral,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Oesophagitis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Oliguria,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Oral candidiasis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Oral herpes,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Oropharyngeal pain,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Osteoporosis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,3,3,NA,3,Pain,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Pancytopenia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Paraesthesia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Paronychia,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,3,3,NA,3,Pleural effusion,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Pruritus,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Renal failure,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Renal function test abnormal,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Rhinitis,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Skin lesion,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,2,Sleep disorder,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Somnolence,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,2,Tremor,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,2,Urinary tract infection,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,2,3,NA,2,Vomiting,0,MedDRA (19.0),Systematic Assessment
NCT01841632,EG000,The period of (S)AE reported for each trial patient was from the time of first study-specific procedure until 30 days after the final trial visit (approximately 52 weeks) or until the date of patient withdrawal.,other,NA,NA,1,3,NA,1,Wound infection,0,MedDRA (19.0),Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Angina pectoris,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Angina pectoris,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Arrhythmia,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Arrhythmia,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Cardiac arrest,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Cardiac arrest,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Cardiac failure,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Cardiac failure,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Small intestinal obstruction,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Small intestinal obstruction,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Oedema peripheral,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,2,Oedema peripheral,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Erysipelas,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Erysipelas,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Gangrene,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Gangrene,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Pneumonia,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Pneumonia,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Wound sepsis,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Wound sepsis,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Humerus fracture,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Humerus fracture,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Lower limb fracture,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Lower limb fracture,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Multiple injuries,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,2,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,2,Multiple injuries,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Traumatic haematoma,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Traumatic haematoma,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Metastases to lung,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Metastases to lung,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Vulval cancer,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Vulval cancer,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Metrorrhagia,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Metrorrhagia,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Dermatitis contact,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Dermatitis contact,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Pemphigoid,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Pemphigoid,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Purpura,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Purpura,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Skin ulcer,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Skin ulcer,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,0,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,0,Stasis dermatitis,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",serious,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,1,Stasis dermatitis,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,5,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,9,Gastrointestinal disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,6,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,8,Gastrointestinal disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,3,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,3,General disorders and administration site conditions,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,9,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,11,General disorders and administration site conditions,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,15,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,20,Infections and infestations,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,19,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,23,Infections and infestations,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,7,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,9,Infected skin ulcer,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,5,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,7,Infected skin ulcer,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,18,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,22,"Injury, poisoning and procedural complications",3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,13,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,13,"Injury, poisoning and procedural complications",3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,10,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,12,Excoriation,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,6,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,6,Excoriation,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,2,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,2,Metabolism and nutrition disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,4,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,4,Metabolism and nutrition disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,9,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,13,Musculoskeletal and connective tissue disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,14,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,19,Musculoskeletal and connective tissue disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,5,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,6,Pain in extremity,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,12,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,15,Pain in extremity,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,2,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,7,Nervous system disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,4,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,4,Nervous system disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,30,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,62,Skin and subcutaneous tissue disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,39,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,87,Skin and subcutaneous tissue disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,4,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,6,Dermatitis,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,1,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,2,Dermatitis,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,4,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,4,Erythema,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,5,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,6,Erythema,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,2,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,3,Skin maceration,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,7,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,13,Skin maceration,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,17,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,34,Skin ulcer,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,20,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,37,Skin ulcer,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,6,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,6,Venous ulcer pain,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,3,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,3,Venous ulcer pain,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,5,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,8,Vascular disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,10,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,11,Vascular disorders,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG000,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,5,131,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,8,Hypertension,3,MedDRA v 13.1,Systematic Assessment
NCT01853384,EG001,"Up to 19 Weeks or subjects who completed 12 weeks of treatment and the post-treatment follow up. For subjects who had wound closure, collection time included the treatment period and the post-treatment period",other,NA,NA,7,121,All subjects randomized to treatment were questioned about adverse events and were included in the number of participants assessed for safety. The first assessments at each weekly visit were about changes in general health and concomitant medications and the occurrence of adverse events.,8,Hypertension,3,MedDRA v 13.1,Systematic Assessment
NCT02340299,EG000,Adverse event data was collected until discharge from the neonatal unit. Patients were discharged approximately at 3 months of age.,other,NA,NA,2,4,NA,2,Highly viscous secretions,5,NA,Non-systematic Assessment
NCT02340299,EG001,Adverse event data was collected until discharge from the neonatal unit. Patients were discharged approximately at 3 months of age.,other,NA,NA,0,2,NA,0,Highly viscous secretions,5,NA,Non-systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,1,4,NA,1,PULMONARY EMBOLISM,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,0,6,NA,0,PULMONARY EMBOLISM,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,1,4,NA,1,HYPERGLYCEMIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,0,6,NA,0,HYPERGLYCEMIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,1,4,NA,1,CONSTIPATION,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,0,6,NA,0,CONSTIPATION,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,0,4,NA,0,HERPES ZOSTER,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,1,6,NA,1,HERPES ZOSTER,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,0,4,NA,0,ACUTE CORONARY SYNDROME,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,1,6,NA,1,ACUTE CORONARY SYNDROME,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,0,4,NA,0,GENERAL MALAISE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,1,6,NA,1,GENERAL MALAISE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,0,4,NA,0,SEIZURE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",serious,NA,NA,1,6,NA,1,SEIZURE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,4,4,NA,10,NAUSEA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,4,6,NA,4,NAUSEA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,3,4,NA,4,VOMITING,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,3,6,NA,4,VOMITING,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,1,DEEP VEIN THROMBOSIS,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,6,NA,0,DEEP VEIN THROMBOSIS,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,3,4,NA,4,DIARRHEA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,4,6,NA,4,DIARRHEA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,1,ANEMIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,6,NA,0,ANEMIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,1,VERTIGO,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,6,NA,0,VERTIGO,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,1,FATIGUE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,5,6,NA,5,FATIGUE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,1,HYPONATREMIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,6,NA,0,HYPONATREMIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,1,PLATELET COUNT DECREASED,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,PLATELET COUNT DECREASED,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,2,WEIGHT LOSS,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,WEIGHT LOSS,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,2,ANOREXIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,3,6,NA,3,ANOREXIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,3,ASTHENIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,6,NA,0,ASTHENIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,INFECTION OF UNKNOWN ORIGIN,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,3,INFECTION OF UNKNOWN ORIGIN,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,DIZZINESS,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,2,6,NA,2,DIZZINESS,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,HEADACHE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,HEADACHE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,INSOMNIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,INSOMNIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,NECK PAIN,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,NECK PAIN,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,2,CONSTIPATION,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,2,6,NA,NA,CONSTIPATION,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,BODY PAIN,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,BODY PAIN,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,DOUBLE VISION,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,DOUBLE VISION,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,PAIN INGUINAL RIGHT,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,PAIN INGUINAL RIGHT,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,BACK PAIN,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,BACK PAIN,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,SENSORY NEUROPATHY,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,SENSORY NEUROPATHY,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,NEUTROPHIL COUNT DECREASED,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,NEUTROPHIL COUNT DECREASED,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,2,4,NA,2,BLURRED VISION,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,BLURRED VISION,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,COUGH,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,2,6,NA,2,COUGH,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,DYSGEUSIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,DYSGEUSIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,HEARING IMPAIRMENT,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,HEARING IMPAIRMENT,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,FLU-LIKE SYMPTOMS,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,FLU-LIKE SYMPTOMS,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,DYSPNEA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,DYSPNEA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,MALAISE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,MALAISE,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,4,NA,0,HYPOKALEMIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,6,NA,1,HYPOKALEMIA,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG000,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,1,4,NA,1,POLYNEUROPATHY,0,NCI CTC AE v4.03,Systematic Assessment
NCT02384850,EG001,"Adverse Events were monitored from the date of informed consent until 30 days after the last dose of study medication (end of treatment visit). Patients who discontinued for reasons other than withdrawal of consent were followed for a maximum of 24 months for progression-free survival and overall survival, so deaths were monitored for up to 2 years for patients in follow-up.",other,NA,NA,0,6,NA,0,POLYNEUROPATHY,0,NCI CTC AE v4.03,Systematic Assessment
NCT02891863,EG000,from the time of the acute testing until 7 days post-procedure,serious,NA,NA,1,9,NA,1,post-procedure VT recurred,0,NA,Systematic Assessment
NCT02891863,EG000,from the time of the acute testing until 7 days post-procedure,serious,NA,NA,1,9,NA,1,VT accelerated to VF,0,NA,Systematic Assessment
NCT02891863,EG000,from the time of the acute testing until 7 days post-procedure,serious,NA,NA,1,9,NA,1,LV impairment,0,NA,Systematic Assessment
NCT02891863,EG000,from the time of the acute testing until 7 days post-procedure,other,NA,NA,1,9,NA,1,muscle soreness,0,NA,Systematic Assessment
NCT02891863,EG000,from the time of the acute testing until 7 days post-procedure,other,NA,NA,1,9,NA,1,VT acceleration to VF,0,NA,Systematic Assessment
